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List of Definitions and Abbreviations 
Definitions 
Antimalarial Any medicine recognized by the WHO for the treatment of malaria. 
Medicines used solely for the prevention of malaria were excluded 
from analysis. 
Artemisinin-
based 
Combination 
Therapy (ACT) 
An antimalarial that combines artemisinin or one of its derivatives 
with an antimalarial or antimalarials of a different class. Refer to 
Combination Therapy.   
Artemisinin 
monotherapy 
(AMT) 
An antimalarial medicine that has a single active compound, where 
this active compound is artemisinin or one of its derivatives. 
Censused 
cluster 
A cluster/sub-district where field teams conducted a full census of 
all outlets with the potential to sell antimalarials.  
Cluster 
 
The primary sampling unit, or cluster, for the outlet survey. It is 
supposed to be an administrative unit typically determined by the 
Ministry of Health (MoH) that hosts a population size of 
approximately 10,000 to 15,000 inhabitants.  
 
In Ghana there is no existing intermediate administrative unit 
which is equivalent to a sub-district/cluster of 10,000-15,000 
inhabitants. The smallest functional administrative units are the 
assemblies (district, municipal and metropolitan), which are 
subdivided into Enumeration Areas (EA) with average size of 750 
inhabitants per each EA. Artificial sub-districts (clusters) were 
created by combining EAs for the purposes of the AMFm survey in 
Ghana.  
Combination 
therapy 
The use of two or more classes of antimalarial drugs/molecules in 
the treatment of malaria that have independent modes of action.  
Dosing/treatme
nt regimen 
The posology or timing and number of doses of an antimalarial 
used to treat malaria. This schedule often varies by patient weight. 
Enumerated 
Outlets 
Outlets that were visited by a member of one of the field teams, and 
where minimum basic descriptive information was collected  
First-line 
treatment  
The government recommended treatment for uncomplicated 
malaria. Ghana’s first line treatment is Artesunate – Amodiaquine 
and the alternate first line treatment is Artemether – Lumefantrine.  
Monotherapy An antimalarial medicine that has a single mode of action. This 
may be a medicine with a single active compound or a synergistic 
combination of two compounds with related mechanisms of action. 
Non-
artemisinin 
therapy (nAT) 
An antimalarial medicine that does not contain artemisinin or any 
of its derivatives.  
  xii 
Outlet Any point of sale or provision of a commodity to an individual. 
Outlets are not restricted to stationary points of sale and may 
include mobile units or individuals. Refer to Appendix 9.6 for a 
description of the outlet types visited for this survey.   
Quality 
Assured 
Artemisinin-
Based 
Combination 
Therapies 
(QAACTs) 
QAACTs are ACTs that comply with the Global Fund to Fight 
AIDS, Tuberculosis and Malaria’s Quality Assurance Policy. For 
the purpose of the Independent Evaluation, a QAACT is any ACT 
which appeared on the Global Fund's indicative list of antimalarials 
meeting the Global Fund's quality assurance policy prior to baseline 
or endline data collection  
(see:http://www.theglobalfund.org/en/procurement/quality/pharma
ceutical/#General), or which previously had C-status in an earlier 
Global Fund quality assurance policy and was used in a program 
supplying subsidized ACTs. At endline, QAACTs were defined as 
any ACT which appeared on the Global Fund’s indicative list of 
antimalarials meeting its quality assurance policy as at September 
2011, or which previously had C-status in an earlier Global Fund 
quality assurance policy and was used in a program supplying 
subsidized ACTs. 
Screened An outlet that was administered the screening questions of the 
outlet survey questionnaire (see Screening criteria).  
Screening 
criteria 
The set of requirements that must be satisfied before the full 
questionnaire is administered. 
 
In this survey, an outlet met the screening criteria if (1) they had 
antimalarials in stock at the time of the survey visit, or (2) they 
report having stocked them in the past three months. 
 
 
List of Acronyms/Abbreviations 
 
ACT Artemisinin-based Combination Therapy 
AL Artemether-Lumefantrine  
AMFm Affordable Medicines Facility-malaria 
ASAQ Artesunate-Amodiaquine 
BCC Behavior Change Communication 
CHPS Community Health Planning Services 
FDB Food and Drugs Board 
GHS Ghana Health Services 
Global Fund The Global Fund to Fight AIDS, Tuberculosis and Malaria 
GPS Global Positioning System 
IE Independent Evaluation 
IEC Information Education & Communication 
IRS Indoor Residual Spraying 
  xiii 
ITN Insecticide-Treated Nets 
LCS Licensed Chemical Seller / Shop 
LLITNs Long Lasting Insecticide Treated Nets 
MoH Ministry of Health 
NMCP National Malaria Control Program 
PPS Probability Proportional to Size 
QAACT Quality Assured ACT 
RBM Roll Back Malaria 
WHO World Health Organization  
SIVs Supporting Interventions 
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Chapter 1: Specific Aims 
The use of artemisinin-based combination therapies (ACTs), the most effective 
treatments for uncomplicated malaria, remains far below need. Reasons for low ACT 
uptake include: unreliable public sector supply; high prices and limited availability in the 
private sector, which is the most widely used source of treatment in many malaria 
endemic regions; and patient self-treatment with less expensive monotherapies. The 
Affordable Medicines Facility – malaria (AMFm), hosted by The Global Fund to Fight 
AIDS, Tuberculosis and Malaria, is a financing mechanism designed to increase 
affordability, availability, market share and use of quality assured artemisinin-based 
combination therapies (QAACTs). AMFm involves manufacturer price negotiations, 
factory gate price subsidies, and supporting interventions such as Information, Education 
and Communications (IE&C) campaigns.  
Between 2010 and 2012, the AMFm was implemented in 8 pilots including 
Ghana, where its outcomes were independently evaluated. The AMFm Independent 
Evaluation (IE) was commissioned to gather evidence needed to inform decisions 
regarding the future of the AMFm. As part of the IE, national level baseline and endline 
outlet surveys were conducted involving the collection and analysis of primary data to 
answer three questions related to the availability, affordability and market share of 
quality-assured ACTs using a cluster sampling approach.  
With a budget of up 450 million dollars and some uncertainty about its potential 
for success, AMFm was fraught with controversy, and provoked intense debate within the 
global health community on whether or not the program should be continued following 
the presentation of the IE findings to the Global Fund Board.  
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As some kind of "middle ground" stance, at the end of the 2-year pilot period of 
AMFm, in November 2012 the Global fund Board decided to integrate the AMFm into 
core Global Fund grant management and financial processes, following a transition 
period in 2013. In countries like Ghana, where the phase I pilot was shown to be highly 
successful, stakeholders were disappointed and angry with this decision, believing that 
the decision would reverse the gains made in availability and affordability of ACTs. The 
Global fund Board’s decision further meant eligible countries would decide whether or 
not to allocate funding from their core Global Fund grants to subsidies for ACTs, and 
Ghana has already indicated that it will be moving in this direction. 
Being a complex intervention, there are many aspects of the AMFm that can be 
researched. The purpose of this work is to contribute to the emerging body of knowledge 
on the outcomes of the AMFm in Ghana by exploring “why” and “how” the outcomes 
documented in the IE report came to be observed. The following specific aims are being 
pursued: 
 
Specific Aims 
1. In both the public and private sectors, to assess the differences in characteristics between 
outlets stocking QAACTs and those not having QAACTs in stock by exploring the 
relationship between having received training on co-paid QAACTs and stocking of 
QAACTs. 
2. To further examine pricing of QAACT by determining how retailer’s knowledge of the 
recommended retail price for QAACTs and other factors account for outlet’s adherence 
to their recommended retail price in the private-for-profit sector. 
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3. To identify differences between urban and rural outlets in the impact of training on 
knowledge of the recommended retail price for co-paid QAACTs in private-for-profit 
outlets.  
Findings from this project will shed light on the factors influencing the outcomes of 
the AMFm in Ghana and inform the implementation of subsequent interventions 
involving price subsidies on antimalarials and possibly other essential medicines in 
Ghana. 
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Chapter 2: Statement of Purpose and Background 
Introduction 
Malaria remains a leading parasitic cause of morbidity and mortality worldwide, 
accounting for almost one million deaths in 2011, 90% of which occurred in sub-Saharan 
Africa  (WHO, 2012). The malaria-causing Plasmodium parasite is transmitted from 
human to human by the bite of the female Anopheles mosquito.  
The entire Ghanaian population of 25 million lives at risk of malaria, and the 
disease accounts for 38.2% of all outpatient illnesses, 34.9% of all admissions, and 33.7% 
of all deaths in children under-five years (NMCP, 2010). The US Presidential Malaria 
Initiative (PMI) committed an amount of US$ 26,100,000 to malaria control activities in 
Ghana for 2013 (PMI, 2013). Also, over the past decade Ghana has received over US$ 
150,000,000 to fund the prevention and treatment of malaria from the Global Fund to 
Fight AIDS, Tuberculosis and Malaria (Global Fund) (The Global Fund, 2013).  
A high level of coverage in use of effective antimalarials has been recognized as 
critical to the overall success of malaria control efforts globally (White et al., 1999). As 
such the Ghana National Malarial Control Program (NMCP) has included in its national 
strategic plan for malaria to, by 2015, be treating 90% of malaria patients in both public 
and private facilities with effective antimalarials (MoH, 2008). 
Antimalarial policy and use 
The World Health Organization (WHO) specifically recommends artemisinin-
based combination therapies (ACTs) as first-line treatment for uncomplicated P. 
falciparum malaria1 (WHO, 2006). Artesunate-Amodiaquine (ASAQ) was therefore 
                                                 
1 Symptomatic infection with malaria caused by Plasmodium falciparum without evidence of vital organ 
dysfunction. P. falciparum is responsible for 98% of malaria infections in Africa. 
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selected by policy makers in Ghana as the first-line drug for uncomplicated malaria, 
following overwhelming evidence of widespread resistance to the previous first-line 
drugs, chloroquine and Sulphadoxine/Pyrimethamine (SP) (Driessen, Van Kerkhoven, 
Schouwenberg, Bonsu, & Verhave, 2002; Landgraf, Kollaritsch, Wiedermann, & 
Wernsdorfer, 1994; Trape et al., 1998). Artemether-Lumefantrine (AL) and 
Dihydroartemisinin-Piperaquine (DHAP) were later added as alternative first-line 
therapies for individuals who are intolerant to ASAQ (MoH, 2008). All the ACTs 
recommended in the national formulary have been declassified from prescription-only to 
over-the-counter medicines. ACTs can therefore be stocked, prescribed and supplied by 
all health providers, including practitioners in licensed retail medicine outlets like 
pharmacies and chemical shops (FDB, 2010).  
Despite these efforts, ACTs account for only one in five anti-malarial treatments 
taken and are provided almost entirely by the public sector (The Global Fund, 2012a), 
through which the most part of developmental assistance for health is channeled (Adeyi 
& Atun, 2010). Over 60% of patients access anti-malarial treatment through the private 
sector, where ACTs make up only 5% of treatments provided (The Global Fund, 2012a). 
The relatively high prices and limited availability of ACTs particularly in rural areas, 
encourage treatment with other more common and much cheaper antimalarials, and has 
contributed to the low uptake of ACTs (O. J. Sabot et al., 2009). Making ACTs more 
available and lowering the price paid by the end user, could therefore be an effective way 
to increase their uptake (Arrow, Panosian, & Gelband, 2004; Moszynski, 2008).  
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The Affordable Medicines Facility - malaria 
In 2002, the Board on Global Health of the Institute of Medicine (IOM) convened 
a committee to explore the economics of various treatment strategies for malaria. The 
committee published their report in 2004 advocating for a global subsidy on ACTs in 
both the public and private health sectors. This subsidy was to help ACTs outcompete 
older oral artemisinin monotherapies (AMTs)2 and other cheaper and ineffective non-
artemisinin therapies (nATs) on the market by making ACTs more available for use 
(Arrow et al., 2004).  
Mathematical models comparing the introduction of a subsidy on ACTs with 
counterfactual scenarios, strongly supported the recommendations for a global subsidy on 
ACTs put forward by the IOM report (R. Laxminarayan, Over, & Smith, 2006). This idea 
of a global antimalarial subsidy received widespread international media attention, 
including features on the BBC and the Voice of America and in The Lancet, British 
Medical Journal and Science (Enserink, 2007; Samarasekera, 2008; Tanne, 2006). 
The Bill & Melinda Gates Foundation funded the Finance and Resources 
Working Group of the Roll Back Malaria (RBM) Partnership, chaired by the World Bank 
to draft a technical design for the operationalization of a global antimalarial subsidy. The 
subsidy was to facilitate access to ACTs by: 1) reducing prices through negotiations with 
manufacturers in order to reduce the maximum “factory gate”3 price of the ACTs; 2) 
providing a co-payment on ACTs that meet specific quality standards at the top of the 
global ACT supply chain on behalf of eligible first-line buyers from the public, private 
                                                 
2 Persistent use of oral artemisinin monotherapies (AMTs) increases the risk of widespread parasite 
resistance to artemisinin, which remains the only widely effective first-line treatment. 
3 The factory gate price is technically known as the ex-works price, and is the price of a drug at the 
manufacturer warehouse excluding all transportation and import/export costs. 
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for-profit and private not-for-profit health sectors; and 3) supporting various other 
interventions promoting the appropriate use of ACTs (see Figure 1) (Adeyi & Atun, 
2010; RBM, 2007). This subsidy was to be administered by the Global Fund as a two-
year pilot project in a selected number of countries, and was labeled the “Affordable 
Medicines Facility – malaria phase I” (AMFm). 
Figure 1: Projected Effect of a Global Subsidy on ACT Prices 
 
 
MSP: Manufacturer Sales Price; AMFm: Affordable Medicines Facility-malaria 
Source: (Dalberg Global Development Advisors, 2007) 
 
 
Implementation of the AMFm 
Roll-out of the AMFm phase I was delayed till 2008, owing to key stakeholder’s 
uncertainty of the outcomes of this multidisciplinary complex health systems intervention 
(Ramanan Laxminarayan & Gelband, 2009). The AMFm Phase 1 pilot stated four 
objectives: 1) increased ACT affordability, 2) increased ACT availability, 3) increased 
ACT use, including among vulnerable groups, and 4) “crowding out” AMTs and nATs 
by gaining market share (The Global Fund, 2009b). The pilot cost approximately USD 
463 million, and funding covering the amount was made available by the Bill & Melinda 
 8 
 
Gates Foundation, the Governments of the United Kingdom and Canada, and UNITAID 
in addition to funds from the regular Global Fund grants to finance the supporting 
interventions at country level (Maxmen, 2012a; The Global Fund, 2008).  
Ghana was among eight countries successful in securing AMFm Phase I funding 
(Ghana CCM, 2009). Following Ghana’s approval, eligible wholesalers known as first-
line buyers (FLBs), signed contracts with the Global Fund and placed orders for the co-
paid ACTs with eligible manufacturers (The Global Fund, 2009b). Of the 32 Ghanaian 
FLBs who registered with the Global Fund, only 14 private sector FLBs and the MoH 
were able to place orders for co-paid ACTs, because manufacturers preferred working 
with FLBs with whom they had previous experience as local distributors or agents 
(AMFm IE Team, 2012). ACTs that were eligible for Global Fund co-pays had to be 
approved by the WHO Prequalification Programme (The Global Fund, 2010) and were 
referred to as Quality Assured ACTs (QAACTs).  
On September 02, 2010, the first co-paid QAACTs entered the Ghanaian private 
sector supply chain, and although scheduled to have begun earlier, Information Education 
& Communication (IEC) as well as Behavior Change Communication (BCC) activities 
commenced within that same month (J. Amuasi, Nguah, Diap, Ansong, & The 
Independent Evaluation Team, 2012).  
The AMFm Independent Evaluation and its limitations 
Although several smaller studies had been carried out to ascertain the impact that 
price subsidies and other related interventions could have on availability and price of 
antimalarials (Yamey, Schäferhoff, & Montagu, 2012), the AMFm was the first ever 
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large scale implementation of a subsidy scheme on medicines (Bump, Fan, Lanthorn, & 
Yavuz, 2012).  
The Global Fund developed a multi-faceted monitoring and evaluation framework 
for the AMFm Phase I. A key component of this framework was an Independent 
Evaluation (IE) to assess how AMFm played out in each pilot country. An Independent 
Evaluation team was contracted to conduct and measure changes between baseline and 
endline surveys in availability, price, market share and use of quality-assured ACTs 
(QAACTs). Evidence from the IE was to inform the Global Fund Board’s decision 
regarding the future of AMFm after the Phase I period (The Global Fund, 2009a).  
The IE was based on a non-experimental design, with pre- and post-test 
intervention assessment of key indicators and measurement of changes for rural and 
urban domains.  Tougher et al describe the data collection and analysis process (Tougher 
et al., 2012). In Ghana the baseline survey took place in August 2010, and the endline 
survey took place in November  2011 (J. Amuasi et al., 2012).  
The IE of AMFm phase I was focused on outputs and outcomes, although some 
effort was made to contextualize these by analysis of qualitative information on the 
AMFm implementation process in each country (The Global Fund, 2009a; Willey et al., 
2014). Nevertheless, apart from measuring changes in key indicators pre- and post-
intervention, an analysis of some aspects of the process; “how” and “why” the changes 
observed took place is lacking, and is critical to determining implementation failure, 
genuine ineffectiveness of an intervention or the best way forward (Craig et al., 2008; de 
Savigny & Adam, 2009; Habicht, Victora, & Vaughan, 1999).  
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Purpose of the Dissertation 
The gaps in understanding the AMFm and how it impacted the countries where it 
was piloted, allow several opportunities for further research. The ongoing interest in the 
AMFm and its incorporation into the core Global Fund grant management and financial 
processes means subsidies for antimalarial drugs will remain a subject of attention for the 
foreseeable future. In this regard additional understandings of the dynamics of the AMFm 
intervention are needed. 
This dissertation aims to improve understanding of “how” and “why” the AMFm 
had the impact it did in Ghana as elaborated in the IE report by: 1) exploring the 
relationship between various outlet characteristics and QAACT stocking in both the 
public and private sector; 2) further examining QAACT pricing by determining factors 
accounting for outlet’s adherence to their recommended retail price in the private-for-
profit sector; and 3) identifying differences between urban and rural outlets in the impact 
of training on knowledge of the recommended retail price for co-paid QAACTs in 
private-for-profit outlets. The malaria control policy implications of our findings are also 
discussed. 
 
Theory and Conceptual Model 
The AMFm IE identified increases in availability, affordability, market share and 
use of QAACTs as the desired outputs, and increase in access to and use of QAACTs as 
desired outcomes of the AMFm Phase I, as shown in Figure 2 (The Global Fund, 2009a). 
While these labels are appropriate, based on the pre-test and post-test intervention 
assessment design of the IE, the naïve reader may get the impression that the outputs and 
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by extension outcomes are “stacked on each other” or occur simultaneously. However, 
careful examination of these outputs/outcomes, as well as inputs (funds for ACT co-
payment and SIs) and processes (FLBs access to ACTs, country roll out of SIs etc.) 
reveals important relationships that can be examined to better explain why the observed 
outputs and outcomes. 
Figure 2: The AMFm (Phase 1) Monitoring and Evaluation Results Framework 
 
ACTs: Artemisinin-based combination therapies; IEC: Information Education and Communication; GF: Global Fund, 
AMTs: Antimalarial Treatment; SP: Sulfadoxine-pyrimethamine, CQ: Chloroquine; TA: Technical Assistance, SIVs: 
Supporting Interventions 
Source: (The Global Fund, 2009a) 
 
The conceptual model shown in Figure 3 depicts our hypothesized relationship 
between training and knowledge of the AMFm intervention and of the recommended 
retail price for the co-paid QAACTs. An important product/intermediary outcome of the 
country roll out of SIVs, particularly training of retailers, prescribers and dispensers, was 
 12 
 
the creation of knowledge about the AMFm intervention and the recommended retail 
price (RRP) for QAACTs. FLBs needed to actively seek out contracts with 
manufacturers, and outlets in turn needed to purchase from FLBs for retail to consumers. 
Thus, knowledge about the AMFm intervention was cardinal to achieving widespread 
availability of QAACTs. Knowledge is further hypothesized as being directly related to 
stocking of QAACTs and stocking of co-paid QAACTs at the RRP. 
 Stopping at this linear description of relationships would be overly simplistic, as 
there are several potential influencing factors/characteristics and interrelationships among 
them. As such we hypothesize that a number of geographic, socio-economic, malaria 
epidemiologic and other factors are also related to training, knowledge of the 
AMFm/RRP and stocking of QAACTs.  
The conceptual model is however limited to depicting only the relationships of 
interest and relevance to antimalarial policy in Ghana and mainly those which are 
measurable using the data available from the IE and other secondary sources.  
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Figure 3: Conceptual Model 
 
Note: The variables in the dashed blue boxes are not measurable from the data available. 
 
The data set 
Data from the AMFm Phase I independent evaluation endline survey in Ghana 
was used as the primary source of data used to achieve the aims outlined in this 
dissertation. The data collection, analysis process and findings of the IE endline survey 
are described in other sources (J. Amuasi et al., 2012; Tougher et al., 2012; Willey et al., 
2014). Shapefiles and other geographic information systems data on districts in Ghana 
were obtained from the Centre for Remote Sensing and Geographic Information Services 
of the University of Ghana via ESRI’s GeoCommons platform (CERSGIS, 2012). Data 
on Plasmodium falciparum malaria prevalence by district were obtained from the 2010 
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posterior predictive distribution model estimates produced by the Malaria Atlas Project 
(MAP). Further details on the MAP methodology are available from other publications 
(Gething et al., 2011; MAP, 2010). 
The IE endline survey data comprise information on 1,093 outlets and 7,389 
antimalarial products. We however excluded outlets which were not screened (n=91), did 
not meet the screening criteria (n=28), were not interviewed (n=6), did not fully complete 
the interview and antimalarial audit (n=3), a community health worker (n=1), and those 
that were private not-for-profit facilities (n=13) from the dataset. 
Antimalarials were divided into four broad categories; non-artemisinin therapies 
(nAT), artemisinin monotherapies (AMT), antimalarials no longer used for treatment but 
only for prophylaxis (nRx), and artemisinin-based combination therapy (ACT). nATs 
were classified into Sulphadoxine-pyrimethamine (SP - WHO recommended for 
intermittent preventive therapy in pregnancy [IPTp]), quinine (used for treating severe 
malaria), and other nATs. AMTs were classified into oral and non-oral AMTs. ACTs 
were subdivided into quality-assured ACTs (QAACTs) and non-quality-assured ACTs, 
and QAACTs were further classified based on whether or not the AMFm green-leaf logo 
was present on the packaging. The presence of the logo on a product’s packaging was 
used to identify those QAACTs which were subsidized by AMFm.  
The data used for this dissertation, including variables, is described in Table 1 
below. 
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Table 1: Distribution of outlet and respondent characteristics in AMFm IE dataset 
Characteristics 
*Type of outlet, n or N (%) 
Public Private All 
n = 303 
(31.9) 
n = 648 
(68.1) 
N = 951 
(100) 
Stocked an antimalarial 298 (98.4) 642 (99.1) 940 (98.8) 
Stocked at least 1 QAACT 242 (79.9) 563 (86.9) 805 (84.7) 
Stocked at least 1 co-paid QAACT 228 (75.3) 545(84.1) 773 (81.3) 
Stocked at least 1 SP or Quinine 175 (57.8) 436 (67.3) 611 (64.3) 
Stocked at least 1 oral AMT 5 (1.7) 348 (53.7) 353 (37.1) 
Stocked at least 1 nAT** 9 (3) 343 (52.9) 352 (37) 
Stocked at least 1 antimalarial used for prophylaxis or no longer 
used for treatment 0 19 (2.9) 19 (2) 
Stocked at least 1 co-paid QAACTs without stocking any AMTs or 
nATs** 215 (71) 130 (20.1) 345 (36.2) 
Malaria testing (microscopy/RDT) available 121 (39.9) 29 (4.5) 150 (15.8) 
At least 1 employee was a nurse, pharmacists or doctor 256 (89.8) 333 (53.5) 589 (65) 
At least 1 employee had a health-related qualification 281 (98.6) 435 (70.6) 716 (79.5) 
At least 1 employee had completed secondary/high school 293 (96.7) 598 (92.3) 891 (93.7) 
At least 1 employee received training on QAACTs with the logo 178 (58.8) 298 (46) 476 (50.1) 
Respondent owned the outlet - 237 (36.6) 237 (24.9) 
Respondent correctly stated the recommended first-line 
antimalarial 294 (97) 566 (87.5) 860 (90.5) 
Respondent correctly stated the max. RRP for co-paid QAACTs 262 (95.3) 535 (94) 797 (94.4) 
Respondent had heard about the AMFm intervention 263 (86.8) 499 (77) 762 (80.1) 
Respondent was able to recognize the AMFm logo 292 (96.4) 609 (94.4) 901 (94.7) 
Location Urban 95 (31.4) 474 (73.2) 569 (59.8) 
Rural 208 (68.7) 174 (26.9) 381 (40.2) 
Malaria epidemiologic zone§ 
Coastal 
savanna/Mangrove 
swamps 73 (24.1) 310 (47.9) 383 (40.3) 
Tropical rain forest 151 (49.8) 247 (38.1) 398 (41.9) 
Northern savanna 79 (26.1) 91 (14) 170 (17.9) 
Number of prescribers/dispensers 
employed 
1 - 2 141 (46.5) 381 (58.8) 522 (54.9) 
3 - 4 103 (34) 210 (32.4) 313 (32.9) 
5 or more 57 (18.8) 53 (8.2) 110 (11.6) 
Survey weighted mean number of prescribers/dispensers employed 
(95% CI) 3.4 (3.1, 3.7) 2.6 (2.5, 2.7) 2.8 (2.7, 3) 
Survey weighted mean number of antimalarials audited (95% CI) 4 (3.8, 4.3) 9.5 (9, 10) 7.7 (7.4, 8.2) 
  
*Percentages may not total 100 because of rounding or missing data 
**Excludes SP, Quinine, and those antimalarials used strictly for prophylaxis or no longer for treatment 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the Ghana 
Statistical Service  
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Importance of the dissertation to malaria research 
Right from its inception, the idea of a subsidy on antimalarials was subjected to 
intense debate among powerful stakeholders with differing opinions as to its feasibility 
and potential outcomes (A. Talisuna et al., 2009). The major concerns of opponents of the 
subsidy included the safety of widespread distribution of ACTs based on clinical 
diagnosis only, particularly in the private sector; and the cost-effectiveness of the AMFm 
relative to other malaria interventions. Therefore the final consensus to pilot the subsidy 
for 2 years as AMFm Phase I was reached with considerable effort from proponents of 
the subsidy (Ramanan Laxminarayan & Gelband, 2009; The Lancet, 2009).  
Even after the AMFm was launched, the debate on its viability continued (Adeyi 
& Atun, 2009; Bate, Milligan, & Mooney, 2012; Moon, Pérez Casas, Kindermans, de 
Smet, & von Schoen-Angerer, 2009; O. Sabot, Gordon, Moonen, Talisuna, & Amofah, 
2011; Siva, 2009). Critics continued to voice their opposition to the program (Bate & 
Hess, 2009; Kamal-Yanni, 2010), including challenging the approaches to measurement 
of the program’s effectiveness (Tren & Hess, 2011). Thus, before the Global Fund Board 
met to decide on what to do with AMFm (continue, amend or terminate), there was a 
renewed frenzy of debate on the subject (Maxmen, 2012a, 2012b), with critics tendering 
in what they believed was evidence justifying their concerns about the AMF intervention 
(Bate, Hess, et al., 2012; Kamal-Yanni, 2012). Supporters of the intervention were 
concerned that it would be terminated, despite what they touted as evidence from the 
independent evaluation that benchmarks of success had largely been achieved (Ramanan 
Laxminarayan, Arrow, Jamison, & Bloom, 2012). 
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As some sort of "middle ground" stance, at the end of the 2-year pilot period of 
the AMFm, in November 2012, the Global Fund Board decided to integrate the AMFm 
into core Global Fund grant management and financial processes, following a transition 
period in 2013 (The Global Fund, 2012b). This decision meant eligible countries would 
decide whether or not to allocate funding from their core Global Fund grants to subsidies 
for ACTs. Proponents of the AMFm were disappointed given what they believed was 
evidence of the success of the AMFm Phase I (Bump et al., 2012). Authors of the 2004 
IOM report that proposed the idea of a global subsidy on antimalarials labeled the 
decision as “effectively killing the AMFm program”, because countries Global Fund 
budgets are already committed to public sector priorities, and reallocating some of this to 
include private sector support would be most unlikely (Arrow et al., 2012).  
In countries like Ghana, where the phase I pilot was shown to be highly 
successful, stakeholders were concerned about the uncertainty that shrouded the AMFm 
Phase I as to its continuation or otherwise (Maxmen, 2012b; A. O. Talisuna et al., 2012). 
Thus, many were disappointed and angry with the Global Fund’s decision, believing that 
it would reverse the gains made in availability and affordability of ACTs. Concerns have 
also been raised about the implications the Global Fund Board’s decision has for the 
global supply of raw materials for ACTs, especially artemisinin (Shretta & Yadav, 2012). 
However, it is not clear as yet if the “final chapter in the AMFm’s story” has yet been 
written (Ramanan Laxminarayan & Gelband, 2009), as it depends on how countries 
respond to the new financing arrangement put forward by the Global Fund. 
This dissertation sheds light on some of what accounted for the findings of the 
AMFm IE in Ghana. It is critical to informing malaria policy and its implementation for 
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optimal outcomes. Some AMFm phase I countries including, Ghana, have expressed 
willingness to voluntarily commit some of their Global Fund allocation and other 
resources to antimalarial drug subsidies after the AMFm. Thus, knowing the critical 
components of success of the AMFm, and the pitfalls to avoid, is useful for the future 
design of further interventions involving subsidies for medicines and diagnostics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19 
 
Chapter 3: The AMFm in Ghana: Exploring Training and other Factors as 
Predictors of Stocking Practices 
Introduction 
The Affordable Medicines Facility-malaria (AMFm) phase 1 sought to increase 
the availability of quality-assured artemisinin-based combination therapies (QAACTs) in 
public and private health sector outlets. We examine the association between outlet and 
other characteristics and availability in public and private health sector outlets in Ghana 
following the AMFm intervention. 
We used data collected as part of the AMFm Independent Evaluation endline 
survey in Ghana. We used chi-square analyses and logistic regression to generate the 
predicted probability of whether an outlet had QAACTs available defined in three 
different ways: i) Stocked at least 1 QAACT, ii) Stocked at least 1 co-paid QAACT, and 
iii) Stocked at least 1 co-paid QAACT without stocking any oral artemisinin 
monotherapies or non-artemisinin therapies. Variables in the model included participation 
in training, education and health-related qualification, number of prescribers, availability 
of testing, rural/urban status and malaria epidemiologic zone. 
 Factors associated with QAACT availability in the 951 (31.9% public and 68.1% 
private sector) outlets included in our study differed between and within public and 
private sectors for the various QAACT availability definitions. While a high percentage 
of public (75.3%) and private (84.1%) outlets stocked at least 1 co-paid QAACT, there 
was a large disparity (71% vs. 20.1%) between the two sectors when not stocking 
artesunate monotherapies (AMTs) and non-artemisinin therapies (nATs) was included in 
the definition of QAACT availability. In the private sector, having received training was 
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associated with a high predicted probability of stocking at least 1 QAACT (85.2%, 
p=0.039) and stocking at least 1 co-paid QAACT (84.9%, p=0.020), but not with 
stocking co-paid QAACTs without stocking any AMTs or nATs” (22.9%, p=0.171). 
However in the public sector, training was not a statistically significant predictor of any 
definition of QAACT availability.  
Although high QAACT availability was achieved post the AMFm across public 
and private sector antimalarial markets in Ghana, predictors of antimalarial stocking vary 
considerably between the two sectors. The centralized nature of public sector commodity 
procurement and service delivery mechanisms makes it simpler to achieve adherence to 
antimalarial policy with respect to not stocking AMTs and nATs. The larger more 
complicated nature of the private sector antimalarial market makes it more difficult for it 
to be regulated, monitored and aligned with national policy. In-service training is 
generally an important tool towards improving QAACT stocking practices especially in 
the private sector. However, getting outlets to hire staff with health-related qualifications 
should be pursued as an effective long-term approach towards achieving ACT stocking 
benchmarks and recommended treatment practice.  
 
Background 
The entire Ghanaian population of over 25 million lives at risk of malaria, and 
transmission in Ghana occurs throughout the whole year with a slight increase during the 
rainy season (MoH, 2008, 2009b; NMCP, 2010). Data from mainly government health 
facilities shows that malaria accounts for 38.2% of all outpatient illnesses, 34.9% of all 
admissions, and 34% of all deaths in children under 5 years in Ghana (NMCP, 2010). As 
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with other malaria-endemic countries, these estimates of malaria burden may account for 
a small fraction of actual malaria infections, since a significant number may present for 
treatment in the private sector, particularly pharmacies and licensed chemical shops 
(Adeyi & Atun, 2010; J G Breman, 2001; Buabeng, Matowe, Smith, Duwiejua, & 
Enlund, 2010; PMI, 2011).  
Owing to widespread resistance to chloroquine and other long-serving 
antimalarials (Driessen et al., 2002; Landgraf et al., 1994; Trape et al., 1998), the World 
Health Organization (WHO) has specifically recommended artemisinin-based 
combination therapies (ACTs) as first-line treatment for uncomplicated P. falciparum 
malaria (WHO, 2006). The overall success of malaria control efforts in reducing 
morbidity and mortality from the disease depends in part on a high level of availability 
and use of these highly effective ACTs (Bhattarai et al., 2007; Otten et al., 2009). 
However, use of ACTs in several malaria endemic countries including Ghana has 
remained chronically low (Flegg et al., 2013), significantly below the levels needed to 
achieve favorable health outcomes (WHO, 2010b). 
Public and private sector outlets in many malaria endemic countries in sub-
Saharan Africa play complementary roles in providing access to antimalarial treatment 
(Littrell et al., 2011; O’Meara, Obala, Thirumurthy, & Khwa-Otsyula, 2013; Williams & 
Jones, 2004). However the two sectors function in different and complex ways, resulting 
in different kinds of challenges with regard to availability and accessibility of ACTs. For 
example it was reported both in East and West African countries that in the public sector, 
although outlets stocked ACTs, low uptake resulted more from frequent stock-outs. In 
contrast, private sector outlets hardly stocked any ACTs, and those that did, sold them at 
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much higher prices than other less effective antimalarials (J. H. Amuasi et al., 2012; J. 
Amuasi, Diap, et al., 2011; B. B. Kangwana et al., 2009; Zurovac et al., 2008). Yet in 
several malaria endemic countries, over 60% of malaria patients have no option other 
than to obtain their antimalarials via the private sector because of poor access to public 
sector facilities (Cohen et al., 2010; Goodman, Kachur, Abdulla, Bloland, & Mills, 2009; 
Littrell et al., 2011; The Global Fund, 2012a). Thus the high prices of ACTs in the private 
sector left them unaffordable to those who need them the most (Arrow et al., 2004; 
Cohen et al., 2010; Patouillard, Hanson, & Goodman, 2010; O. J. Sabot et al., 2009; A. 
Talisuna et al., 2009).  
In 2004, a committee convened by the US Institute of Medicine (IOM) published 
a report advocating for a global subsidy on ACTs in both the public and private health 
sectors (Arrow et al., 2004). This was even though traditionally, most developmental 
assistance for health has been channeled through the public sector (Adeyi & Atun, 2010). 
It was argued that a global subsidy on ACTs would help them outcompete other cheaper 
and ineffective antimalarials on the market by making ACTs more available and 
affordable (Arrow et al., 2004). Following intense debate on the feasibility of its 
implementation and expected outcomes (Ramanan Laxminarayan & Gelband, 2009), the 
Affordable Medicines Facility – malaria (AMFm) was initiated in 2008, administered by 
a dedicated secretariat at the Global Fund (Adeyi & Atun, 2010). The intervention was 
aimed at influencing markets, and did not involve any change in malaria treatment 
policies.  
The AMFm comprised: 1) price reductions through negotiations with 
manufacturers of ACTs; 2) providing a co-payment on behalf of eligible wholesalers 
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known as first-line buyers (FLBs), for ACTs that met specific quality standards; and 3) 
supporting interventions (SIVs) promoting the appropriate use of ACTs (Adeyi & Atun, 
2010). SIVs included training of prescribers/dispensers on how to treat uncomplicated 
malaria using existing policy-recommended ACTs with a focus on co-paid QAACTs. For 
easy identification, the Global Fund designed a logo depicting a green leaf (referred to as 
the “AMFm Logo”), which manufacturers with orders from FLBs printed on the 
packages and blisters they produced. ACTs that were eligible for purchase with Global 
Fund resources as part of the AMFm intervention had to be prequalified by the WHO 
Prequalification Programme (The Global Fund, 2010) and were referred to as Quality 
Assured ACTs (QAACTs).  
Making QAACTs widely available and removing non-ACTs from the market is a 
key policy goal of market-based malaria control interventions like the AMFm (Adeyi & 
Atun, 2009). The AMFm was designed to run as a two-year pilot project known as the 
“AMFm Phase I” in Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania 
(mainland and Zanzibar). The AMFm Phase 1 pilot had four objectives: 1) increased 
ACT affordability, 2) increased ACT availability, 3) increased ACT use, including 
among vulnerable groups, and 4) “crowding out” oral artemisinin monotherapies, 
chloroquine and sulfadoxine-pyrimethamine (SP) by gaining market share (The Global 
Fund, 2009b).  
The Global Fund initiated a multi-faceted monitoring and evaluation framework 
for the AMFm Phase I. A key component of this framework was an Independent 
Evaluation (IE) in each pilot country. The Independent Evaluation (IE) team was 
therefore commissioned to assess the achievement of the AMFm objectives by measuring 
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changes between baseline and endline surveys in availability, price, market share and use 
of QAACTs (AMFm IE Team, 2012; The Global Fund, 2009a). In Ghana the AMFm IE 
was national in scale, covering the country’s ten regions. The AMFm IE in Ghana 
showed that the promotion of the AMFm led to a high provider awareness of the 
intervention, logo, and recommended retail price (RRP) at endline (J. Amuasi et al., 
2012). Correspondingly, QAACT availability across all outlets in Ghana increased by 52 
percentage points, from 31% at baseline to 83% at endline (p<0.0001) (AMFm IE Team, 
2012; Tougher et al., 2012). See Appendix 1 for a summary of the AMFm outcomes in 
Ghana. 
This paper examines public and private sector outlet characteristics and how these 
characteristics are able to predict outlets that did and those that did not have QAACTs in 
stock. 
 
Methods 
Data source 
We used data collected as part of the AMFm IE endline survey in Ghana. The IE 
used a non-experimental design with pre- and post-test intervention assessment of key 
indicators and measurement of changes for rural and urban domains.  A cluster sampling 
approach was adopted with a predetermined number of geographic clusters selected with 
probability proportional to size. Other sources describe the IE data collection and analysis 
process in detail (J. Amuasi et al., 2012; Tougher et al., 2012). In Ghana the endline 
survey took place from November 7–28, 2011, 15 months after the baseline survey (J. 
Amuasi et al., 2012). Ethical clearance for the IE surveys in Ghana was obtained from the 
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Ghana Health Service Ethical Review Committee on Research Involving Human Subjects 
(ERCRIHS). The University of Minnesota Institutional Review Board (IRB) further 
determined that our study was using secondary data, did not meet the regulatory 
definition of research with human subjects, and so did not require IRB clearance. 
Data management 
The IE endline survey data comprise information on 1,093 outlets and 7,389 
antimalarial products. In our study, we included outlets that were enumerated and 
completed the interview regardless of whether or not they stocked antimalarials. 
Excluded from the sample were those outlets which were not screened, did not meet the 
screening criteria, were not interviewed, did not fully complete the interview and 
antimalarial audit, a community health worker, and those that were private not-for-profit 
facilities.  
We divided antimalarials into four broad categories; non-artemisinin therapies 
(nAT), artemisinin monotherapies (AMT), antimalarials no longer used for treatment but 
only for prophylaxis (nRx), and artemisinin-based combination therapy (ACT). nATs 
were classified into Sulphadoxine-pyrimethamine (SP - recommended by the WHO for 
intermittent preventive therapy in pregnancy [IPTp]), quinine (used for treating severe 
malaria), and other nATs. AMTs were classified into oral and non-oral AMTs. ACTs 
were subdivided into quality-assured ACTs (QAACTs) and non-quality-assured ACTs, 
and QAACTs were further classified based on whether or not the AMFm green-leaf logo 
was present on the packaging. The presence of the logo on a product’s packaging was 
used to identify those QAACTs which were subsidized by AMFm.  
 
 26 
 
Variables 
We measured QAACT availability in an outlet, in three different ways: i) The 
outlet “stocked at least 1 QAACT” (yes/no), ii) it “stocked at least 1 co-paid QAACT” 
(yes/no), and iii) it “stocked at least 1 co-paid QAACT without stocking any AMTs or 
nATs”, excluding those used strictly for prophylaxis, SP, and quinine, (yes/no). Having 
an employee who attended a training session on co-paid QAACTs was selected as the 
main potential independent predictor of QAACT availability. Ghana can be stratified into 
three main malaria epidemiologic zones: i) the northern savanna, ii) the tropical 
rainforest, and iii) the coastal savanna and mangrove swamps (GSS, 2011; MoH, 2009b) 
(see Appendix 2). We also evaluated the association between QAACT availability and 
other outlet-level characteristics, such as location features (malaria epidemiologic zone, 
rural/urban designation), availability of diagnostic testing, outlet size, and education level 
of outlet staff (see Table 2). 
Statistical approach 
The AMFm was the first major market-based intervention whose scope included 
the private sector along with the public sector.  Although interconnected and 
complementary, the fundamental differences in characteristics and operations between 
the public and private antimalarial markets in Ghana alluded to earlier, led us to stratify 
all analyses by public and private sector.  
For all analyses, we used the IE endline survey weights to account for the 
complex survey design used. We used chi-squared tests to assess the unadjusted 
relationship between our three definitions of QAACT availability and the independent 
variables listed in Table 2.  We followed with multivariate logistic regression and post-
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estimation techniques to determine the predicted probability of our three outcome 
definitions of QAACT availability. We adjusted for training, urban/rural status, and only 
those other variables that were statistically significant from our examination of the 
unadjusted relationships between independent variables and the outcomes. Thus, different 
models were specified for public and private sector outlets. Certain variables were 
excluded from consideration a priori. For example, the variable “respondent owned 
outlet” (yes/no) was not applicable in the model specified for the public sector. In all 
models, we performed sensitivity analyses to ensure that the observed effects were not an 
artifact of our modeling decisions (see Appendices 3 - 9). All analyses were carried out 
using STATA v12 and p-values were 2-sided with a level of significance of ≤ 0.05.  
 
Results 
Outlet characteristics 
From the AMFm IE dataset, we identified 951 outlets (87% of the IE dataset) that 
were enumerated and completed the interview; 31.9% were public sector outlets and 
68.1% were private sector outlets. Table 3 shows the distribution of the characteristics of 
the outlets included in this study. For public sector outlets, the majority were from rural 
areas (68.7%), whereas the opposite was true for private sector outlets, where 73.2% 
were from urban areas. With respect to malaria epidemiologic zones, half of public sector 
outlets were from the forest zone (49.8%), while the remaining half was equally 
distributed between the coastal (24.1%) and savanna (26.1%) zones. On the other hand, 
almost half of private sector outlets were from the coastal zone (47.9%) and 38.1% and 
14% were from the forest and savanna zones respectively. Hardly any outlets from the 
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private sector offered any kind of malaria testing (4.5%), whereas over one-third of 
outlets from the public sector had malaria testing available (39.9%).  
Table 4 shows the distribution of variables and survey weighted percentage of 
outlets with the three outcomes in public and private for-profit outlets. Without adjusting 
for other covariates, consistently, the proportion of outlets for all three outcome 
definitions was higher among urban outlets in the private sector, and vice versa in the 
public sector. The rural/urban location of the outlet had a relationship with stocking 
QAACTs and stocking co-paid QAACTs among private sector outlets only (p=0.026 and 
p=0.015 respectively).  Also without adjusting for other covariates, malaria 
epidemiologic zone was associated with all the outcome definitions across both public 
and private sector outlets except with stocking “at least 1 co-paid QAACT without 
stocking any AMTs or nATs” in the private sector (p=0.153). However the proportion of 
outlets with the outcomes did not follow a consistent pattern across malaria 
epidemiologic zones and/or outcome definitions. Availability of malaria testing was 
positively associated with only stocking “at least 1 co-paid QAACT without stocking any 
AMTs or nATs” in the private sector in our analysis without adjusting for other 
covariates. For private sector outlets, 36.6% of the survey respondents were the owners. 
We were concerned that owners might be more inclined to withhold information they 
might consider as casting their outlet in bad light. However there was no relationship 
between the interviewee’s ownership status and any of the outcome definitions. 
 In the private sector, a high number of outlets (92.3%) had at least one member 
of staff who had completed secondary/high school, which was positively associated with 
stocking at least 1 QAACT (p<0.001) and stocking at least 1 co-paid QAACT (p<0.001). 
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In outlets from the public sector, 84.5% had at least 1 member of staff who was formally 
trained and certified to prescribe or dispense medications (a nurse/midwife, 
pharmacist/dispensing technician or medical doctor/medical assistant); only 51.4% of 
outlets form the private sector had the same. Category of health-related qualification was 
positively associated with all the outcome definitions in only the private sector. 
 Almost half (46.5%) of the outlets from the public sector and over half (58.8%) 
of private sector outlets had 1-2 prescribers/dispensers, while 34% and 32.4% of public 
and private sector outlets respectively had 3-4 prescribers. Only 8.2% (53) of outlets from 
the private sector had 5 or more prescribers. All these larger outlets had at least 1 
QAACT in stock, and 52 out of 53 had at least 1 co-paid QAACT in stock. The category 
of number of prescribers was positively associated with all the outcome definitions in 
both sectors except with respect to stocking “at least 1 co-paid QAACT without stocking 
any AMTs or nATs”  in the public sector. At 3.6 (95% CI: 3.1 – 4), the survey weighted 
mean number of prescribers/dispensers per outlet was higher in the public sector than in 
the private sector at 2.2 (95% CI: 2.1 – 2.4). 
Training and antimalarial stocking practices 
Almost half (46%) of private sector outlets had at least one member of staff who 
had received training on the AMFm intervention, while 58.8% of public sector outlets 
had the same. Without adjusting for other covariates, training was a significant predictor 
of stocking at least 1 QAACT and stocking at least 1 co-paid QAACT in only the private 
sector (p=0.032 and p=0.020 respectively).  
With respect to achieving the three QAACT availability outcomes, the percentage 
of outlets in both public and private sectors decreased with increasing level of complexity 
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of the outcome definition:  In the public sector, 79.9% stocked at least 1 QAACT; 75.3% 
stocked at least 1 co-paid QAACT; and 71% stocked at least 1 co-paid QAACT without 
stocking any AMTs or nATs. A similar trend is seen in the private sector, with 86.9% of 
outlets stocking at least 1 QAACT; 84.1% stocking at least 1 co-paid QAACT; and a 
precipitous drop to 20.1% of outlets stocking at least 1 co-paid QAACT without stocking 
any AMTs or nATs. While only 1.7% and 3% public sector outlets stocked the non-
policy recommended AMTs and nATs respectively, disappointingly, 53.7% and 52.9% 
respectively of private sector outlets stocked AMTs and nATs.  
Predicted probability of stocking QAACTs after adjusting for other covariates 
Tables 5 and 6 show the adjusted probability of the various outcome definitions 
for outlets that “had an employee who received training on the AMFm QAACTs” 
(yes/no) in private and public sector outlets respectively. The adjusted probabilities of 
QAACT availability for the variable rural/urban and the other outlet and respondent 
characteristics that were statistically significant in the unadjusted analysis of weighted 
percentages of outlets with the outcomes (shown in Table 4), are also included in Tables 
5 and 6.  
 Although in the adjusted analysis, training remained a significant predictor of the 
first two outcomes (availability of QAACTs and co-paid QAACTs) in private sector 
outlets (p=0.039 and p=0.020), it was not a predictor of any of the outcomes in the public 
sector. On the other hand, “Category of highest health-related qualification or training of 
at least 1 staff” was a highly significant predictor of all definitions of QAACT 
availability among both private and public outlets. For all outcome definitions, the 
predicted probability of QAACT availability in private sector outlets increased from 
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those that had at least 1 staff with no health-related qualification, to those that had 
qualifications other than for prescribing or dispensing, to those that had formally trained 
prescribers/dispensers. However the trend in association between health-related 
qualification and our outcomes was the opposite in public sector outlets, although all 
outlets had at least one employee with a health-related qualification.  
 After adjusting for other covariates, the number of prescribers/dispensers in an 
outlet remained a significant predictor of QAACT availability in public sector outlets 
irrespective of how it was defined. Outlets with higher numbers of prescribers had a 
higher predicted probability of the outcomes. On the other hand, among private sector 
outlets, though the trend in association was the same as in the public sector, the number 
of prescribers/dispensers was a significant predictor only of stocking “at least 1 co-paid 
QAACT without stocking any AMTs or nATs” (p=0.001).  
Both the public and private sector show interesting variation by effect and trend 
with respect to malaria epidemiologic zone after adjusting for covariates in the separate 
models. In the private sector for instance, although not statistically significant, there was 
a positive correlation between malaria epidemiologic zone and the outcomes: “stocked 
QAACTs” and “stocked co-paid QAACTs” i.e. predicted probability of the two outcomes 
increased from the northern zone through to the coastal zone. However the direction of 
this correlation was reversed for our most conservative outcome measure; stocked “at 
least 1 co-paid QAACT without stocking any AMTs or nATs”, and this was statistically 
significant (p=0.011). In the public sector however, malaria epidemiologic zone remained 
a significant predictor of all definitions of QAACT availability. The pattern of predicted 
probability being highest in the northern savanna zone, followed by the coastal zone and 
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then the forest zone having the relatively lowest predicted probability, was consistent 
across all the outcome definitions in the public sector.  
 
Discussion 
 The AMFm Phase 1 pilot involved a factory-gate subsidy on “green leaf logo” 
branded, quality-assured ACTs (QAACTs), and one of the objectives of the intervention 
was to “increase ACT availability” (The Global Fund, 2009b). Therefore in this study, we 
declared the outcome of interest broadly as the availability of quality-assured ACTs 
(QAACTs) in an outlet, and further examined this outcome with specific reference to 
availability of QAACTs with the AMFm “green leaf logo” (co-paid ACTs). However 
another objective of the AMFm intervention with respect to availability was to “crowd 
out” oral artemisinin monotherapies (AMTs) and non-artemisinin therapies (nATs). Thus 
we further scrutinized the intervention by investigating to what degree outlets stocked at 
least 1 co-paid QAACT without stocking any AMTs or nATs.  
Pre-existing differences in characteristics and the complex interconnectedness of 
the public and private antimalarial markets in Ghana, may explain why even carefully 
thought out and executed interventions like the AMFm yielded varying degrees of 
success across sectors. For example, as has been shown in many sub-Saharan countries 
(Albertini et al., 2012), including Ghana (Chandler, Whitty, & Ansah, 2010), malaria 
testing was barely available in the private sector  (4.5% of outlets), while 40% of public 
sector outlets offered malaria testing. Also, while a high percentage of public (75.3%) 
and private (84.1%) outlets stocked at least 1 co-paid QAACT, a large difference 
between the two sectors emerged (71% vs. 20.1%) when not stocking AMTs and nATs 
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was included in the outcome definition. Thankfully, only 1.7% and 3% of public sector 
outlets stocked AMTs and nATs respectively, while deplorably, 53.7% and 52.9% of 
private sector outlets stocked the same. These findings indicate that despite high QAACT 
availability in the private sector, the desired policy goal of crowding out AMTs and nATs 
requires further attention. 
We found that at the time of the interview and antimalarial audit, 80% and 87% of 
public and private sector outlets respectively stocked at least 1 QAACT. Furthermore, 
only 5.8% (14) of public, and 3.2% (18) of those private sector outlets that stocked at 
least 1 QAACT, did not stock any co-paid QAACTs. This is encouraging, and 
maintaining a reliable supply-chain while minimizing the shortage (stock-out) of ACTs in 
outlets is an important component of market-based malaria interventions such as the 
AMFm and a key ingredient for success (Cohen et al., 2010; Kindermans, Pilloy, Olliaro, 
& Gomes, 2007; Shretta & Yadav, 2012; Yadav et al., 2012). Only 1.65% of public and 
1.78% of private sector QAACT stocking outlets had experienced shortages (stock-outs) 
for at least 1 day in the last 7 days leading up to the interview and antimalarial audit. 
These low stock-out levels are encouraging, contrary to the documented pattern of 
frequent stock-outs of ACTs, in both public and private sector outlets (J. H. Amuasi et al., 
2012; B. B. Kangwana et al., 2009; Zurovac et al., 2008), and are a positive find 
suggestive of a stable antimalarial supply chain in Ghana. 
While various supporting interventions within the framework of a large 
intervention such as the AMFm, have the potential to modify key provider/outlet and 
consumer characteristics to enhance desired outcomes, other characteristics cannot easily 
be modified. For example malaria epidemiologic zone, rural urban differences, and 
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variation in number of prescribers/dispensers have the potential to impact on the 
outcomes of complex interventions like the AMFm. Nevertheless, policy makers need an 
understanding of how both the modifiable and less-modifiable characteristics of 
providers/outlets and consumers, their geographies, and economies function, so as to 
inform the design and implementation of effective interventions such as the AMFm 
(Craig et al., 2008; de Savigny & Adam, 2009; Habicht et al., 1999). Understanding 
factors accounting for the outcomes of the AMFm in Ghana is additionally important, 
considering that the Ghana Ministry of Health has indicated its willing to commit some of 
its Global Fund resources to antimalarial drug subsidies after the AMFm.  
For the implementation of malaria control interventions to be successful, it is 
critical that both providers and consumers are empowered with adequate knowledge, 
which can be achieved through training (B. P. Kangwana et al., 2013). In a recent 
systematic review, Wafula et al show that knowledge is able to induce compliance/action, 
whether it be using ACTs, adhering to treatment regimen, or purchasing and sleeping 
under bed nets (Wafula, Miriti, & Goodman, 2012). Key supporting interventions to the 
AMFm included training staff of both public and private sector outlets on the need to use 
QAACTs for treating uncomplicated malaria and on the green leaf logo as and identifier 
for the co-paid QAACTs (J. Amuasi et al., 2012; RBM Partnership, 2013; Tougher et al., 
2012).  
From our adjusted analysis in the private sector, training was a predictor of 
stocking QAACTs in general and specifically, co-paid QAACTs. Similar to our findings, 
a study conducted by the Clinton Health Access Initiative in Madagascar, another AMFm 
phase 1 pilot country, showed that in the private sector, training via academic detailing 
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was directly linked to an increase in ACT stocking (Ward, Lesage, Morris, Lam, & 
Cohen, 2012). The importance of training in the private sector is further emphasized by 
the positive correlation between training and even the very conservative outcome 
definition of stocking at least 1 co-paid QAACT without stocking any AMTs or nATs, 
although this was not statistically significant (p=0.171).  
Our findings further suggest that while trainings such as workshops and seminars 
might be important for improving availability of recommended ACTs in private sector 
outlets, training alone might not suffice if removal of AMTs and nATs from their shelves 
is to be achieved. Research carried out among private sector outlets in Uganda (also an 
AMFm phase 1 pilot country) showed that although shop assistants were less likely to 
attend training sessions, those that attended did not necessarily have any higher 
probability of being able to correctly identify the recommended first-line treatment than 
those who did not attend (Rusk et al., 2012). Another Uganda-based study  also showed 
that malaria in-service training did not significantly predict health worker selection of an 
ACT for treating uncomplicated malaria (Zurovac et al., 2008). Thus it is possible that 
since training focused on the AMFm QAACTs, it might be associated with stocking 
QAACTs, but might not necessarily be associated with a deep knowledge about malaria 
treatment, allowing outlets to persist in stocking the non-recommended AMTs and nATs.  
The insignificance of training for predicting any of our outcomes in public sector 
outlets is however not surprising. This is because in the public sector, stocking decisions 
are made centrally (at district and regional level). Thus the presence or absence of 
training becomes less important for predicting stocking in the public sector. In the private 
sector however, stocking decisions are often made by the outlet owner or manager in 
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consultation with prescribers/dispensers and based on consumer demand, reflected by 
sales figures.  
While basically high QAACT availability was achieved post the AMFm across 
both sectors, the centralized nature of public sector commodity procurement and service 
delivery mechanisms makes it simpler to achieve adherence to antimalarial policy with 
respect to not stocking AMTs and nATs. On the other hand private sector procurement is 
largely driven by demand and profit margins (Shretta & Yadav, 2012). Approaches to 
improving policy adherence in the private sector, such as imposing severe penalties on 
importers of oral AMTs and nATs, coupled with explicit campaigns vilifying their use for 
the treatment of uncomplicated malaria, are therefore worth considering by policy 
makers. As of now, most campaigns have focused on the positives of using QAACTs 
without stressing much on the negatives of using AMTs and nATs. Negative 
campaigning as a means of modifying demand and supply patterns has been shown to be 
successful in many spheres, including where health, public policy, and politics intersect 
(Beaudoin, Fernandez, Wall, & Farley, 2007; Dixon, Scully, Wakefield, White, & 
Crawford, 2007; Emery, Szczypka, Powell, & Chaloupka, 2007; Frieden, Dietz, & 
Collins, 2010; Hanenberg & Rojanapithayakorn, 1998; Hoffman, 2003; Kearney, 2010; 
Orleans, 2007; Wakefield, Loken, & Hornik, 9). 
Almost 100% of staff in public sector outlets had a health-related qualification as 
against 67% of private sector outlets. The positive and statistically significant trend in the 
relationship between health-related qualifications and all definitions of QAACT 
availability in the private sector is consistent with the impact of training on our stocking 
outcomes. It is therefore reasonable to infer that in the private sector, the more 
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sophisticated the retailer (having received training on co-paid QAACTs and having a 
health-related qualification), the more likely they were to have positive stocking out 
comes.  
In the public sector however, although also statistically significant we found a 
negative trend in the relationship between health qualification and stocking outcomes. 
Although all public sector outlets by default have at least 1 employee with some health-
related qualification, we found that those outlets with an employee formally trained to 
prescribe or dispense medications had lower predicted probabilities of the outcomes 
compared to outlets with only employees without formal training or certification for 
prescribing or dispensing medications. While this negative association is counter intuitive 
and requires further analyses to explain, it at least indicates how differently from each 
other the public and private sectors behave. 
Although slightly different with respect to the outcome measure, private sector 
findings are echoed by other research. A recent study conducted among private sector 
outlets in Uganda showed that having a formal health-related qualification significantly 
predicted correctly identifying policy recommended antimalarials (Rusk et al., 2012). An 
older study also conducted in Uganda, showed that being a formally trained health 
worker significantly predicted selection of an ACT for treatment (Zurovac et al., 2008). 
The importance of health-related qualification and training in the private sector is 
further reflected in the association between availability of malaria testing and the 
outcome: “stocked at least 1 co-paid QAACT without stocking any AMTs or nATs”. 
Based on this association, although further analyses are required, we hypothesize that an 
outlet with qualified and/or trained personnel is more likely to recognize the importance 
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of testing before treating malaria, and so will offer testing. By extension, staff in outlets 
where tests are available are also likely to know the recommended treatment to offer, and 
therefore would stock co-paid QAACTs and not AMTs or nATs. 
Our study also showed that the number of dispensers/prescribers was significantly 
positively associated with all QAACT stocking measures in the public sector. Here, for 
all three stocking outcome definitions, outlets that had 3-4, and those that had 5 or more 
prescribers/dispensers, had the same predicted probabilities of the stocking outcomes, 
both of which were about 20% higher than that for outlets with 1-2 
prescribers/dispensers. This lower probability of the outcomes in smaller public sector 
outlets could reflect the increased opportunity for non-adherence to policy and for 
malfeasance among outlets with just 1 or two staff, coupled with lower levels of central 
supervision, given that these are often found in more rural and hard-to-reach areas. In the 
private sector however, number of dispensers/prescribers was significantly associated 
only with stocking “at least 1 co-paid QAACT without stocking any AMTs or nATs”. 
Nevertheless we found a generally positive correlation between increasing number of 
dispensers/prescribers and the probability of the stocking outcomes. In a related study 
following the AMFm in Kenya, O’Meara et al also showed that a higher number of 
prescribers in an outlet was associated with more desirable stocking practices (O’Meara 
et al., 2013). Our findings suggest that efforts at improving QAACT stocking need to pay 
special attention to smaller outlets with less than 5 prescribers/dispensers.  
The coastal and forest zones include Accra (the capital) and Kumasi respectively, 
which are both bustling cities with high economic activity. Both zones also contain most 
of the economic wealth of the country, and their inhabitants generally have higher 
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socioeconomic status relative to the northern savanna zone. Malaria prevalence is 
generally highest in the northern savanna zone and lowest in the coastal zone (GSS, 
2011). The co-paid QAACTs were much more affordable than other QAACTs, AMTs 
and most nATs (J. Amuasi et al., 2012). From the above, taking malaria prevalence and 
socio-economic status into consideration, in the private sector, the higher probability of 
stocking “at least 1 co-paid QAACT without stocking any AMTs or nATs” in the 
northern savanna zone relative to the coastal (lowest probability) and forest zones is 
understandable. It is also possible that in the coastal and forest zones where people are 
wealthier, the less expensive co-paid QAACTs were perceived to be less “powerful” than 
the well-known, more expensive non-subsidized QAACTs without the logo, AMTs or 
nATs. Therefore if consumers could afford the better known, more expensive 
antimalarials, they might have preferred to buy them over the much less expensive 
AMFm co-paid QAACTs. Prescribers and dispensers eager to exhaust their stock of 
relatively more expensive AMTs and nATs were perhaps also more likely to recommend 
and sell them to consumers whom they perceived as having greater purchasing power.  
We had earlier asserted that adherence to antimalarial policy was more easily 
achieved in the public sector, owing to the centralized nature of public sector commodity 
procurement and service delivery mechanisms. The combination of central control 
stocking choice constraints, affordability of the co-paid QAACTs relative to AMTs and 
nATs, together with the generally lower purchasing power in the northern zone, may 
account for it having the highest predicted probability for all definitions of the QAACT 
stocking outcomes. However this hypothesis does not fit with our observation of the 
forest zone having a lower predicted probability of stocking QAACTs defined in any way 
 40 
 
compared to the coastal zone, given that the coastal sector is arguably wealthier than the 
forest zone. It could be that a combination of various geographic, socio-economic, and 
public sector ease of policy implementation factors interact in more complicated ways to 
yield this picture, calling for further research. 
There are a number of limitations to our study. We are constrained to explaining 
stocking of QAACTs primarily using variables available from the AMFm endline IE 
survey. There are additional factors that may explain QAACT stocking, such as 
variations in socio-economic standing of surveyed clusters, which we could not include 
in our models. In Ghana epidemiologic zones with higher malaria prevalence levels are 
often found in areas of low socio-economic status (Gardiner, Biggar, Collins, & 
Nkrumah, 1984). Nevertheless factors such as local population density, fever prevalence 
and measures of wealth have been suggested to have no correlation with ACT stocking 
and sales practices (O’Meara et al., 2013).  
Another limitation of concern is that some of the data obtained with respect to 
outlet characteristics was reported by respondents and was not directly observed, 
increasing the risk of reporting bias. Of particular concern are the data on training and 
qualifications, where over-reporting has been recognized in similar studies as a challenge 
(Rusk et al., 2012). It is also important to bear in mind that determinants of stocking 
practices may differ from determinants of prescribing/dispensing practice, and from 
determinants of use patterns. Antimalarial use patterns are what directly impacts on 
malaria morbidity and mortality.  
Our research findings confirm that while the private and public antimalarial 
markets are interconnected and complimentary in nature, the private sector market is 
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much larger and less aligned with national policy. The complicated nature of the private 
sector makes it difficult to regulate and monitor. We also find that predictors of 
antimalarial stocking vary considerably between the two sectors. These variations call for 
different approaches or emphasis to be placed on various aspects of interventions like the 
AMFm in the public and private sectors.  
While especially in the private sector, “in-service” training was generally shown 
to be an important tool towards improving ACT stocking practices and should continue to 
be promoted. Getting outlets to hire staff with health-related qualifications should also be 
pursued as an effective longer-term approach towards achieving ACT stocking 
benchmarks and recommended treatment practice. Also, in carrying out training, extra 
effort must be made to ensure that smaller outlets (especially those with 1-2 employees) 
are specially targeted and covered. 
This work is an important addition to the gradually expanding body of knowledge 
being gathered from the AMFm experience in the various pilot countries and, is of 
importance as several countries consider the best use of their Global Fund malaria 
allocations, including towards subsidies on ACTs in both their public and private sectors.  
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Table 2: Independent variables 
Independent variables 
Categories 
Main predictor variable 
An employee from the outlet received training on QAACTs 
with the logo 
Yes/No 
Other variables 
Malaria testing (microscopy/RDT) available Yes/No 
Respondent owned the outlet Yes/No 
At least 1 employee had completed secondary/high school Yes/No 
Location Rural/Urban 
Malaria epidemiologic zone* Coastal/ Forest/ Savanna 
Highest health-related qualification of at least one 
employee 
None/ Not trained or certified to 
prescribe or dispense¢/ Trained or 
certified to prescribe or dispenseº 
Number of prescribers/dispensers employed 1-2/ 3-4/ 5 or more 
  
*Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by 
the Ghana Statistical Service  
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical 
doctor/medical assistant 
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Table 3: Unweighted distribution of outlet characteristics 
Characteristics 
*Type of outlet, n or N (%) 
Public Private All 
n = 303 
(31.9) 
n = 648 
(68.1) 
N = 951 
(100) 
Stocked an antimalarial 298 (98.4) 642 (99.1) 940 (98.8) 
Stocked at least 1 QAACTs 242 (79.9) 563 (86.9) 805 (84.7) 
Stocked at least 1 co-paid QAACTs 228 (75.3) 545(84.1) 773 (81.3) 
Stocked at least 1 SP or Quinine 175 (57.8) 436 (67.3) 611 (64.3) 
Stocked at least 1 oral AMT 5 (1.7) 348 (53.7) 353 (37.1) 
Stocked at least 1 nATs** 9 (3) 343 (52.9) 352 (37) 
Stocked at least 1 antimalarial used for prophylaxis or no longer 
used for treatment 0 19 (2.9) 19 (2) 
Stocked at least 1 co-paid QAACTs without stocking any AMTs 
or nATs** 215 (71) 130 (20.1) 345 (36.2) 
An employee from the outlet received training on QAACTs with 
the logo 178 (58.8) 298 (46) 476 (50.1) 
Malaria testing (microscopy/RDT) available 121 (39.9) 29 (4.5) 150 (15.8) 
Respondent owned the outlet N/A 237 (36.6) 237 (24.9) 
At least 1 employee had completed secondary/high school 293 (96.7) 598 (92.3) 891 (93.7) 
Location Urban 95 (31.4) 474 (73.2) 569 (59.8) 
Rural 208 (68.7) 174 (26.9) 381 (40.2) 
Malaria 
epidemiologic zone§ 
Coastal savanna/Mangrove swamps 73 (24.1) 310 (47.9) 383 (40.3) 
Tropical rain forest 151 (49.8) 247 (38.1) 398 (41.9) 
Northern savanna 79 (26.1) 91 (14) 170 (17.9) 
Category of highest 
health-related 
qualification 
Non-health-related 2 (0.7) 181 (27.9) 183 (19.2) 
¢No formal training or certification for 
prescribing or dispensing medications 27 (8.9) 102 (15.7) 129 (13.6) 
ºFormally trained to prescribe or 
dispense medications 256 (84.5) 333 (51.4) 589 (61.9) 
Number of 
prescribers/dispensers 
employed 
1 - 2 141 (46.5) 381 (58.8) 522 (54.9) 
3 - 4 103 (34) 210 (32.4) 313 (32.9) 
5 or more 57 (18.8) 53 (8.2) 110 (11.6) 
Survey weighted mean number of prescribers/dispensers 
employed (95% CI) 3.6 (3.1, 4) 2.2 (2.1, 2.4) 2.4 (2.2, 2.5) 
Survey weighted mean number of antimalarials audited (95% CI) 4 (3.6, 4.4) 7.3 (6.6, 7.9) 6.9 (6.2, 7.5) 
  
*Percentages may not total 100 because of rounding or missing data 
**Excludes SP, Quinine, and those antimalarials used strictly for prophylaxis or no longer for treatment 
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical doctor/medical 
assistant 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the Ghana 
Statistical Service  
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Table 4: Survey weighted percentage of outlets with the outcomes 
Variables 
Stocked some QAACTs Stocked some co-paid QAACTs 
Stocked some co-paid 
QAACTs without stocking 
any AMTs or nATs 
Private, N = 
563 
Public, N = 
242 
Private, N = 
545 
Public, N = 
228 
Private, N = 
130 
Public, N = 
215 
w% p-value w% p-value w% p-value w% 
p-
value w% p-value w% 
p-
value 
At least 1 employee from the 
outlet had received training 
on QAACTs with the logo 
Yes 86.1 
*0.032 
77.8 
0.824 
84.8 
*0.020 
73.6 
0.989 
23 
0.144 
69.9 
0.961 
No 75.3 79.1 73 73.6 18.1 70.2 
Malaria testing 
(microscopy/RDT) available 
Yes 88.4 0.352 77.9 0.565 
88.5 
0.256 
70.2 
0.303 
54.5 
*0.000 
66.1 
0.287 
No 81.3 80.9 79.3 77.8 18.6 73.9 
Respondent owned the outlet Yes 78.9 0.190 - - 
77.6 
0.369 - - 
19.7 
0.696 - - 
No 83.2 - 80.8 - 20.9 - 
At least 1 employee had 
completed secondary school 
Yes 83.4 *0.000 - - 
81.7 
*0.000 - - 
20.1 
0.731 - - 
No 62.2 - 59.8 - 22 - 
Category of highest health-
related qualification 
Non-health-related 72.9 
*0.000 
- 
0.070 
71.2 
*0.000 
- 
0.116 
14.3 
*0.002 
- 
*0.047 
¢No formal training or 
certification for 
prescribing or 
dispensing 
medications 
80.4 91.7 78.8 85.6 21.5 85.6 
ºFormally trained to 
prescribe or dispense 
medications 
94.7 78.9 92.7 74.7 28.4 71.5 
Number of 
prescribers/dispensers 
employed 
1 - 2 79.2 
§0.040 
71.5 
*0.007 
77.5 
*0.004 
65.6 
*0.007 
19 
*0.000 
63.9 
0.075 3 - 4 86.2 84.4 83.5 80.8 19.1 75.5 
5 or more §- 89 97.2 83.3 44.7 76.9 
P-values were derived from χ2 tests of significance for differences in the survey weighted distribution of each variable for the outcomes, between its categories. 
"Yes", "Non-health-related", "1 -2", "Rural", and "Coastal savanna" were reference groups. This is analogous to "univariate" logistic regressions 
*Statistically significant p-value (≤0.05) 
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical doctor/medical assistant 
§All 53 private sector outlets with more than 5 prescribers stocked at least 1 QAACT and so were excluded by STATA from the analysis 
**Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the Ghana Statistical Service 
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Table 4 (Continued): Survey weighted percentage of outlets with the outcomes 
Variables 
Stocked some QAACTs Stocked some co-paid QAACTs 
Stocked some co-paid 
QAACTs without stocking 
any AMTs or nATs 
Private, N = 
563 
Public, N = 
242 
Private, N = 
545 
Public, N = 
228 
Private, N = 
130 
Public, N = 
215 
w% p-value w% p-value w% p-value w% 
p-
value w% p-value w% 
p-
value 
Location Rural 74.1 *0.026 82.6 0.181 
71.4 
*0.015 
76.2 
0.536 
17.5 
0.237 
73.9 
0.269 
Urban 85.4 72.3 83.9 70.6 21.9 63 
Malaria epidemiologic 
zone** 
Coastal savanna 86.5 
*0.024 
79.4 
*0.032 
84.6 
*0.029 
73.1 
*0.031 
16.6 
0.153 
66 
*0.007 Tropical rain forest 82.5 73 80.4 67.4 22.8 62.8 
Northern savanna 67.2 91.6 65.7 89 22.5 89 
P-values were derived from χ2 tests of significance for differences in the survey weighted distribution of each variable for the outcomes, between its categories. 
"Yes", "Non-health-related", "1 -2", "Rural", and "Coastal savanna" were reference groups. This is analogous to "univariate" logistic regressions 
*Statistically significant p-value (≤0.05) 
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical doctor/medical assistant 
§All 53 private sector outlets with more than 5 prescribers stocked at least 1 QAACT and so were excluded by STATA from the analysis 
**Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the Ghana Statistical Service 
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Table 5: Adjusted probability of outcomes in PRIVATE sector outlets 
Variables 
Stocked at 
least 1 
QAACT 
Stocked at 
least 1 co-
paid QAACT 
Stocked at 
least 1 co-
paid QAACT 
without 
stocking any 
AMTs or 
nATs 
N = 563 N = 545 N = 130 
Pr 
p-
value Pr 
p-
value Pr 
p-
value 
At least 1 employee from 
the outlet received training 
on QAACTs with the logo 
Yes 85.2 
*0.039 
84.9 
*0.020 
22.9 
0.171 
No 76.6 75.8 18 
Malaria testing 
(microscopy/RDT) 
available 
Yes 74.4 
0.445 
78.3 
0.767 
48.4 
*0.000 
No 81.3 80.8 19.2 
At least 1 employee had 
completed secondary school 
Yes 81.6 0.513 
81.3 
0.371 
19.7 
0.056 
No 78.5 76.8 33.6 
Category of highest health-
related qualification 
Non-health-related 75 
*0.000 
74.6 
*0.000 
13.8 
*0.006 
¢No formal training or 
certification for 
prescribing or 
dispensing 
medications 
78.5 78.6 25.3 
ºFormally trained to 
prescribe or dispense 
medications 
92.9 91.1 27.4 
Number of 
prescribers/dispensers 
employed 
1 - 2 80.6 
§0.450 
80.3 
0.217 
20.9 
*0.001 3 - 4 83.8 81.2 16.5 
5 or more §- 92.3 35.6 
Location Rural 80.1 0.620 
79 
0.465 
17.1 
0.136 
Urban 82 81.9 22.6 
Malaria epidemiologic 
zone** 
Coastal savanna 83.6 
0.348 
82.1 
0.344 
16 
*0.011 Tropical rain forest 81.7 81.8 22.2 
Northern savanna 76.1 75.8 30.5 
P-values were derived from χ2 tests of significance of the differences in adjusted survey weighted 
predicted probabilities of the outcomes for the categories of each variable. "Yes", "Non-health-related", "1 
-2", "Rural", and "Coastal savanna" were reference groups 
*Statistically significant p-value (≤0.05) 
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical 
doctor/medical assistant 
§All 53 private sector outlets with more than 5 prescribers stocked at least 1 QAACT and so were excluded 
by STATA from the analysis 
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Table 6: Adjusted probability of outcomes in PUBLIC sector outlets 
Variables 
Stocked at 
least 1 
QAACT 
Stocked at 
least 1 co-paid 
QAACT 
Stocked at 
least 1 co-
paid QAACT 
without 
stocking any 
AMTs or 
nATs 
N = 242 N = 228 N = 215 
Pr p-value Pr p-value Pr p-value 
At least 1 employee 
from the outlet received 
training on QAACTs 
with the logo 
Yes 79.1 
0.974 
74.1 
0.823 
71.5 
0.905 
No 79.2 75.7 72.4 
Category of highest 
health-related 
qualification 
Non-health-related N/A 
*0.006 
N/A 
*0.007 
N/A 
*0.002 
¢No formal training 
or certification for 
prescribing or 
dispensing 
medications 
93.6 90.4 90.5 
ºFormally trained to 
prescribe or dispense 
medications 
77.2 72.9 69.7 
Number of 
prescribers/dispensers 
employed 
1 - 2 69.4 
*0.001 
64.7 
*0.005 
62.6 
*0.007 3 - 4 87.2 83.2 79.9 
5 or more 87.3 83.1 79.2 
Location Rural 81.5 0.294 
74.8 
0.978 
72.6 
0.794 
Urban 73.7 74.5 70.3 
Malaria epidemiologic 
zone** 
Coastal savanna 79.4 
*0.029 
71.8 
*0.026 
68.2 
*0.009 Tropical rain forest 72.6 67.3 63.4 
Northern savanna 90.7 89.6 89.4 
P-values were derived from χ2 tests of significance of the differences in adjusted weighted predicted 
probabilities of the outcomes for the categories of each variable. "Yes", "Non-health-related", "1 -2", 
"Rural", and "Coastal savanna" were reference groups 
*Statistically significant p-value (≤0.05) 
¢Examples include: laboratory technician, healthcare assistant etc. 
ºComprises any of the following: Nurse/midwife, pharmacist/dispensing technician, medical 
doctor/medical assistant 
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Chapter 4: The AMFm in Ghana: Factors Associated with Private Retailer’s  
Adherence to the Recommended Retail Price 
 
Introduction 
The Affordable Medicines Facility-malaria (AMFm) was initiated as a pilot in 7 
countries aimed at increasing availability, reducing prices, increasing market share and 
increasing use of co-paid quality-assured artemisinin-based combination therapies 
(QAACTs). As part of the AMFm supporting interventions to facilitate the high level 
subsidy on QAACTs reaching consumers, the AMFm green leaf-logo was widely 
publicized, along with a recommended retail price (RRP) in Ghana.  
Using data from the 2011 endline survey of the Global Fund-commissioned 
AMFm independent evaluation, we explored factors associated with outlets stocking 
some co-paid QAACTs at RRP, and those stocking all at RRP in the private-for-profit 
health sector in Ghana. Analyses accounted for the complex survey design. We used 
multivariate logistic regressions to determine the association between being aware of the 
RRP and correctly specifying it, and the probability of stocking some or all QAACTs at 
RRP.   
Among the 545 outlets making up our sample, and which stocked at least 1 co-
paid QAACT, 1,440 co-paid QAACTs were audited, with a mean number of 2.3 per 
outlet (95% CI: 2.1, 2.4). Twenty-four percent of outlets stocked no co-paid QAACTs at 
RRP, while 68% had some, but not all their co-paid QAACTs at RRP. Almost half of all 
the co-paid QAACTs audited were available at RRP. Many more outlets stocked some 
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co-paid AL compared to those that stocked some ASAQ (93 % vs. 46%). Knowledge of 
the RRP was associated with a much higher predicted probability of stocking some co-
paid QAACTs at RRP than stocking all at RRP (83% vs. 41%), although it was a strong 
predictor of both outcomes (p<0.001 for both). The type of co-paid QAACT being 
stocked (ASAQ, AL, or both) was an important predictor of an outlet stocking both some 
(p=0.014) and all (p=0. 005) co-paid QAACTs at RRP. Malaria prevalence was also 
associated with stocking some co-paid QAACTs at RRP (p=0.013).  
Our study shows that retailer’s adherence to the RRP for co-paid QAACTs can be 
high when knowledge about the RRP is present. Information on the AMFm subsidy needs 
to be disseminated to retailers with greater focus on those areas of high malaria 
prevalence, such as the northern savanna zone. All recommended policy interventions 
should be coupled with regular monitoring of prices and other indicators in the market in 
order to accurately measure the trend of the effects of the interventions. 
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Background 
In Ghana, health facility data shows that malaria accounts for 38.2% of all 
outpatient illnesses, 34.9% of all admissions, and 34% of all deaths in children under 5 
years in Ghana (NMCP, 2010). At the country level, high mortality from malaria is 
strongly correlated with lower gross national income per capita, while at the individual 
level, mortality is strongly associated with living on less than USD 1.25 per person per 
day (Worrall, Basu, & Hanson, 2005). Economic inequality, leading to competition for 
resources, is a major cause of persistent disparities in health outcomes along socio-
economic lines (Wilkinson, 1997; Willson, 2009), despite significant improvements in 
overall population health (Link, 2008; Marmot, 2002). Therefore the poor become not 
only more susceptible to getting malaria, but are also less able to access and afford 
effective treatment (Arrow et al., 2004; Worrall et al., 2005). 
Since 2001, the World Health Organization (WHO) has recommended 
artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated 
P. falciparum malaria (WHO, 2006). However, ACTs have remained relatively expensive 
to manufacture. High quality ACTs averaged around USD 10.00 per adult treatment, 
making them unaffordable to many patients in malaria endemic countries, whose 
disposable income ranges from USD1 to USD 2 per day (RBM Partnership, 2013). The 
limited availability and relatively high prices of high quality ACTs particularly in rural 
areas, encourages treatment with other, more common, and usually much less expensive, 
antimalarials, though these are less effective and often of poor quality. Thus the uptake of 
high quality ACTs has been slow (O. J. Sabot et al., 2009).  
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To address the problem of cost as a barrier to access, the public health sectors of 
many malaria endemic countries have introduced a policy of free or highly subsidized 
distribution of ACTs to patients. Despite these efforts, the limited number and access 
offered by the public sector, coupled with the high cost of quality ACTs in the private 
sector, led major global malaria stakeholders to adopt the Affordable Medicines Facility 
– malaria (AMFm) in 2010 (Cohen et al., 2010; Goodman et al., 2009; Littrell et al., 
2011; The Global Fund, 2012a). The AMFm was based on evidence that increasing the 
availability of ACTs and lowering the price paid by the end user could be an effective 
way to increase their uptake (Arrow et al., 2004; R. Laxminarayan et al., 2006; 
Moszynski, 2008) and crowd out non-ACTs by gaining market share (The Global Fund, 
2009b).  
The AMFm involved a factory-gate co-payment of up to 95% of the cost of 
quality assured ACTs (QAACTs) on behalf of public and private sector first-line buyers 
(FLBs), along with a number of supporting interventions. As part of the AMFm design, 
the ex-factory cost had already been drastically reduced following complex negotiations 
between the Global Fund to Fight Aids Tuberculosis and Malaria (The Global Fund – 
hosts of the AMFm secretariat) and manufacturers. The FLBs were required to pass on 
the massive cost savings to distributers (wholesalers and retailers) who were in-turn 
expected to finally pass them on to patients, so that the QAACTs would be affordable and 
therefore become the antimalarial of choice for even the most rural and poor populations 
(Dalberg Global Development Advisors, 2007). Although the final price to consumers 
was not formally restricted in the AMFm design, the Ghana AMFm Coordinating 
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Committee in consultation with the private sector, determined and widely publicized a 
recommended retail price (RRP) for the QAACTs of USD 0.96 per treatment (J. Amuasi 
et al., 2012). The co-paid QAACTs were made easily identifiable by a logo depicting a 
green leaf on their packaging, which we refer to as the “AMFm Logo”.  
The AMFm was a 2-year pilot intervention in seven countries including Ghana. 
By measuring changes between baseline and endline surveys in availability, price, market 
share and use of QAACTs, a Global Fund commissioned Independent Evaluation (IE) of 
the impact of the AMFm phase I was carried out in each pilot country (AMFm IE Team, 
2012; The Global Fund, 2009a). Among private sector outlets in Ghana, the median 
endline price of co-paid QAACTs was the same as the RRP of USD 0.96 (2010 prices), 
whereas QAACTs without the AMFm logo had a very high median price of USD 7.51 (J. 
Amuasi et al., 2012; J. Amuasi, Nguah, Diap, Buabeng, & The Independent Evaluation 
Team, 2011). 
Although subsidies have been shown to lower the prices of antimalarial drugs 
significantly (N. Smith et al., 2011), during monitoring of the AMFm Phase I in Ghana, 
there were reports suggesting that some retailers were capturing the AMFm subsidy by 
not adhering to the RRP and were selling the co-paid ACTs at more than 200% of the 
approved price, making super-normal profits (Cofie, 2011; Daily Graphic, 2011). 
Monitoring reports from other countries also suggested that retailers took advantage of 
the subsidy to maximize profits with wide variations in pricing of the co-paid ACTs 
between USD 0.25 and USD 3.00. Some retailers claimed that they had to inflate the 
prices beyond the RRP simply because if they adhered to it, they would make overall 
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losses when costs of transporting the drugs and other inputs were taken into 
consideration. Some retailers did not stock the co-paid ACTs at all because they claimed 
the profit margins from them were simply too small and sales volumes were not high 
enough (Esipisu, 2011).  
At the end of the AMFm phase I, the Roll Back Malaria (RBM) Partnership 
hosted by the World Health Organization (WHO), described the AMFm as having a 
“dramatic impact on the antimalarial market” in the private sector; including large 
decreases in ACT prices (RBM Partnership, 2013) [page 8]. More recently, results from a 
systematic review of available indicate that the AMFm subsidy led to an increase in the 
use of private sector QAACTs (Morris, Ward, Moonen, Sabot, & Cohen, 2014). In this 
paper we explore outlet characteristics that were associated with private for-profit sector 
outlets stocking co-paid QAACTs at or below the recommended retail price (RRP) of 
USD 0.96. 
 
Methods 
Data Source 
The AMFm Independent Evaluation endline survey was carried out in late 2011 
and was our main source of data. The survey was based on a non-experimental design 
with assessment of key indicators in rural and urban domains on a national scale. The 
data collection, analysis process and findings of the IE are described in other sources (J. 
Amuasi et al., 2012; Tougher et al., 2012; Willey et al., 2014). Shapefiles and other 
geographic information systems data on districts in Ghana were obtained from the Centre 
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for Remote Sensing and Geographic Information Services of the University of Ghana via 
ESRI’s GeoCommons platform (CERSGIS, 2012). Data on Plasmodium falciparum 
malaria prevalence by district were obtained from the 2010 posterior predictive 
distribution model estimates produced by the Malaria Atlas Project (MAP). Further 
details on the MAP methodology are available from other publications (Gething et al., 
2011; MAP, 2010). Ethical clearance for the IE surveys in Ghana was obtained from the 
Ghana Health Service Ethical Review Committee on Research Involving Human Subjects 
(ERCRIHS). Our study was deemed not to fall within the University of Minnesota 
Institutional Review Board’s regulatory definition of research with human subjects. 
Data Management 
A total of 765 private sector outlets contributed to the IE endline survey data. Our 
study sample included only outlets that were enumerated, completed the interview, and 
stocked some co-paid QAACTs. A total of 117 outlets fell into at least one of the 
following categories and so were excluded from the sample: 1.) Were not screened, 2.) 
Did not meet the screening criteria, 3.) Were not interviewed, 4.) Did not fully complete 
the interview and antimalarial audit, 5.) Were private not-for-profit facilities, and 6.) Did 
not have antimalarials in stock. A further 103 outlets did not stock any co-paid QAACTs 
were and were also excluded from the sample.  
The IE endline survey divided antimalarials into artemisinin-based combination 
therapies (ACTs) and non-ACTs. ACTs were subdivided into quality-assured ACTs 
(QAACTs) and normal ACTs (non-QAACTs). QAACTs were further classified into co-
paid (had the AMFm logo) and non-co-paid. Details on the definition of QAACTs can be 
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found in other sources (AMFm IE Team, 2012). The non-ACTs were subdivided into 
three broad categories; non-artemisinin therapies (nATs), artemisinin monotherapies 
(AMTs), and antimalarials no longer used for treatment but only for prophylaxis (nRx). 
AMTs were further classified into oral and non-oral AMTs, while nATs were classified 
into Sulphadoxine-pyrimethamine (SP), which is recommended by the WHO for 
prophylaxis in pregnancy, quinine (for treating severe malaria), and other nATs. The 
endline survey data on outlet location was layered on the map of Ghana districts using 
ArcMap v10.2 (ESRI, 2013). The data on Plasmodium falciparum malaria prevalence by 
district was extracted from the MAP database and merged with the endline survey data 
using the “spatial join” feature in ArcMap.  
Variables 
Antimalarial prices and sales volumes are reported in terms of adult equivalent 
treatment doses (AETDs), determined using an AETD calculator, and is defined as the 
number of milligrams of an antimalarial drug needed to treat a 60 kg adult (Shewchuk et 
al., 2011). We investigated two distinct outlet-level outcomes: 1) Whether the outlet 
stocked at least one co-paid QAACT at or below the recommended retail price (RRP) 
(yes/no), and 2) whether all co-paid QAACTs stocked in an outlet were at or below the 
RRP (yes/no). We subsequently simplify the phrase “at or below the RRP” to “at RRP”. 
Whether or not the survey respondent knew there was a RRP for the QAACTs with the 
logo and was able to correctly specify it to be USD 0.96 was our main predictor 
investigated for both pricing outcomes.  
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A number of other factors and outlet characteristics potentially associated with 
QAACT pricing were included in the analysis, either directly or using proxies, such as 
Falciparum malaria prevalence (Pfpr), ownership, rural/urban status, stocking practices 
for QAACTs and other antimalarials, level of sophistication, size of the outlet, and 
malaria epidemiologic zone. Variables reflecting outlet sophistication included: 
availability of malaria testing; the survey respondent having completed secondary school; 
and having a pharmacist, nurse or doctor on staff. Variables describing outlet’s stocking 
practices included whether the outlet stocked the antimalarials artesunate-amodiaquine 
(ASAQ), artemether-lumefantrine (AL) or both active ingredient types of QAACTs with 
the logo; adult, pediatric or both formulations of QAACTs with the logo; QAACTs 
without the logo; non-QAACTs; AMTs; or nATs.  
We used the number of workers employed in the outlet and the number of 
different co-paid QAACTs stocked as proxies for outlet size. Both variables were 
included in our analysis after confirming that they do not pose the problem of 
multicollinearity. We recognize that it would be methodologically elegant to create a 
composite measure of size using number of workers and number of co-paid QAACTs 
stocked. However the two variables allow for an appreciation of the structure and nature 
of the outlets from different but equally important perspectives of size. Further discussion 
on the choice of proxies for outlet size can be found in Appendix 10. 
Statistical Approach 
For all analyses, we used the IE endline survey weights to account for the 
complex survey design used. We used t-tests to investigate how malaria prevalence 
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differed between rural and urban outlets and also among the three malaria epidemiologic 
zones: Coastal savanna/mangrove swamps, tropical rain forest, and northern savanna (see 
Table 3). The independent association between the outcome variables and continuous 
predictors (e.g. Pfpr, sales volume etc.), was also determined using t-tests of the 
difference in means of the predictors among outlets that had the pricing outcome vs. those 
that did not (see Table 2). We used chi-square tests to assess the unadjusted relationship 
between predictors that were expressed as binary or categorical variables and the pricing 
outcomes and (see Tables 4a and 4b).  
We used multivariate logistic regressions to determine the association between 
malaria prevalence, knowing the AMFm and correctly specifying the RRP (knowledge), 
and the probability of our pricing outcomes. We adjusted/controlled for other variables 
that were statistically significant from our examination of the unadjusted relationships 
between independent variables and the pricing outcomes. Certain variables were 
excluded from the multivariate regression model due to concerns that they were highly 
correlated with other variables in the model. In all analyses, we performed several 
sensitivity analyses using alternate models, including using different variable 
categorizations, to confirm that the observed effects were not artifacts (see Appendices 
11-14). P-values ≤ 0.05 were considered significant. All analyses were carried out using 
STATA v12 (StataCorp, 2012).  
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Results 
Outlet Characteristics 
There were 545 private-for-profit enumerated outlets which completed the 
interview and stocked at least 1 co-paid QAACT. Out of these, 412 stocked some (at least 
1) co-paid QAACTs at or below the recommended retail price (RRP) of USD 0.96, and 
173 outlets stocked all at RRP. Table 7 shows the distribution of the characteristics of 
outlets included in our study. 
 In 87% of outlets, the interviewee was aware there was a RRP and was able to 
correctly specify it as being USD 0.96 (knowledge). Knowledge was associated with a 
much higher predicted probability of stocking some co-paid QAACTs at RRP than 
stocking all co-paid QAACTs stocked at RRP (83% vs. 41%). Nevertheless in the 
unadjusted analyses, knowledge was a strong predictor of both stocking some QAACTs 
at RRP (p<0.001) and stocking all at RRP (p=0.008) (see Table 10a). Knowledge 
remained a strong predictor of both outcomes (p<0.001 for both) even after adjusting for 
other factors (see Tables 11 and 12). 
 Only 5% of outlets offered malaria tests to clients, and 35% of respondents owned 
the outlet (see Table 7). Although ownership status was associated with stocking all co-
paid QAACTs at RRP (p=0.002) in the unadjusted analyses (see table 10a), this 
association disappeared after other factors were controlled for as shown in Table 12 
(p=0.217). Without adjusting for other factors, an outlet having at least one employee 
being a pharmacist, nurse or doctor; and the number of employees, were strongly 
associated with the outlet stocking all co-paid QAACTs at RRP (p=0.009 and p<0.001 
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respectively). However after adjusting for other factors, both these associations were 
eliminated (p=0.302 and p=0.272 respectively) (see Tables 10a & 12). The mean number 
of employees per outlet in our sample was 2.5 (95% CI: 2.3, 2.7). 
Stocking and sales volume 
A total of 1,440 co-paid QAACTs were audited among the 545 outlets in our 
sample with a mean number of 2.3 QAACTs per outlet (95% CI: 2.1, 2.4) and a mean 
sales volume of 31.7 adult equivalent treatment doses (AETDs) per outlet (95% CI: 25.1, 
38.3) over the week preceding the survey. The mean relative sales volume of co-paid 
QAACTs to all other antimalarials per outlet was 56.8% (95% CI: 53.2, 60.4). Out of the 
1,440 QAACTs audited, 46.6% were stocked at RRP.  
Ideally, an outlet should stock both adult and pediatric co-paid QAACTs at the 
RRP, however 24% of outlets in our sample stocked no co-paid QAACTs at RRP, while 
68% had some, but not all their co-paid QAACTs at RRP. Only 27% of outlets had non 
co-paid QAACTs in stock and 81% had ACTs that were not QAACTs in stock. Many 
more outlets stocked some co-paid AL over ASAQ (93 % vs. 46%), and 54% stocked 
only co-paid AL while barely 7% stocked ASAQ only (see Table 7). Even after adjusting 
for other factors, the type of co-paid QAACTs being stocked (ASAQ/AL/both) was an 
important predictor of an outlet stocking both some (p=0.014) and all (p=0. 005) co-paid 
QAACTs at RRP (see Tables 11 and 12, and Appendix 15). After adjusting for other 
factors, the predicted probability of all co-paid QAACTs in an outlet being sold at RRP 
was 46.8% for outlets that stocked adult co-paid QAACTs only and 8.7% for those that 
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stocked both adult and pediatric QAACTs (p<0.001) (see table 12). None of the 13 
outlets that stocked only pediatric co-paid QAACTs had them at RRP (see Table 7). 
 At a mean number of 2.4 (95% CI: 2.2, 2.6) and 1.3 (95% CI: 1.2, 1.4) co-paid 
QAACTs per outlet for those that sold some and those that sold all co-paid QAACTs at 
RRP respectively, the number of co-paid QAACTs audited in an outlet was an important 
predictor of both pricing outcomes. After adjusting for other important factors, the 
number of co-paid QAACTs audited in an outlet was positively associated with the 
predicted probability of stocking some co-paid QAACTs at RRP (p=0.082). However, 
number of co-paid QAACTs in an outlet was negatively associated with the predicted 
probability of stocking all co-paid QAACTs at RRP (p=<0.001) (see Tables 11 & 12). 
The relationship between the number of co-paid QAACTs in an outlet and the proportion 
which are stocked at RRP is shown in Table 13 (also see Appendix 16). 
Malaria prevalence and epidemiologic zones 
From our sample, the mean prevalence of falciparum malaria (Pfpr) was 32.8% 
(95% CI: 28.3, 37.2) and ranged from 12.5 to 68.2%. Without adjusting for other factors, 
Pfpr was not associated with stocking some co-paid QAACTs at RRP (p=0.722). 
However after adjusting for other factors, a positive association became evident 
(p=0.013) with a 78% predicted probability of stocking some co-paid QAACTs at RRP 
among outlets within the highest Pfpr category (see Tables 10a & 11). On the other hand, 
without adjusting for other factors, Pfpr was positively associated with stocking all co-
paid QAACTs at RRP (p=0.008), but the association was weakened after adjusting for 
other factors (p=0.238). This association between Pfpr and stocking all co-paid QAACTs 
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at RRP however remained positive, with a 40% predicted probability of stocking all co-
paid QAACTs at RRP among outlets within the highest Pfpr category (see Tables 10a & 
12, and Appendix 17). 
 Among both outlets that stocked some and those that stocked all co-paid 
QAACTs at RRP, the mean malaria prevalence was higher among outlets in rural 
compared to urban areas (39% vs. 30%, p=0.014 and 41% vs. 32%, p=0.038) 
respectively. Mean Pfpr also increased progressing from the coastal savanna to the 
northern savanna for both outlets that stocked some and all co-paid QAACTs at RRP 
(p=0.001 and p<0.001) respectively (see Table 9). 
 
Discussion 
The AMFm subsidy was applied directly by the Global Fund at the ex-factory 
level (top of the supply chain), and several factors act to influence markups applied 
throughout the chain by different actors (Palafox et al., 2014). Stakeholders were 
particularly concerned that retailers, who are the final interface between the patient and 
the QAACT, would seize the opportunity to make super-normal profits and not pass the 
subsidy on to consumers (O. Sabot et al., 2011). An outlet that stocked co-paid QAACTs, 
but sold them above and beyond the RRP, defeated one of the AMFm’s core objectives of 
increasing affordability of ACTs (The Global Fund, 2009b). In this paper we explored 
factors influencing two levels of adherence to the RRP: stocking some co-paid QAACTs 
at RRP and stocking all available co-paid at RRP. 
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The survey respondent knowing there was a RRP for the QAACTs with the logo 
and being able to correctly specify it to be USD 0.96 was our main predictor for the 
pricing outcomes, and we refer to this simply as “knowledge”. Although the RRP was set 
by the Ghana AMFm Coordinating Committee, the figure was arrived at in close 
consultation with the private for-profit sector. In contrast to Resale Price Maintenance 
and other legal approaches to price maintenance, a key feature of a Recommended Retail 
Price is that the retailer is not obliged to adhere to it (Mathewson & Winter, 1998; Puppe 
& Rosenkranz, 2011). One way recommend retail pricing is believed to act, is by 
influencing the behavior of both retailers and consumers. Based on the assumption that 
consumers suffer from “loss aversion”, RRPs based on good market intelligence 
contribute to setting some kind of reference point or ceiling of consumers’ willingness to 
pay (Kahneman, Knetsch, & Thaler, 1991; Tversky & Kahneman, 1991). Research shows 
that even monopolistic retailers voluntarily adhere to the RRP when they are concerned 
that consumer’s exercise of personal agency in purchasing an antimalarial (influenced by 
their awareness of the RRP), might be lower than the price the retailer would have 
otherwise set (Puppe & Rosenkranz, 2011). Thus for RRPs to be effective, achieving high 
levels of awareness for both consumers and retailers is critical, especially considering 
that the RRP for co-paid QAACTs was not printed on the packaging. 
Empowering key actors with knowledge has been shown to be critical for the 
successful implementation of various malaria control interventions (B. P. Kangwana et 
al., 2013). Knowledge is able to induce action/compliance, whether it be using ACTs, 
adhering to a treatment regimen, or purchasing and sleeping under bed nets (Aborah et 
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al., 2013; Wafula et al., 2012). There is convincing evidence that the level of knowledge 
of the RRP was a direct outcome of the intensity and extent of communication campaigns 
to boost both retailer and consumer awareness, and that knowledge translated into retailer 
adherence to the RRP (Tougher et al., 2012; Willey et al., 2014). In Ghana, over 10,000 
radio spots and 400 television commercials were aired in English and 7 other local 
languages, and training on the AMFm was administered to providers across the health 
sector (AMFm IE Team, 2012). In Ghana and other AMFm countries where the green-
leaf logo identifying the co-paid QAACTs and the RRP was widely promoted, 
knowledge of the RRP among retailers was found to be high (84% in Ghana) (J. Amuasi 
et al., 2012; Willey et al., 2014). From a qualitative study, this high level of knowledge 
corresponded with a very narrow interquartile price range for co-paid QAACT prices and 
a median price just below the RRP (Willey et al., 2014).  
The hypothesis of a relationship between knowledge and adherence to the RRP is 
further supported by our findings showing awareness of the RRP and correctly specifying 
it (knowledge), to be a strong independent predictor of stocking some or all co-paid 
QAACTs at RRP (p<0.001 for both). However the difference in predicted probability of 
stocking some co-paid QAACTs at RRP between those who had knowledge and those 
who did not was 49%, while for those outlets stocking all at RRP, the difference was 
26%. The “difference-in-differences” of 23 percentage points, and the evidence of other 
independent predictors of adherence to the RRP, indicates that aside from knowledge, 
there are other important factors to consider if improvements in adherence to the RRP are 
desired. A yet-to-be-published report examining the AMFm data from a number of pilot 
 64 
 
countries also suggests that there is potential for further reductions in price if greater 
adherence to the RRP is achieved (Tougher et al, in press). 
Compared to outlets in low prevalence areas, we hypothesized that outlets in areas 
of high malaria prevalence would be more likely to stock QAACTs due to a greater 
demand for antimalarials and that these outlets would be more likely to sell QAACTs at 
the RRP due to the higher levels of poverty among populations in high prevalence, often 
rural, regions. Previous analyses on the association between malaria prevalence and 
QAACT pricing during the AMFm have shown mixed results. An analysis of remote 
regions of Tanzania during the first year of the AMFm found that towns with lower 
malaria prevalence had slightly higher prices of co-paid QAACTs than high prevalence 
towns (Yadav et al., 2012). On the other, an analysis 3 months after the launch of the 
AMFm in Kenya found no correlation between the incidence of fever and ACT stocking 
and pricing (O’Meara et al., 2013). In our analysis,  
We observed the hypothesized positive association between Pfpr and stocking 
some co-paid QAACTs at RRP manifesting only after adjusting for knowledge, number 
of co-paid QAACTs audited, and the kinds of active ingredients stocked (p=0.013). After 
confirming the absence of multicollinearity between Pfpr and the other predictors in our 
multivariate regression model, we conclude that the association between Pfpr and 
stocking some co-paid QAACTs at the RRP was being “negatively confounded” by 
knowledge (MacKinnon, Krull, & Lockwood, 2000). We have already established that 
lower levels of knowledge are associated with lower levels of stocking at RRP 
independent of Pfpr. Further analysis (not captured in our results section), shows that 
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high Pfpr is strongly associated with lower levels of knowledge relative to low Pfpr 
(p=0.003). Higher Pfpr is often associated with lower wealth quintiles, which further 
lowers the probability of ownership of radios or televisions and by extension exposure to 
information on the AMFm. Therefore by adjusting for knowledge, the positive 
association between Pfpr and stocking some co-paid QAACTs at RRP becomes evident. 
Our results showed that with increasing number of co-paid QAACTs in an outlet, 
the probability that some would be stocked at RRP increased, while the probability that 
all would be stocked at RRP decreased. The number of co-paid QAACTs and the type 
being stocked (ASAQ or AL, adult or pediatric) in an outlet were important factors 
associated with whether or not an outlet stocked some or all its co-paid QAACTs at RRP. 
The importance of the number and type of co-paid QAACTs in an outlet in relation to 
stocking at the RRP is highlighted when we consider that 34% of our sample (184 
outlets) stocked only 1 co-paid QAACT. Out of these 184 single co-paid QAACT-
stocking outlets, 73% of 158 and 35% of 26 stocked AL and ASAQ respectively at the 
RRP (21% and 2% of our sample respectively). See Appendix 18 and 19 for further 
details. Further analysis (see Appendix 20) shows that the median prices per AETD of 
co-paid ASAQ and AL in our sample were different at USD 1.25 and USD 0.94 
respectively (p=0.004). It is therefore not surprising that overall, stocking AL only led to 
a higher predicted probability of stocking some or all co-paid QAACTs at RRP than 
stocking ASAQ only, and a higher predicted probability of stocking all at RRP than 
stocking both ASAQ and AL. 
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Going beyond the outlet level analyses to examine the distribution of the 
antimalarials themselves, we find that of all the co-paid QAACTs that were ASAQ (428), 
29% were pediatric formulations, whereas out of all the co-paid QAACTs that were AL 
(1,018), only 17% were pediatric. Also, out of the 294 pediatric co-paid QAACTs, 42% 
were ASAQ and the rest were AL, whereas out of the 1,152 adult co-paid QAACTs, only 
26% were ASAQ and the rest were AL. These findings indicate that although there was 
much more AL than ASAQ stocked in the private sector (70% vs. 30%), there was a bias 
in favor of adult formulations for AL and pediatric formulations for ASAQ. These 
phenomena are likely to be a reflection of existing consumer preferences, which have 
been observed and echoed by the National Malaria Control Program (J. Amuasi, 2013).  
Our results showed that for both ASAQ and AL, AETDs of pediatric co-paid 
QAACTs were mostly sold above the RRP. This is not surprising, considering that a 
number of pediatric treatment packs have to be combined to achieve an adult equivalent 
treatment dose (AETD), which has the potential to bias the price of the AETD upwards, 
as opposed to a straight adult treatment pack. A lot of the research on pricing of 
antimalarials therefore separates the analysis of adult treatments from pediatric 
treatments. Further, because markets generally have higher volumes of adult treatments, 
many antimalarial pricing studies focus only on adult treatments to achieve greater 
statistical power. However we believe that analyzing adult and pediatric treatments 
together and adjusting for the influence of their distribution is a better policy-oriented 
approach to pricing studies than separate analyses or outright exclusions.  
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We see from this study that outlets sometimes stock only adult or pediatric 
treatment packs. In such situations, adult customers are compelled to achieve the required 
treatment dose by either adding up a number of pediatric treatment packs to make up an 
adult equivalent treatment dose (AETD), or dividing an adult pack to achieve a pediatric 
dose. In this regard, capturing the influence of the adult/pediatric distribution in this 
pricing study allows us to better translate our results into realistic policy 
recommendations based on the prevailing scenario in the antimalarial market. The higher 
average cost per AETD of pediatric formulations and the finding that pediatric 
formulations were more biased towards ASAQ than AL, accounts for the observed higher 
median price of ASAQ compared to AL. 
Notwithstanding the importance of our findings, we must acknowledge there are a 
number of important limitations to this study. First, the pricing information we are using 
was collected as part of the AMFm IE, and was obtained from retailer’s responses to 
questions posed by data collectors. Although likely to be much more costly, to avoid 
issues associated with self-reporting (B. P. Kangwana et al., 2013), we recommend that 
subsequent pricing studies consider employing mystery shopping as the approach to 
collecting information on antimalarial prices. 
Second, competition is known to often be an important influencer of medicine 
prices. However we cannot include any relevant measure of competition using our data 
because of the cluster sampling approach used for data collection.  
Third, in studying the private-for-profit sector, owing to sample size limitations 
our study does not make any distinction among stand-alone pharmacies, pharmacies 
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attached to private health facilities, licensed chemical shops and itinerant vendors. While 
the private sector is arguably fairly homogeneous, several unmeasured factors (e.g. the 
high concentration of pharmacies in urban areas in Ghana) (F. Smith, 2004), could 
influence our findings in ways potentially important for policy considerations. 
Finally, the data collected focuses only on retailer behavior and not on 
consumer’s behavior. Considering that the impact of the AMFm subsidy is a function of 
the interaction between retailers and consumers, we could be missing some valuable 
information which could enrich our understanding of the observed phenomena and help 
refine recommended policy actions. Future studies on the impact of price subsidy 
interventions such as the AMFm on antimalarial availability, pricing and use should 
therefore include consumer exit interviews.  
In spite of these limitations, the strengths of our data and analyses far outweigh 
any weaknesses. This study has shown that retailer’s adherence to the RRP for co-paid 
QAACTs can be high when knowledge is made available to both consumers and retailers. 
The RRP was set by the Ghana AMFm Coordinating Committee in consultation with key 
stake-holders, including the private sector, which provided various estimates of costs at 
various stages of their supply chain. Therefore information asymmetry between the 
private sector actors in the supply chain and the rest of the policy makers who decided on 
the RRP, could have resulted in an inflated RRP. An inflated RRP might have resulted in 
unfair profits for retailers and prevented customers from experiencing the full potential 
benefit of the subsidy.  
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Since specifying a RRP inadvertently sets a price floor (AMFm IE Team, 2012), 
we recommend that careful consideration continue to be given to the level at which the 
RRP is set so that it resonates with both consumers’ willingness to pay and fair profits for 
retailers. While printing the RRP on the packaging could be a powerful tool for 
modifying market forces, it risks creating more confusion, considering the instability of 
the Ghana Cedi relative to the US Dollar, the wide range of QAACT formulations 
available, and the shelf-life of ACTs. 
We also recommend that information on the AMFm subsidy be disseminated with 
greater focus on those areas of high malaria prevalence such as the northern savanna 
zone. Innovative ways of delivering information on the subsidy tailored specifically to 
these high Pfpr areas is more likely to increase awareness of the availability and RRP of 
the co-paid QAACTs than more generalized approaches. 
Finally, Dihydroartemisinin-Piperaquine (DHAP) is an ACT that has been 
included as an alternative first-line therapy for treating uncomplicated malaria in Ghana, 
and is used mainly by adults (Abuaku, Duah, Quaye, Quashie, & Koram, 2012), and is 
likely to soon attain QAACT status (EMEA, 2012). We therefore recommend that the 
Ministry of Health in Ghana consider initiating steps to improve the popularity of DHAP 
among consumers. Increased knowledge about the relatively newer drug should lead to 
an increase in demand for it, and an increase in competition between DHAP and AL for 
use among adults, eventually driving both prices down. 
The above must be followed by the Ministry of Health adopting policies 
supporting the use of ASAQ for children and AL or DHAP for adults for the treatment 
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uncomplicated malaria. Our findings and other sources indicate that this population 
segmentation approach to multiple first-line antimalarial therapy is already the de-facto 
situation in Ghana (J. Amuasi, 2013). By taking advantage of a situation that has already 
been created naturally by market forces, the message on co-paid QAACTs and their 
importance for treatment of uncomplicated malaria can be reinforced to allow for even 
better compliance with RRP.  
Any policy change should be coupled with monitoring of prices and other 
indicators in the market in order to accurately measure the effects of the interventions 
over time, and monitoring of resistance to ACTs. 
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Table 7: Unweighted distribution of outlet characteristics 
Characteristics 
Stocked co-
paid 
QAACTs 
Stocked some 
co-paid 
QAACTs at 
RRP 
Stocked all 
co-paid 
QAACTs at 
RRP 
   
Total: N, % 545, 100% 412, 100% 173, 100% 
Respondent knew and specified the RRP for co-paid 
QAACTs 86.8 93.9 91.3 
Stocked at least 1 co-paid QAACT that was ASAQ 46.2 46.6 16.2 
Stocked at least 1 co-paid QAACT that was AL 92.8 96.4 94.8 
Stocked at least 1 oral AMT 56.7 57.8 46.2 
Stocked at least 1 nAT* 54.1 54.6 52.6 
Stocked at least 1 non-AMFm QAACT 27.5 28.2 12.7 
Stocked at least 1 non-QAACT 81.3 83.3 71.7 
Respondent owned the outlet 35.1 35.9 44.5 
Malaria testing (microscopy/RDT) available 4.8 4.4 2.9 
At least 1 employee completed secondary/high school 94.3 95.2 91.3 
At least 1 employee is a  pharmacist, nurse or doctor  56.7 58 44.5 
Number of 
employees** 
One 13 13.6 22 
Two 33.9 32.3 41 
Three 22.6 22.6 19.7 
Four or more 30.3 30.3 17.3 
Number of co-paid 
QAACTs audited 
One 33.8 30.4 72.2 
Two-Three 40.5 40.5 27.2 
Four or more 25.7 29.2 0.6 
Active ingredients of 
co-paid QAACTs 
ASAQ only 7.2 3.6 5.2 
AL only 53.8 53.4 83.8 
Both ASAQ and AL 39 43 11 
Formulation of co-
paid QAACTs 
Adult only 55.8 55.8 97.7 
Pediatric only 2.4 0 0 
Both Adult and Pediatric 41.8 44.2 2.3 
Geographic area Urban 76.7 77.2 66.5 
Rural 23.3 22.8 33.5 
Malaria 
epidemiologic zone§ 
Coastal savanna/Mangrove 
swamps 50.4 49.5 39.9 
Tropical rain forest 38.2 39.3 42.2 
Northern savanna 11.4 11.2 17.9 
Falciparum malaria 
prevalence (%) 
Low (10-24) 35.8 35.4 22.5 
Medium (25-34) 34.5 35.4 39.9 
High (35-70) 29.7 29.2 37.6 
*Excludes SP, Quinine, and those antimalarials used strictly for prophylaxis or no longer for treatment 
**Percentages may not add up to 100% because of rounding or missing data 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Northern) used by the 
Ghana Statistical Service  
AETD: Adult Equivalent Treatment Dose 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RDT: Rapid Diagnostic Test for malaria 
RRP: Recommended Retail Price 
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Table 8: Survey weighted means of continuous variables by outcomes 
Variables 
Some co-paid QAACTs sold at RRP All co-paid QAACTs sold at RRP 
mean (95%CI) mean (95%CI) 
Yes No p-value Yes No p-value 
n=412 n=133 n=173 n=372 
Falciparum malaria prevalence (percent) 32.5 (27.9, 37.1) 
33.7 (28.8, 
38.5) 0.451 
35.5 (31.1, 
39.9) 
31.1 (26.5, 
35.7) *0.001 
Number of employees 2.6 (2.4, 2.8) 2.4 (2.2, 2.7) 0.34 2.2 (2, 2.4) 2.7 (2.5, 2.9) *0.001 
Number of co-paid QAACTs audited 2.4 (2.2, 2.6) 1.9 (1.6, 2.1) *<0.001 1.3 (1.2, 1.4) 2.9 (2.7, 3.1) *<0.001 
Sales volume of all antimalarials (in AETDs. 
Mean, 95% CI) 
69.2 (53.4, 
84.9) 
34.5 (20.1, 
48.9) *<0.001 47.2 (37.3, 57) 
68.5 (48.3, 
88.6) 0.050 
Sales volume of co-paid QAACTs (in AETDs. 
Mean, 95% CI) 
37.8 (29.6, 
46.1) 13.8 (8.6, 19) *<0.001 
27.7 (20.1, 
35.3) 
34.2 (25.2, 
43.2) 0.242 
Relative sales volume of co-paid QAACTs (in 
percent. Mean, 95% CI) 58.4 (55, 61.9) 
51.4 (42.7, 
60.1) 0.119 
57.1 (51.6, 
62.5) 
56.6 (52.6, 
60.6) 0.886 
P-values were derived from t-tests of significance for differences between the response categories "Yes" and "No" in the survey weighted mean 
of each variable 
*Statistically significant p-value (≤0.05) 
AETD: Adult Equivalent Treatment Dose 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RRP: Recommended Retail Price 
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Table 9: Survey weighted mean falciparum malaria prevalence among outlet locations by pricing outcomes 
Variables 
Falciparum malaria prevalence (%) 
 
Some co-paid QAACTs 
sold at RRP (n=412/545)  
All co-paid QAACTs sold 
at RRP (n=173/545) 
mean (95% CI) 
p-
value mean (95% CI) p-value 
Location 
Rural 39.3 (34.5, 44) 
*0.014 
40.7 (36.1, 45.3) 
*0.038 
Urban 29.7 (23.7, 35.6) 32.3 (25.9, 38.8) 
Malaria epidemiologic zone§ 
Coastal savanna/Mangrove swamps 22.6 (17.1, 28) 
*0.001 
25 (18.5, 31.5) 
*<0.001 Tropical rain forest 34.7 (31, 38.4) 34.6 (31.3, 37.9) 
Northern savanna 54.1 (50.5, 57.7) 54.4 (51, 57.8) 
  
P-values were derived from t-tests of significance for differences between the categories for the variables in the survey weighted 
mean malaria prevalence 
*Statistically significant p-value (≤0.05) 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Northern) used by the Ghana Statistical Service  
RRP: Recommended Retail Price 
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Table 10a: Survey weighted percentages of outlets with the pricing outcomes 
Characteristics 
Some co-paid 
QAACTs sold at 
RRP  
All co-paid 
QAACTs sold 
at RRP 
N=545 
w% p-value w% p-value 
Respondent knew and specified 
the RRP for co-paid QAACTs 
Yes 82.9 
*<0.001 
40.8 
*0.008 
No 32.5 23.1 
Malaria testing 
(microscopy/RDT) available 
Yes 61.7 
0.104 
27.3 
0.185 
No 74.9 38.3 
Respondent owned the outlet 
Yes 77.9 
0.173 
44.6 
*0.002 
No 72 32.2 
At least 1 employee completed 
secondary/high school 
Yes 75.7 
0.132 
36.9 
0.128 
No 66.3 50.5 
At least 1 employee is a  
pharmacist, nurse or doctor  
Yes 76.3 
0.339 
31.5 
*0.009 
No 73 42.5 
Number of employees 
One 79.7 
0.423 
58.1 
*<0.001 
Two 72.1 39 
Three 76.1 29.2 
Four or more 76.2 23.4 
Location 
Rural 70.5 
0.280 
46.0 
*0.047 
Urban 76.6 34.2 
Malaria epidemiologic zone§ 
Coastal savanna/Mangrove 
swamps 73.6 
0.926 
30.4 
*0.001 Tropical rain forest 75.6 39 
Northern savanna 74.8 56.4 
Falciparum malaria prevalence 
(%) 
Low (10-24) 75.0 
0.722 
25.7 
*0.008 Medium (25-34) 76.6 42.8 
High (35-70) 72.8 42.6 
P-values were derived from χ2 tests of significance of the differences in adjusted survey weighted 
predicted probabilities of the outcomes for the categories of each variable. "Yes", "One", "Rural", 
"Coastal savanna" , and "Low" were reference groups 
*Statistically significant p-value 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Northern) used by the 
Ghana Statistical Service  
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RDT: Rapid Diagnostic Test for malaria 
RRP: Recommended Retail Price 
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Table 10b: Survey weighted percentages of outlets with the pricing outcomes (for antimalarial 
stocking-related variables) 
Antimalarial stocking characteristics 
Some co-paid 
QAACTs sold 
at RRP  
All co-paid 
QAACTs sold 
at RRP 
N=545 
w% p-value w% p-value 
Active ingredients of co-paid 
QAACTs 
ASAQ only 46.7 
*<0.001 
24.8 
*<0.001 AL only 74.6 55.8 
Both ASAQ and AL 81.3 11.7 
Formulation of co-paid QAACTs§ 
Adult only 74.8 
0.294 
59.2 
*<0.001 Both Adult and 
Pediatric 78.8 2.4 
Number of co-paid QAACTs 
audited 
One 69.3 
*0.011 
69.3 
*<0.001 Two-Three 74.9 24.4 
Four or more 85.3 0.3 
Stocked  oral AMTs 
Yes 76.4 
0.370 
29.6 
*<0.001 
No 73 46.3 
Stocked at least 1 non-AMFm 
QAACT 
Yes 80.1 
0.179 
21.7 
*0.001 
No 73.8 40.5 
Stocked at least 1 non-QAACT 
Yes 77 
*0.040 
34.3 
*0.007 
No 68.5 47.5 
Stocked at least 1 nAT** 
Yes 76.2 
0.321 
35.4 
0.090 
No 72.6 41.1 
P-values were derived from χ2 tests of significance of the differences in adjusted survey weighted 
predicted probabilities of the outcomes for the categories of each variable. "Yes", "ASAQ only", "Adult 
only" and "One" were reference groups 
*Statistically significant p-value 
§"Pediatric only" excluded because no outlet that stocked only pediatric co-paid QAACTs sold any at 
RRP 
**Excludes SP, Quinine, and those antimalarials used strictly for prophylaxis or no longer for treatment 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
AMT: Artemisinin Monotherapy 
nAT: non-Artemisinin Therapy 
RRP: Recommended Retail Price 
ASAQ: Artesunate-Amodiaquine 
AL: Artemether-Lumefantrine 
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Table 11: Adjusted probability of stocking some co-paid QAACTs at RRP 
Characteristics 
Some co-paid 
QAACTs sold 
at RRP  
N=545 
Pr p-value 
Respondent knew and specified 
the RRP for co-paid QAACTs 
Yes 82.1 
*<0.001 
No 33.1 
Falciparum malaria prevalence 
(%) 
Low (10-24) 68.1 
*0.013 Medium (25-34) 74.3 
High (35-70) 77.9 
Active ingredients of co-paid 
QAACTs 
ASAQ only 56.2 
*0.014 AL only 76.8 
Both ASAQ and AL 76.9 
Number of co-paid QAACTs 
audited 
One 71.8 
0.082 Two-Three 74.1 
Four or more 82.6 
  
P-values were derived from χ2 tests of significance of the differences in adjusted 
survey weighted predicted probabilities of the outcome for the categories of 
each variable. "Yes", "Low", ASAQ only", and "One" were reference groups 
*Statistically significant p-value (≤0.05) 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RRP: Recommended Retail Price 
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Table 12: Adjusted probability of stocking all co-paid QAACTs at RRP 
Characteristics 
All co-paid 
QAACTs sold at 
RRP 
N=545 
Pr p-value 
Respondent knew and specified the 
RRP for co-paid QAACTs 
Yes 43.9 
*<0.001 
No 18 
Respondent owned the outlet 
Yes 40.6 
0.217 
No 37 
At least 1 employee is a  pharmacist, 
nurse or doctor  
Yes 40.9 
0.302 
No 37.4 
Number of employees 
One 45.5 
0.272 
Two 37.3 
Three 38 
Four or more 34.5 
Active ingredients of co-paid 
QAACTs 
ASAQ only 27.6 
*0.005 AL only 42.6 
Both ASAQ and AL 31 
Formulation of co-paid QAACTs§ 
Adult only 46.8 
*<0.001 
Both Adult and Pediatric 8.7 
Number of co-paid QAACTs audited 
One 48.2 
*<0.001 Two-Three 32.6 
Four or more 2.3 
Location 
Rural 40.2 
0.582 
Urban 37.9 
Malaria epidemiologic zone** 
Coastal savanna/Mangrove swamps 38.4 
0.877 Tropical rain forest 38.2 
Northern savanna 40.9 
Falciparum malaria prevalence (%) 
Low (10-24) 34.1 
0.238 Medium (25-34) 39.8 
High (35-70) 40.3 
P-values were derived from χ2 tests of significance of the differences in adjusted survey weighted 
predicted probabilities of the outcome for the categories of each variable. "Yes", "One", ASAQ only", 
"Adult only", "Rural", "Coastal savanna", and "Low" were reference groups 
*Statistically significant p-value (≤0.05) 
§"Pediatric only" excluded because no outlet that stocked only pediatric co-paid QAACTs sold any at RRP 
**Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the 
Ghana Statistical Service  
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RRP: Recommended Retail Price 
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Table 13: Survey weighted relationship between number of co-paid QAACTs and proportion at 
RRP 
Proportion (%) of 
co-paid QAACTs 
at RRP 
Number of co-paid QAACTs in an outlet 
One 
(n=184) 
Two-Three 
(n=221) 
Four or more 
(n=140) TOTAL, (N = 545) 
None, n=133 30.7% 25.1% 14.7% 25.3% 
12.5 - 44.4, n=86 0 12.9% 33.2% 11.6% 
50, n=89 0 28.1% 27.8% 16.7% 
55.6 - 80, n=64 0 9.5% 24.1% 8.5% 
All, n=173 69.3% 24.4% 0.3% 37.9% 
TOTAL, (N = 545) 100% 100% 100% 100% 
χ2 test p-value  <0.001 (8 df) 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RRP: Recommended Retail Price 
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Chapter 5: The Impact of Training on Knowledge of the Recommended Retail Price 
for AMFm Co-paid Antimalarials in Urban and Rural Outlets in Ghana 
 
Introduction 
Even though the World Health Organization (WHO) has recommended 
artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated 
P. falciparum malaria, they remain relatively expensive and largely unaffordable to the 
rural poor, who are both more susceptible to getting malaria and often face challenges 
accessing antimalarial outlets. Malaria stakeholders therefore created the Affordable 
Medicines Facility – malaria (AMFm), which was piloted in 7 countries including Ghana 
between 2010 and 2013, as a financing mechanism for quality-assured ACTs (QAACTs), 
which had a relatively low recommended retail price tag (RRP). The AMFm involved 
price negotiations with manufacturers, subsidies, and supporting interventions (SIs).  
Retailer awareness of the RRP and correctly specifying it (knowledge) has been 
shown to be a strong independent predictor of stocking QAACTs at the RRP. The AMFm 
objectives were increasing affordability, availability, market-share, and use of QAACTs. 
Creation of knowledge about the AMFm intervention and the RRP for the co-paid 
QAACTs was an important intermediary outcome of the SIs accompanying its 
implementation in Ghana. Using data from the independent evaluation (IE) of the 
AMFm, we employed survey weighted multivariate logistic regression techniques to 
explore differences between urban and rural outlets in the association between exposure 
to training and knowledge of the RRP for co-paid QAACTs in private-for-profit outlets. 
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Among outlets in rural locations, the odds of having knowledge of the RRP was 
10.23 times higher for outlets with at least one AMFm trained employee compared to 
those with none (p<0.001). On the other hand, for outlets without any AMFm trained 
employees, the odds of having knowledge of the RRP was 9.53 times higher for outlets in 
urban locations compared to those in rural areas (the reference category) (p<0.001). The 
similarity of these two odds ratios (10.23 and 9.53) indicates that training raises outlets in 
rural locations to an odds ratio of having knowledge of the RRP equivalent to that of 
outlets in urban locations that had not undergone any training (rural untrained outlets as 
reference group).  Our computations further showed the marginal impact of training for 
rural outlets as increasing the probability of knowledge by 46% (p<0.001), while for 
urban outlets it was only 4.8% (p=0.208). Thus knowledge of the RRP as an outcome of 
having received training was particularly important for rural outlets. In contrast, the 
impact of training on knowledge among urban outlets was much less impressive. We 
believe that this difference is due to there being many other sources of knowledge of the 
AMFm beyond training, especially in urban areas, allowing less room for improvement in 
knowledge with training in urban areas compared to rural areas. 
Based on these findings and estimates of malaria cases per outlet across malaria 
epidemiologic zones in Ghana, we recommend that in addition to increasing the 
proportion of retailers trained and intensifying other SIs in high prevalence and rural 
areas, ongoing measures aimed directly at increasing access to outlets and driving down 
the case-outlet ratio are intensified. These measures include building of Community-
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based Health Planning and Services compounds, promoting the use of long lasting 
insecticide treated nets, and carrying out indoor residual spraying. 
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Background 
Malaria continues to be a major public health concern in Ghana. Transmission 
occurs year round, with peaks during the rainy season. Though there is risk of malarial in 
all regions of the country, infection rates are higher in rural than in urban areas. Public 
sector health facility data show that malaria accounts for 38.2% of all outpatient illnesses, 
34.9% of all admissions, and 33.7% of all deaths in children under 5 years old (NMCP, 
2010). Data from the public healthcare sector reflects a small fraction of actual malaria 
infections, since about 60% of the population access treatment from the private for-profit 
sector, particularly from pharmacies and licensed chemical shops (Adeyi & Atun, 2010; 
Buabeng et al., 2010; PMI, 2011; RBM Partnership, 2013). 
Socioeconomic factors (which also affect the urban poor) (WHO, 2010a), often 
limit access to prompt treatment in rural areas, compounded by the fact that more health 
outlets are located in urban areas (GSS and ICF Macro, 2009). This combination means 
that  the rural poor are both more susceptible to getting malaria, and less able to access 
and afford effective treatment (Worrall et al., 2005). 
Since 2001, the World Health Organization (WHO) has recommended 
artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated 
P. falciparum malaria (WHO, 2006). Ghana’s current antimalarial policy includes three 
ACTs: Artesunate-Amodiaquine (ASAQ), Artemether-Lumefantrine (AL) and 
Dihydroartemisinin-Piperaquine (DHAP) as recommended first-line therapies for the 
treatment of uncomplicated malaria (MoH, 2009a). Even though the WHO recommends 
ACTs for the treatment of uncomplicated malaria, their high cost relative to less-effective 
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medicines remains a major barrier to access. The Affordable Medicines Facility – malaria 
(AMFm), hosted by The Global Fund to Fight AIDS Tuberculosis and Malaria, was a 
financing mechanism for quality-assured ACTs (QAACTs) involving price negotiations 
with manufacturers, subsidies,  and supporting interventions (SIVs). The AMFm was 
designed to increase affordability, availability, market-share, and use of QAACTs. 
Between 2010 and 2013, the AMFm was piloted in 7 countries including Ghana, where 
its outcomes were measured and evaluated by an Independent Evaluation (IE) team 
(Tougher et al., 2012). 
The AMFm IE in Ghana showed significant increases in QAACT market share in 
the private-for-profit sector between baseline and endline surveys (from 6.5% to 51.8% 
of all antimalarials sold/distributed in the week preceding the survey). This increase was 
similar for rural and urban areas. However, both recognition of the AMFm green-leaf 
logo and knowledge of the recommended retail price (RRP) for QAACTs were higher in 
urban outlets than in rural ones (AMFm IE Team, 2012; J. Amuasi et al., 2012). Despite 
these patterns, at endline, the AMFm IE in Ghana found no differences in outlets having 
at least one staff member that received training on co-paid QAACTs between urban and 
rural areas. However at endline, more private-for-profit outlets in urban than rural areas 
(45% vs. 21%) had an employee with a health-related qualification (pharmacy, nurse or 
medical doctor related training).  
An important intermediary outcome of the country roll-out of AMFm SIVs was 
the creation of knowledge about the AMFm intervention and the RRP for the co-paid 
QAACTs (see Figure 3: Conceptual Model). The hypothesized relationship between 
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knowledge and adherence to the RRP is supported by findings that awareness of the RRP 
and correctly specifying it (knowledge), was a strong independent predictor of stocking 
some or all co-paid QAACTs at RRP (p<0.001 for both) (Amuasi et al., unpublished 
manuscript).  
Of the 24.7 million co-paid QAACTs delivered to Ghana within the AMFm 
evaluation period, 95% were purchased by private for-profit first-line buyers 
(wholesalers). The private for-profit sector was responsible for at least two-thirds of all 
antimalarials sold or distributed at baseline and endline, with a higher market share of 
QAACTs at endline in urban areas than in rural areas (76% vs. 57%). These findings 
confirm the importance of the private sector in malaria control, and reflect the positive 
impact that the AMFm had on the antimalarial delivery system in Ghana. The private 
health sector is much larger and more complicated than the public sector, resulting in 
different kinds of challenges with regard to making ACTs accessible.  
Comparing sectors for changes in QAACT availability, the largest rise in QAACT 
availability was seen in private for-profit outlets (from 24.8% of outlets at baseline to 
82.6% at endline stocking at least one QAACT). Between baseline and endline, QAACT 
availability also increased proportionately more in rural than in urban areas (by 58 vs. 38 
percentage points). This difference resulted in a reduction in the urban-rural gap in 
QAACT availability at baseline from 28.3 percentage points, to 10.8 percentage points at 
endline (AMFm IE Team, 2012). 
Irrespective of the disease/condition of interest, age group, or economic standing 
of a country, rural/urban differences in access to health services persist (Fotso, 2006; 
 85 
 
Kozhimannil, Hung, Prasad, Casey, & Moscovice, 2014; Moscovice & Casey, 2009; 
Strasser, 2003; Virnig, Ma, Hartman, Moscovice, & Carlin, 2006). Recognizing and 
understanding their underlying causes is therefore critical to improving outcomes from 
interventions (WHO, 2010a). 
In this paper, we explore differences between urban and rural outlets in the impact 
of training on knowledge of the recommended retail price for co-paid QAACTs in 
private-for-profit outlets. We also discuss the malaria control policy implications of our 
findings. 
 
Methods 
Data Source 
We used data collected as part of the AMFm IE endline survey in Ghana carried 
out in 2011. The IE took into account the well-known malaria prevalence and socio-
economic disparities between rural and urban areas by calculating sample sizes separately 
for urban and rural domains (Tougher et al., 2012). A multi-phase cluster sampling 
approach was adopted with a predetermined number of geographic clusters selected with 
probability proportional to size. Other sources describe the unique IE sampling approach 
in Ghana, data collection, and analysis process in detail (J. Amuasi et al., 2012; Tougher 
et al., 2012).  
Data on Plasmodium falciparum malaria prevalence by district were obtained 
from the 2010 posterior predictive distribution model estimates produced by the Malaria 
Atlas Project (MAP). Shapefiles and other geographic information systems data on 
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districts in Ghana were obtained from the Centre for Remote Sensing and Geographic 
Information Services of the University of Ghana via ESRI’s GeoCommons platform 
(CERSGIS, 2012).  
The University of Minnesota Institutional Review Board (IRB) determined that 
our study was using secondary data, did not meet the regulatory definition of research 
with human subjects, and so did not require additional IRB clearance. Prior to the IE data 
collection in Ghana, IRB clearance was obtained from the Ghana Health Service Ethical 
Review Committee on Research Involving Human Subjects (ERCRIHS).  
Data Management 
The Ghana IE endline survey dataset comprise information on 765 private sector 
outlets and a total of 6,117 antimalarial products. All outlets that were enumerated and 
completed the interview were included in our study, irrespective of whether or not they 
stocked antimalarials. A total of 117 outlets were excluded from the sample because they 
fell into either of the following categories:  1) Were not screened, 2.) Did not meet the 
screening criteria, 3) Were not interviewed, 4) Did not fully complete the interview and 
antimalarial audit, and 5) Were private not-for-profit facilities. 
The endline survey data on outlet location was layered on the map of Ghana 
districts using ArcMap v10.2 (ESRI, 2013). The data on Plasmodium falciparum malaria 
prevalence by district was extracted from the MAP database and merged with the endline 
survey data using the “spatial join” feature in ArcMap.  
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Variables 
Knowledge of the RRP for the QAACTs with the AMFm logo and being able to 
correctly specify it to be USD 0.96 was our outcome of interest.  The primary predictors 
included in our analysis were whether at least one employee of the outlet had received 
training on co-paid QAACTs at endline, and whether the outlet was in an urban or rural 
location.  
We included other potentially confounding outlet characteristics as independent 
variables in our analyses. These included type of outlet (pharmacy or licensed chemical 
shop), Falciparum malaria prevalence (Pfpr - low, mid or high category), and the 
category of malaria epidemiologic zone within which the outlet was located. The 
availability of malaria testing, completion of secondary school of at least 1 employee, and 
having a pharmacist, nurse or doctor on staff, were also included to account for the 
outlet’s level of sophistication. We also used number of workers employed in the outlet 
as a measure of outlet size. 
Statistical Approach 
We used multivariate logistic regressions to assess the association of exposure to 
training and urban/rural location with knowledge of the RRP, restricted to the private-for-
profit sector. We included an interaction between training and location to assess whether 
the association between training and knowledge differed between urban and rural 
locations. As shown in Table 15, we adjusted/controlled for variables that were 
statistically significant from our examination of the unadjusted relationships between 
independent variables and our knowledge outcome.  
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Odds ratios and predicted probabilities were generated and used to explain the 
associations between training and knowledge among outlets located in urban and rural 
areas. In all models, we performed several sensitivity analyses using alternate models, 
including using different variable categorizations, to confirm that the observed effects 
were not artifacts. P-values ≤ 0.05 were considered significant. All analyses were carried 
out using STATA v12 (StataCorp, 2012). For all analyses, we used the IE endline survey 
weights to account for the complex nature of the survey design.  
 
Results 
Private Sector Outlet Characteristics 
From the AMFm IE dataset, we identified 648 private for-profit outlets that met 
our inclusion criteria (86% of all private for-profit outlets that were enumerated) (see 
Table 14). The sample was composed of near equal numbers of pharmacies and licensed 
chemical shops (53.7% and 41.8% respectively). Outlets located in urban areas 
constituted 73.2% of the sample, and 36.6% of the survey respondents were the outlet 
owners. Outlets with two employees made up almost 40% of the sample, and the mean 
number of prescribers/dispensers per outlet was 2.2 (95% CI: 2.1, 2.4). Just less than half 
of the sampled outlets were from the coastal zone (47.8%), while 38.1% and 14% were 
from the forest and northern savanna zones respectively. At 46%, almost half of the 
sampled outlets had at least one employee who had received training on the co-paid 
QAACTs. About 84% of the sampled outlets stocked at least 1 co-paid QAACT, and 
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82% of outlets had a respondent who knew there was a RRP for the co-paid QAACTs 
and was able to correctly specify it to be USD 0.96 (had knowledge). 
Training, Urban/Rural Location and Knowledge 
After adjusting for those variables that had a significant unadjusted association 
with knowledge, training, urban/rural location, and their interaction, remained 
significantly associated with knowledge. No other variables had significant associations 
with knowledge in our multivariate model. Nevertheless it is worth noting that an outlet 
being a pharmacy vs. a licensed chemical shop, and having at least one employee who 
had completed secondary school, were positively associated with knowledge (OR=1.81, 
p=0.162 and OR=2.03, p=0.187 respectively) (see Table 15 and Appendix 21). 
 Among outlets in rural locations, the odds of having knowledge of the RRP was 
10.23 times higher for outlets with at least one AMFm trained employee compared to 
those with none (p<0.001)  (see Table 15). On the other hand, for outlets without any 
AMFm trained employees, the odds of having knowledge of the RRP was 9.53 times 
higher for outlets in urban locations compared to those in rural areas (the reference 
category) (p<0.001). The similarity of these two odds ratios (10.23 and 9.53) indicates 
that training raises outlets in rural locations to an odds ratio of having knowledge of the 
RRP equivalent to that of outlets in urban locations that had not undergone any training 
(rural untrained outlets as reference group). In contrast, the impact of training on 
knowledge among urban outlets was much less impressive (also see Appendix 22). 
 Although not shown in Table 15 (see Appendix 21), we also examined the 
marginal effect of training on knowledge separately among urban and rural outlets, as the 
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difference between the predicted probability of having knowledge for outlets with and 
without at least one AMFm trained employee. We found that rural outlets without 
training had a predicted probability of knowing the RRP of just under 40% (95% CI: 
23%, 55%), while all other combinations of urban/rural and training/no training had a 
predicted probability of knowing the RRP of over 80%. Urban outlets that had received 
training had the highest predicted probability of knowing the RRP (89%; 95% CI: 84%, 
94%). Our computations showed the marginal impact of training for rural outlets as 
increasing the probability of knowledge by 46% (p<0.001), while for urban outlets it was 
only 4.8% (p=0.208) (see Appendix 23). Again we see knowledge of the RRP as an 
outcome of having received training, was particularly important for rural outlets. 
Nevertheless training still had a positive relationship with knowledge among urban 
outlets. 
Malaria prevalence and epidemiologic zones 
To determine the number of malaria cases per annum, we multiplied population 
size per cluster by malaria prevalence estimates. We calculated the population/outlet and 
malaria cases/outlet ratios for a combined sample of public and private sector outlets. We 
also standardized our computation of number of cases and the case/outlet ratio to the 
population size of the coastal zone and lowest malaria prevalence category, to produce 
tables by malaria epidemiologic zone and malaria prevalence category respectively. We 
restricted these computations to outlets enumerated in clusters only, because a complete 
census of outlets was conducted only in clusters. For both actual and standardized 
computations, the population/outlet and cases/outlet ratios increased from coastal through 
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to the northern savanna zone and from low through to high prevalence area (see figure in 
Appendix 24 and Tables 16a and 16b).  
After adjusting for other covariates in the multivariate model, neither differences 
in Pfpr level nor malaria epidemiologic zone were associated with knowledge of the RRP 
(p=0.342 and p=0.885 respectively). The predicted probability of knowing the RRP was 
85% for low Pfpr areas and 75% for both mid- and high Pfpr areas. Stratified by 
ecological zones, the predicted probability of knowing the RRP was 76%, 79%, and 77% 
for the coastal, forest and northern savanna zones respectively.  
 
Discussion 
Before the turn of the last century, susceptibility to malaria and its negative health 
outcomes was to a large extent focused on genetic polymorphisms, geographic, and 
climatic dispositions (Aidoo et al., 2002; Gething et al., 2011). However over the past 
decade, there has been an increased recognition of the important role socio-economic 
factors play by themselves or in association with epidemiologic determinants of malaria 
(J. D. Sachs, Mellinger, & Gallup, 2001; J. Sachs & Malaney, 2002; Worrall et al., 2005). 
In Ghana, malaria has been shown to be socioeconomically catastrophic especially to the 
rural poor, through a reduction in acquisition of human and physical capital (K. Asenso-
Okyere & Asante, 2003; W. K. Asenso-Okyere & Dzator, 1997).  
One of the critical goals of the AMFm design was to reach and impact rural areas, 
where the poorest of the poor, who also suffer disproportionately from malaria are found 
(Joel G Breman, Alilio, & Mills, 2004; Holtz et al., 2002; J. Sachs & Malaney, 2002; 
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Worrall et al., 2005). Inequities in access to health services, including to antimalarials, 
between the poor in rural areas and people of higher socio-economic status in urban areas 
have consistently been noted (Cohen et al., 2010; MMV, 2008). Also, there is evidence 
that both retail outlet characteristics and practices of retailers differ across rural and urban 
areas (Wafula et al., 2012). Thus, one measure of the success of the AMFm was whether 
the intervention led to an increase in the use of ACTs, including among the poor in rural 
communities (Yamey et al., 2012).  
Since antimalarials are available over-the-counter, consumers might be expected 
to exercise personal agency in requesting their preferred antimalarial during an encounter 
with a private retailer. Therefore one may be inclined to argue that while knowledge of 
the AMFm intervention and RRP among retailers is necessary, as shown by our study, of 
greater importance would be knowledge of the AMFm intervention by consumers. While 
this argument is plausible, findings from exit interviews from the logo study component 
of the IE suggest otherwise. Even though 61% of consumers said they had seen the 
AMFm logo before, 85% purchased a particular antimalarial based on recommendations 
from the retailer, friends, or family. No consumer purchased a particular treatment 
because they heard of the drug from radio/TV, and only 2.3% purchased a particular 
antimalarial because they thought it was inexpensive (AMFm IE Team, 2012). This 
suggests that the consumer knowledge of the AMFm and arguably even about the RRP, 
might not necessarily determine their choice of drug. Consumers did not exercise 
personal agency, but rather deferred choice to the retailer. This finding of choice of 
antimalarial treatment being determined by the retailer brings into question the extent to 
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which a patient-centered approach is being pursued in the Ghanaian private health service 
delivery sector (Ghana News Agency, 2013). 
Our data showed that 93.4% of private-sector retailers (97.3% in the urban and 
87.3% in rural areas) recognized the green-leaf logo. Of those retailers who had seen or 
heard of the logo, 78.3% stated that their source was radio/TV (83.7% in the urban and 
69% in the rural areas).This suggests that among retailers in Ghana, radio/TV is a critical 
source of knowledge. Our findings reinforce the hypothesis that the retailer’s, as opposed 
to the consumers’ knowledge, was most critical to the outcomes of the AMFm. The pilot 
study carried out in Tanzania to provide insight into whether AMFm medicines had the 
potential to reach poor rural communities, also showed that the recommendation of a 
provider was an important factor in the consumer’s decision to purchase an ACT (Cohen 
et al., 2010).  
Our analyses further reveals that while there was no disparity between rural and 
urban outlets in exposure to training (unadjusted OR=1.19, p=0.56), the positive effect of 
training on knowledge of the RRP was significantly weaker in urban areas than in rural 
areas (adjusted OR of the interaction=0.15, p=0.001). In fact, in urban areas, training did 
not have any significant effect (the marginal effect, p=0.208). We believe that this 
difference is due to there being many other sources of knowledge of the AMFm beyond 
training, especially in urban areas, allowing less room for improvement in knowledge 
with training in urban areas compared to rural areas. These other sources of knowledge 
include over 10,000 radio spots and 400 television commercials on the AMFm aired in 
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English and 7 other local languages across the country between the baseline and endline 
survey periods (AMFm IE Team, 2012). 
Inequities in ownership of radio and TV, and by extension electricity and other 
amenities in general, are likely to be associated with inequities in knowledge of the 
AMFm program and the RRP between urban and rural outlets, particularly in the private 
sector. Overcoming these inequities requires extra effort to be made in carrying out 
Information Education & Communication (IE&C) and Behavior Change Communication 
(BCC) training activities in rural areas, in order to achieve outcomes equitable to those in 
urban areas. We suggest that the inequity in knowledge of the AMFm and the RRP 
between urban and rural areas seen from our analyses could be attributable in part to an 
unintentional failure to recognize urban/rural differences and to adapt supporting 
interventions sufficiently enough to address these by focusing more on rural areas.  
Intuitively, it makes sense that greater IE&C, BCC, training and other efforts to 
disseminate knowledge be focused on rural areas, which often tend to be areas of high 
malaria prevalence. The AMFm stakeholders were particularly concerned that rural 
residents would be disadvantaged over urban residents regarding access to the co-paid 
QAACTs. Those in the lower wealth quintiles who stand to benefit the most from co-paid 
QAACTs live in rural areas, which often have the highest malaria prevalence in the 
country. We acknowledge that there often tends to be an association between rural-ness 
and high malaria prevalence. Nevertheless we argue that simply focusing more 
knowledge-generating activities in rural and high malaria prevalence areas might not 
necessarily lead to improved AMFm outcomes such as increased stocking of co-paid 
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QAACTs, their use, and a resulting decrease in morbidity/mortality form malaria. We 
make this argument because the high number of cases-per-outlet seen in the high 
prevalence areas and northern savanna zones suggests that there are simply not enough 
outlets to serve the cases (see Tables 16a and 16b). Thus, even achieving complete 
coverage and saturation in AMFm knowledge among retailers might not mitigate the 
problem of access to outlets and co-paid QAACTs. 
An integrated systems approach (Gyapong et al., 2010) is therefore needed to 
ensure optimal outcomes of interventions involving drug subsidies such as the AMFm 
(Atun, de Jongh, Secci, Ohiri, & Adeyi, 2010; Cavalli et al., 2010; de Savigny & Adam, 
2009). We therefore recommend that in addition to increasing the proportion of retailers 
trained and intensifying other SIVs in high prevalence and rural areas, ongoing measures 
aimed directly at increasing access to outlets and driving down the case-outlet ratio are 
intensified. These measures include building of Community-based Health Planning and 
Services compounds (GoG, 2013; Nyonator, Awoonor-Williams, Phillips, Jones, & 
Miller, 2005), promoting the use of long lasting insecticide treated nets, and carrying out 
indoor residual spraying (Yakob, Dunning, & Yan, 2011). 
The AMFm IE in Ghana investigated the percentage of the population living in 
clusters with at least one outlet that stocked QAACTs. Even before the AMFm (at 
baseline), the IE report showed that Ghana already had 100% coverage for this measure 
(see Appendix 25). However in interpreting this indicator, it should be noted that the 
study design aimed to choose sample clusters with a population size of about 10,000-
15,000. In Ghana, the population size per cluster was often much larger, and these 
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clusters did not represent any formal administrative area. This means that having at least 
one QAACT-stocking outlet available in the cluster did not necessarily reflect reasonable 
access for the whole population. Also, this measure does not reflect other dimensions of 
access such as information, retailer behavior and affordability (AMFm IE Team, 2012; J. 
Amuasi et al., 2012).  
There are a number of limitations to our study. While we adjusted for differences 
in malaria prevalence between urban and rural areas, we did not account for differences 
in exposure to sources of knowledge other than AMFm training, such as radio and TV 
advertisements. Access to these other sources of knowledge is influenced by various 
socio-economic factors which also tend to differ between rural and urban areas. We were 
unable to take these other sources of knowledge into account, although it is fair to say 
these unmeasured factors are often correlated with malaria prevalence (J. Sachs & 
Malaney, 2002; Worrall et al., 2005). Since we controlled for malaria prevalence, these 
unmeasured factors are unlikely to have changed our conclusions.  
More important however, are the definitions of urban and rural. In Ghana and 
most of sub-Saharan Africa, definitions of urban or rural are used for census area 
classifications, survey sampling, and evaluation of geographic and socio-economic 
equity. However, restricting the definition of a location to the binary of urban or rural has 
often been viewed as too simplistic to properly describe the significant variations in a 
population’s potential access to services (Harpham & Tanner, 1995) [page 36] (Wang, 
2005). In Ghana for example, there are also some rural areas in the coastal zone that may 
have better access to knowledge that than urban areas in the northern savanna zone. Thus 
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population density and resources are not completely correlated. In the USA, these 
concerns about rural/urban classification led to the creation of Rural-Urban Commuting 
Area Codes to better aid research and inform policy (Hart, Larson, & Lishner, 2005).  
 By creating indices such as population per outlet and cases per outlet (see Tables 
16a and 16b), we invariably suggest that there is homogeneity in access within malaria 
prevalence or ecologic zones. However it is reasonable to believe that the number of 
cases per outlet would vary widely within malaria prevalence or ecologic zone as a result 
of many factors such as outlet type and size. Nevertheless at the aggregated level, this 
should not compromise the overall policy implications of our findings. 
Our study shows the importance of training as part of the AMFm in generating 
knowledge of the RRP for co-paid QAACTs among retailers, particularly in rural areas. 
We also see that because avenues for acquiring knowledge are limited in rural areas, 
dwellers end up being further disadvantaged when no significant extra effort is put into 
making knowledge of the intervention available directly to the population. Particularly in 
rural areas with high malaria prevalence, improving access to knowledge among retailers 
must be combined with improving access to services among consumers, and intensifying 
efforts at lowering prevalence.  
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Table 14: Unweighted distribution of sample characteristics 
Characteristics 
Private for-
profit outlets 
Total: N, % 648, 100%* 
Respondent knew and specified the RRP for co-paid QAACTs 81.9 
At least 1 employee from the outlet received training on QAACTs with the 
logo 46 
Malaria testing (microscopy/RDT) available at the outlet 4.5 
At least 1 employee completed secondary school 92.3 
At least 1 employee is a  pharmacist, nurse or doctor  51.4 
Type of outlet 
Licensed chemical shop 53.7 
Pharmacy 41.8 
Location Urban 73.2 
Rural 26.9 
Number of employees 
One 13.7 
Two 36.4 
Three 22.1 
Four or more 26.5 
Malaria epidemiologic zone** 
Coastal savanna/Mangrove swamps 47.8 
Tropical rain forest 38.1 
Northern savanna 14 
Falciparum malaria prevalence 
(%) 
Low (10-24) 33.3 
Medium (25-34) 32.3 
High (35-70) 34.4 
  
*Percentages may not add up to 100% because of rounding or missing data 
§Approximation based on demarcations of ecological zones (Coastal, Forest and Northern) used 
by the Ghana Statistical Service  
RRP: Recommended Retail Price 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
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Table 15: Adjusted odds ratio of knowing the RRP for various outlet characteristics 
Outlet Characteristics 
Knowledge of the 
RRP 
Odds 
Ratio p-value 
Location and Training 
categories (using rural and 
untrained as the reference 
group)*** 
Rural and Untrained Ref. - 
Rural and Trained 10.23 *<0.001 
Urban and Untrained 9.53 *<0.001 
Urban and Trained 14.60 *<0.001 
Location and Training 
categories (using urban and 
untrained as the reference 
group)*** 
Rural and Untrained 0.10 *<0.001 
Rural and Trained 1.07 0.854 
Urban and Untrained Ref. - 
Urban and Trained 1.53 0.204 
Trained vs. Untrained§ 
Rural Ref. 
*0.001 
Urban 0.15 
Type of outlet 
Licensed chemical shop Ref. 
0.162 
Pharmacy 1.81 
At least 1 employee completed 
secondary school 
No Ref. 
0.187 
Yes 2.04 
Malaria testing available 
No Ref. 
0.937 
Yes 1.05 
At least 1 employee is a  
pharmacist, nurse or doctor  
No Ref. 
0.719 
Yes 0.90 
Number of employees 
One Ref. 
0.273 
Two 0.68 
Three 0.75 
Four or more 1.38 
Malaria epidemiologic zone** 
Coastal savanna/Mangrove swamps Ref. 
0.885 Tropical rain forest 1.25 
Northern savanna 1.09 
Falciparum malaria prevalence 
(%) 
Low (10-24) Ref. 
0.342 Medium (25-34) 0.44 
High (35-70) 0.44 
P-values were derived from χ2 tests of significance of the differences in adjusted survey 
weighted odds ratios of the outcomes for each variable 
*Statistically significant p-value (≤0.05) 
**Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) 
used by the Ghana Statistical Service  
***Training refers to an employee from the outlet receiving training on QAACTs with the logo. 
Location is either urban or rural 
§This is the interaction (location*training) and the OR is really a ratio of ratios 
QAACT: Quality Assured Artemisinin-based Combination Therapy 
RRP: Recommended Retail Price 
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Table 16a: Malaria epidemiologic zone, population, and number of cases per annum for public and 
private sector outlets within censused clusters† 
Population/Cases 
Malaria Epidemiologic Zones*, N=512 
Coastal (n=194) Forest (n=216) Savanna (n=102) 
Actual Actual Actual 
Population exposed 245,472 349,662 206,236 
Number of cases** 69,280 133,303 116,842 
Number of cases (standardized to coastal zone) - 93,582 139,071 
Population per outlet (public and private) 1,265 1,619 2,022 
Cases per outlet (public and private) 357 617 1,146 
†"Censused clusters" refers to clusters within which all outlets with the potential to sell antimalarials were 
visited 
*Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the Ghana 
Statistical Service  
**Number of cases=Prevalence*population 
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Table 16b: Malaria prevalence, population, and number of cases per annum for public and private 
sector outlets within censused clusters† 
Population/Cases 
Malaria Prevalence (%), N=512 
Low, 10-24 
(n=122) 
Mid, 25-34 
(n=151) 
High, 35-70 
(n=239) 
Actual Actual Actual 
Population exposed 95,854 251,219 454,297 
Number of cases** 15,378 76,175 227,872 
Number of cases (standardized to low 
prevalence area) - 29,065 48,080 
Population per outlet (public and private) 786 1,664 1,141 
Cases per outlet (public and private) 126 504 573 
†"Censused clusters" refers to clusters within which all outlets with the potential to sell antimalarials were 
visited 
*Approximation based on demarcations of ecological zones (Coastal, Forest and Savanna) used by the 
Ghana Statistical Service  
**Number of cases=Prevalence*population 
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Chapter 6: Conclusions and Future Implications 
This 3-paper dissertation examined the relationship between training on the 
Affordable Medicines Facility – malaria (AMFm) co-paid quality assured artemisinin-
based combination therapies (QAACTs), knowledge of the AMFm and the recommended 
retail price (RRP) for QAACTs, and stocking of QAACTs. 
Accounting for 33.7% of all deaths in children under-five years, malaria is a 
disease of great public health importance in Ghana, and the entire Ghanaian population of 
25 million lives at risk of the disease. The World Health Organization (WHO) 
specifically recommends artemisinin-based combination therapies (ACTs) as first-line 
treatment for uncomplicated P. falciparum malaria. In this regard, the Ghana National 
Malarial Control Program (NMCP) has included in its national strategic plan for malaria, 
to by 2015, be treating 90% of malaria patients with ACTs. 
However low uptake of ACTs persists, largely been on account of the following: 
1) ACTs are provided almost entirely by the public sector, and over 60% of patients 
access anti-malarial treatment through the private sector, 2) in the private sector ACTs 
are hardly available because they are much more expensive than other non-recommended 
antimalarials and so many patients, particularly in rural areas, are unable to afford them, 
3) overall there are fewer outlets for obtaining ACTs in rural areas than in urban areas, 
even though the burden of malaria is higher in rural areas. 
Therefore the AMFm was introduced as a factory-gate negotiation and co-
payment (made by the Global Fund) of up to 95% of the QAACTs, along with a number 
of supporting interventions. These QAACTs were identified by a green leaf logo and had 
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a RRP equivalent to USD 0.96. Having been made affordable to consumers in both the 
public and private health sectors, the co-paid QAACTs were expected to become the 
antimalarial of choice for even the most rural and poor populations. The AMFm was run 
as a 2-year pilot in 7 countries including Ghana, starting in 2010. 
The Global Fund commissioned an Independent Evaluation (IE) of the AMFm in 
each pilot country to assess the achievement of the AMFm objectives by measuring 
changes between baseline and endline surveys in availability, price, market share and use 
of QAACTs. The AMFm IE in Ghana showed that particularly in the private sector, the 
promotion of the AMFm led to a high provider awareness of the intervention, its logo, 
and RRP at endline. Correspondingly, QAACT availability across all outlets in Ghana 
increased by 52 percentage points, from 31% at baseline to 83% at endline (p<0.0001). 
Using data from the AMFm IE endline survey, this research contributes to the 
emerging body of knowledge on the outcomes of the AMFm in Ghana by exploring 
“why” and “how” the outcomes documented in the IE report came to be observed, 
specifically by: 1) exploring the relationship between various outlet characteristics and 
QAACT stocking in both the public and private sector; 2) further examining QAACT 
pricing by determining factors accounting for outlet’s adherence to their recommended 
retail price in the private-for-profit sector; and 3) identifying differences between urban 
and rural outlets in the impact of training on knowledge of the recommended retail price 
for co-paid QAACTs in private-for-profit outlets. 
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Predictors of Stocking QAACTs 
Chapter 3 of this dissertation was based on the premise that public and private 
sector outlets function differently, and we examined outlet characteristics and how they 
are able to predict outlets that did and those that did not have QAACTs in stock. 
We found that factors associated with QAACT stocking varied between and 
public and private sectors for the three QAACT availability definitions we created: i) 
Stocked some QAACTs, ii) Stocked some co-paid QAACT, and iii) Stocked some co-
paid QAACTs without stocking any oral artemisinin monotherapies or non-artemisinin 
therapies. While a high percentage of public and private outlets stocked at least one co-
paid QAACT, public sector outlets were by far better at stocking QAACTs than private 
sector outlets when not stocking artesunate monotherapies (AMTs) and non-artemisinin 
therapies (nATs) was included in the definition of QAACT stocking.  
In the private sector, having received training was associated with a high 
predicted probability of stocking some QAACTs and stocking at least one co-paid 
QAACT, but not with stocking some co-paid QAACTs without stocking any oral AMTs 
or nATs. However in the public sector, training was not a statistically significant 
predictor of any definition of QAACT availability.  
We concluded that in-service training is generally an important tool towards 
improving QAACT stocking practices especially in the private sector, where stocking 
decisions are often made by the outlet owner or manager in consultation with 
prescribers/dispensers and based on consumer demand, reflected by sales figures. 
However, the larger more complicated nature of the private sector antimalarial market 
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makes it more difficult to be regulated, monitored and aligned with national policy, 
where QAACTs are to be stocked and oral AMTs and nATs not stocked. Therefore 
beyond training, we recommend that approaches to improving policy adherence in the 
private sector, such as imposing severe penalties on importers of oral AMTs and nATs, 
coupled with explicit campaigns vilifying their use should be adopted by policy makers. 
In the public sector, stocking decisions and the organization of service delivery 
mechanisms are made centrally (at district and regional level). Thus, as expected, training 
was not a significant predictor of any of our stocking outcomes. 
For both public and private sector outlets however, our findings suggested that 
efforts at improving QAACT stocking need to pay special attention to smaller outlets, 
especially those with 1-2 employees. We further recommended that getting outlets to hire 
staff with health-related qualifications should be pursued as an effective long-term 
approach towards achieving ACT stocking benchmarks and recommended treatment 
practice. 
Adherence to the Recommended Retail Price 
Chapter 4 further examined QAACT pricing by determining factors accounting 
for outlet’s adherence to the recommended retail price in the private-for-profit sector. 
This study addresses stakeholder’s concerns that retailers, who are the final interface 
between the patient and the QAACT, could seize the opportunity to make super-normal 
profits and not pass the high-level AMFm subsidy on to consumers. 
Our study indicated that although retailer’s adherence to the RRP for co-paid 
QAACTs can be high when knowledge about the RRP is present, knowledge was 
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associated with a much higher predicted probability of stocking some co-paid QAACTs 
at RRP than stocking all at RRP. We also presented convincing evidence that aside from 
knowledge, there are other important factors to consider if improvement in adherence to 
the RRP is desired. 
We also found that in stocking co-paid QAACTs, stocking AL only led to a 
higher predicted probability of stocking some or all at RRP than stocking ASAQ only, 
and a higher predicted probability of stocking all at RRP than stocking both ASAQ and 
AL. A bias in stocking in favor of adult formulations for AL and pediatric formulations 
for ASAQ was also found, and we concluded that these phenomena are likely to be a 
reflection of existing consumer preferences, which have been observed and echoed by the 
National Malaria Control Program.  
Our study led us to recommend that information on the AMFm subsidy be 
disseminated with greater focus on areas of high malaria prevalence, such as the northern 
savanna zone. Innovative ways of delivering information on the subsidy tailored 
specifically to these high Pfpr areas is more likely to increase awareness of the 
availability and RRP of the co-paid QAACTs than more generalized approaches. We also 
recommended that the Ministry of Health in Ghana consider adopting a policy supporting 
the use of ASAQ for children and AL for adults for the treatment uncomplicated malaria. 
Our findings and other sources indicate that this population segmentation approach to 
multiple first-line antimalarial therapy is already the de-facto situation in Ghana. Thus by 
taking advantage of a situation that has already been created naturally by market forces, 
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the message on co-paid QAACTs and their importance for treatment of uncomplicated 
malaria can be reinforced to allow for even better compliance with RRP.  
Urban-rural Variations in the impact of training on knowledge  
Finally, Chapter 5 identified and examined differences between urban and rural 
outlets in the impact of training on knowledge of the recommended retail price for co-
paid QAACTs in private-for-profit outlets. 
We found that that training raised outlets in rural locations to an odds ratio of 
having knowledge of the RRP equivalent to that of outlets in urban locations that had not 
undergone any training (rural untrained outlets as reference group).  We therefore 
concluded that knowledge of the RRP as an outcome of having received training was 
particularly important for rural outlets. We believe that this difference in impact of 
training in favor of rural outlets is due to there being many other sources of knowledge of 
the AMFm beyond training. These “other sources” are more accessible in urban areas, 
and include radio and TV. Inequities in ownership of radio and TV, and by extension 
electricity and other amenities in general, are likely to be associated with inequities in 
knowledge of the AMFm program and the RRP between urban and rural outlets, 
particularly in the private sector. Overcoming these inequities requires extra effort to be 
made in carrying out Information Education & Communication (IE&C) and Behavior 
Change Communication (BCC) training activities in rural areas, in order to achieve 
outcomes equitable to those in urban areas.  
Based on these findings and estimates of malaria cases per outlet across malaria 
epidemiologic zones in Ghana, we recommended that ongoing measures aimed directly at 
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increasing access to outlets and driving down the case-outlet ratio be intensified along 
with increasing the proportion of retailers trained and intensifying other supporting 
interventions in high prevalence and rural areas. 
In countries like Ghana, where the AMFm pilot was shown to be highly 
successful, the government has expressed willingness to voluntarily commit some of their 
future Global Fund resource allocation and other resources to antimalarial drug subsidies 
post the AMFm. This dissertation therefore lends insight to some of what accounted for 
the findings of the AMFm IE in Ghana, informs policy in the proposed continuation of an 
antimalarial subsidy in the private sector, and is useful for the future design of further 
interventions involving subsidies for essential medicines. 
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Appendices 
 
 
 
Appendix A 
 
 
 
 
Codebook for Appendices 
 
Variable Code Description 
allqaactRRP All co-paid QAACTs sold at or below RRP (yes/no) 
allqaactRRP_oneUSD  All co-paid QAACTs sold at or below 1 USD (yes/no) 
AP_QWLprivate  Formulation of co-paid QAACTs (1-adult only; 2-both adult and pediatric) 
AtleastqaactRRP At least 1 co-paid QAACTs sold at or below RRP (yes/no) 
AtleastqaactRRP_oneUSD  At least 1 co-paid QAACTs sold at or below 1 USD (yes/no) 
Cat3_healthqual  
Category of highest health-related qualification (1-Non-
health-related; 2-No formal training or certification for 
prescribing or dispensing medications; 3-Formally 
trained to prescribe or dispense medications) 
Cat3_NoOfPrescribers  Number of prescribers/dispensers employed (1-1-2; 2-3-4; 3-5 or more) 
Cat3_numberofqaactwithlogo Number of co-paid QAACTs audited (1-1; 2-2-3; 3-4 or more) 
Cat3_PPfpr Falciparum malaria prevalence (%) (1-low; 2-mid; 3-high) 
Cat4_NoOfWorkers_auto  Number of employees/workers (1-1; 2-2; 3-3; 4- 4 or more) 
EcolZoneCFS Malaria epidemiologic zone (1-Coastal; 2-Forest; 3-Savanna) 
fixedoutAmCat4  Stocked at least 1 nAT (yes/no) 
healthqualind At least 1 employee is a pharmacist, nurse or doctor (yes/no) 
identRrp Respondent knew and specified the RRP (yes/no) 
outAmCat1 Stocked at least 1 QAACT (yes/no) 
outAmCat1_logo  Stocked at least 1 co-paid QAACT (yes/no) 
outAmCat1_nologo  Stocked some non-AMFm QAACTs (yes/no) 
outAmCat2 Stocked at least 1 non-QAACT (yes/no) 
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(Continued) Codebook for Appendices 
 
Variable Code Description 
outAmCat3_Oral Stocked at least 1 oral AMT (yes/no) 
Owner The respondent owned the outlet (yes/no) 
pharmlcs The outlet is either a pharmacy or a LCS (1-pharmacy; 2-LCS) 
second At least 1 employee had completed secondary school (yes/no) 
test Malaria testing (microscopy/RDT) available (yes/no) 
trainedProg At least 1 employee from the outlet received training on 
QAACTs with the logo (yes/no) 
typeQWLavail Active ingredients of co-paid QAACTs (1-ASAQ; 2-AL; 3-both ASAQ & AL) 
Urban Urban or rural outlet (1-urban; 2-rural) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 123 
 
Appendix B 
 
 
 
 
 
Weighting 
 
 
To account for these design features in the tabulations, the STATA commands for 
analyzing complex survey data (“svy” commands) were used to weight the data and 
calculate confidence intervals taking clustering and stratification into account.  
 
The IE team declared the primary sampling unit (district), the weight variable (wt), the 
strata and the finite population correction (fpc) factor equaling the sampling fraction for 
each stratum (the number of sampled subdistricts in a stratum divided by the total number 
of subdistricts in the stratum, or 0.5 if the sampling fraction was greater than 50 percent).  
 
Data were survey set as follows: 
svyset district [pweight=wt ], strata(strata) fpc(fpc) 
 
The team calculated a proportion and its 95 percent confidence interval (CI) as follows: 
svy: proportion VariableName 
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Appendix 1 
 
Summary of AMFm outcomes in Ghana 
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Appendix 3 
 
 
Output from the private sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, excluding 
the variable “Malaria testing (microscopy/RDT) available”, because it was not 
significant in the unadjusted analysis 
 
 
 
-------------------------------------------------------------------------------------- 
                     |             Linearized 
           outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
       1.trainedProg |   1.896891   .5367442     2.26   0.028     1.075102    3.346841 
            1.second |   1.208237   .3790141     0.60   0.549     .6438391    2.267394 
                     | 
     Cat3_healthqual | 
                  1  |   1.221203   .4613034     0.53   0.599     .5722583    2.606054 
                  2  |   4.359817    1.84429     3.48   0.001     1.865592    10.18873 
                     | 
Cat3_NoOfPrescribers | 
                  2  |   1.279675    .406632     0.78   0.441     .6763601    2.421149 
                     | 
             1.Urban |   1.145032   .3051363     0.51   0.613      .670781    1.954586 
                     | 
         EcolZoneCFS | 
                  2  |   .8701382   .3425126    -0.35   0.725     .3949564    1.917023 
                  3  |   .6159108   .2539013    -1.18   0.245     .2693167     1.40855 
                     | 
               _cons |   1.869555   .7369135     1.59   0.118     .8476821    4.123288 
-------------------------------------------------------------------------------------- 
--------------------------------------------------- 
                |         df           F        P>F 
----------------+---------------------------------- 
Cat3_healthqual |          2       10.65     0.0001 
         Design |         52 
--------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        0.99     0.3779 
      Design |         52 
------------------------------------------------ 
 
From this model excluding the variable “Malaria testing (microscopy/RDT) available”, 
the p-value for training is even lower than in the model selected (0.028 vs. 0.039). 
However we selected the model in the manuscript in order to maintain homogeneity in 
the model for the 3 different outcomes. The model in the manuscript was selected also 
because the general interpretation of the results did not change with the exclusion of the 
variable “Malaria testing (microscopy/RDT) available”. 
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Appendix 4 
 
 
Output from the private sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 co-paid QAACT”, 
excluding the variable “Malaria testing (microscopy/RDT) available”, because it 
was not significant in the unadjusted analysis 
 
-------------------------------------------------------------------------------------- 
                     |             Linearized 
      outAmCat1_logo | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
       1.trainedProg |    1.93456   .5055809     2.52   0.015     1.145063    3.268398 
            1.second |   1.319177    .424247     0.86   0.393     .6918893    2.515182 
                     | 
     Cat3_healthqual | 
                  1  |   1.269758   .4772431     0.64   0.528      .597274    2.699406 
                  2  |   3.574426   1.349838     3.37   0.001     1.675345    7.626203 
                     | 
Cat3_NoOfPrescribers | 
                  2  |   1.079444   .3019245     0.27   0.786     .6158077    1.892148 
                  3  |    3.15204   2.173213     1.67   0.102     .7902091    12.57307 
                     | 
             1.Urban |    1.20814   .3177029     0.72   0.475      .712765    2.047802 
                     | 
         EcolZoneCFS | 
                  2  |   .9818793   .3588588    -0.05   0.960     .4715739    2.044402 
                  3  |   .6750887   .2571717    -1.03   0.307     .3143232    1.449924 
                     | 
               _cons |   1.486041   .5709749     1.03   0.307      .687365    3.212728 
-------------------------------------------------------------------------------------- -----------
---------------------------------------- 
                |         df           F        P>F 
----------------+---------------------------------- 
Cat3_healthqual |          2       10.36     0.0002 
         Design |         52 
--------------------------------------------------- 
-------------------------------------------------------- 
                     |         df           F        P>F 
---------------------+---------------------------------- 
Cat3_NoOfPrescribers |          2        1.62     0.2082 
              Design |         52 
-------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        1.05     0.3570 
      Design |         52 
------------------------------------------------ 
 
From this model excluding the variable “Malaria testing (microscopy/RDT) available”, 
the p-value for training is even lower than in the model selected (0.015 vs. 0.020). 
However we selected the model in the manuscript in order to maintain homogeneity in 
the model for the 3 different outcomes. The model in the manuscript was selected also 
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because the general interpretation of the results did not change with the exclusion of the 
variable “Malaria testing (microscopy/RDT) available”. 
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Appendix 5 
 
 
Output from the private sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, substituting 
the variable “Category of highest health-related qualification” 
(Cat3_healthqual) with “At least 1 employee is a pharmacist, nurse or doctor” 
(healthqualind) 
 
 
-------------------------------------------------------------------------------------- 
                     |             Linearized 
           outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
       1.trainedProg |   1.934865   .5610293     2.28   0.027     1.081333    3.462118 
              1.test |   .6669057   .3898409    -0.69   0.491     .2063677    2.155197 
            1.second |   1.619007    .460905     1.69   0.097      .914437    2.866446 
     1.healthqualind |    4.12042   1.348712     4.33   0.000      2.13642    7.946875 
                     | 
Cat3_NoOfPrescribers | 
                  2  |   1.335207   .4178673     0.92   0.360     .7125433    2.501994 
                  3  |          1  (empty) 
                     | 
             1.Urban |   1.212351   .3192922     0.73   0.468     .7146793     2.05658 
                     | 
         EcolZoneCFS | 
                  2  |   .8505311   .3264063    -0.42   0.675     .3937731    1.837107 
                  3  |   .5367116   .2000733    -1.67   0.101     .2540245    1.133982 
                     | 
               _cons |   1.502512   .5865469     1.04   0.302     .6864575    3.288686 
-------------------------------------------------------------------------------------- -----------
------------------------------------- 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        1.76     0.1830 
      Design |         52 
------------------------------------------------ 
 
 
Following the variable substitution, the p-value for training is lower than in the model 
selected (0.027 vs. 0.039). However the general interpretation of the results does not 
change. 
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Appendix 6 
 
 
Output from the private sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, substituting 
the variable “Number of prescribers/dispensers employed” 
(Cat3_NoOfPrescribers) with “Number of employees” 
(Cat4_NoOfWorkers_auto) 
 
--------------------------------------------------------------------------------------- 
                      |             Linearized 
            outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
        1.trainedProg |   1.873454   .5219018     2.25   0.028     1.071198    3.276547 
               1.test |   .6787382   .4032137    -0.65   0.517     .2060584    2.235704 
             1.second |   1.320129   .4428995     0.83   0.412     .6733464    2.588177 
                      | 
      Cat3_healthqual | 
                   1  |   1.208561   .4831158     0.47   0.638     .5418772    2.695481 
                   2  |   5.596556   3.160236     3.05   0.004     1.802272    17.37887 
                      | 
Cat4_NoOfWorkers_auto | 
                   1  |   .8528383   .2570929    -0.53   0.600     .4657529    1.561629 
                   2  |   .7143285    .279591    -0.86   0.394     .3256859     1.56674 
                   3  |   .7697251   .4809602    -0.42   0.677     .2196833    2.696959 
                      | 
              1.Urban |   1.138053   .2935647     0.50   0.618     .6782074    1.909689 
                      | 
          EcolZoneCFS | 
                   2  |   .8321154   .2990669    -0.51   0.611     .4045483    1.711578 
                   3  |   .5758858   .2368292    -1.34   0.185     .2523177    1.314392 
                      | 
                _cons |   2.229629     .83272     2.15   0.036     1.053791    4.717486 
----------------------------------------------------------------------------------------- --------
------------------------------------------- 
                |         df           F        P>F 
----------------+---------------------------------- 
Cat3_healthqual |          2        9.59     0.0003 
         Design |         52 
--------------------------------------------------- 
--------------------------------------------------------- 
                      |         df           F        P>F 
----------------------+---------------------------------- 
Cat4_NoOfWorkers_auto |          3        0.25     0.8623 
               Design |         52 
--------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        1.09     0.3454 
      Design |         52 
------------------------------------------------------------------ 
 
 131 
 
Following the variable substitution, the p-value for training is lower than in the model 
selected (0.028 vs. 0.039). However the general interpretation of the results does not 
change. 
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Appendix 7 
 
 
Output from the private sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, substituting 
variables “Category of highest health-related qualification” (Cat3_healthqual) 
and “Number of prescribers/dispensers employed” (Cat3_NoOfPrescribers) 
with “At least 1 employee is a pharmacist, nurse or doctor” (healthqualind) and 
“Number of employees” (Cat4_NoOfWorkers_auto) respectively 
 
--------------------------------------------------------------------------------------- 
                      |             Linearized 
            outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
        1.trainedProg |   1.976544   .5619661     2.40   0.020     1.117199    3.496892 
               1.test |   .7091621   .4278079    -0.57   0.571     .2113589    2.379416 
             1.second |    1.73856    .540635     1.78   0.081     .9315142    3.244815 
      1.healthqualind |   5.117675   2.306947     3.62   0.001     2.071231    12.64494 
                      | 
Cat4_NoOfWorkers_auto | 
                   1  |   .8753062   .2521267    -0.46   0.646     .4910624    1.560211 
                   2  |   .7619214   .2810496    -0.74   0.464      .363454    1.597243 
                   3  |   .7813623   .4989506    -0.39   0.701     .2169495    2.814144 
                      | 
              1.Urban |   1.207329   .3025959     0.75   0.456     .7301394    1.996392 
                      | 
          EcolZoneCFS | 
                   2  |   .8198255   .2870824    -0.57   0.573     .4060246    1.655352 
                   3  |   .5182838   .1922047    -1.77   0.082     .2462535     1.09082 
                      | 
                _cons |    1.70397   .6325797     1.44   0.157     .8089771    3.589116 
----------------------------------------------------------------------------------------------------
--------------------------------------------- 
                      |         df           F        P>F 
----------------------+---------------------------------- 
Cat4_NoOfWorkers_auto |          3        0.18     0.9117 
               Design |         52 
---------------------------------------------------------- 
----------------------------------------------- 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        1.82     0.1726 
      Design |         52 
------------------------------------------------------------------ 
 
Following the variable substitution, the p-value for training is lower than in the model 
selected (0.020 vs. 0.039). However the general interpretation of the results does not 
change. 
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Appendix 8 
 
 
Output from the public sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, excluding 
the variable “Category of highest health-related qualification” 
(Cat3_healthqual)  
 
 
 
 
-------------------------------------------------------------------------------------- 
                     |             Linearized 
           outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------+---------------------------------------------------------------- 
       1.trainedProg |   .9773964   .3103179    -0.07   0.943      .516871    1.848244 
                     | 
Cat3_NoOfPrescribers | 
                  2  |   2.426027   .6114205     3.52   0.001     1.463059    4.022812 
                  3  |   3.161391   1.537797     2.37   0.022     1.191148    8.390552 
                     | 
             1.Urban |    .651126   .2824855    -0.99   0.327     .2726357    1.555061 
                     | 
         EcolZoneCFS | 
                  2  |   .7018858   .3524644    -0.70   0.484     .2562356     1.92262 
                  3  |   2.656754   1.589971     1.63   0.109     .7994748    8.828726 
                     | 
               _cons |   2.726727   1.538461     1.78   0.081     .8789051    8.459436 
--------------------------------------------------------------------------------------                       
-------------------------------------------------------- 
                     |         df           F        P>F 
---------------------+---------------------------------- 
Cat3_NoOfPrescribers |          2        7.58     0.0013 
              Design |         52 
-------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        3.62     0.0338 
      Design |         52 
------------------------------------------------ 
 
In this model we exclude the variable “Category of highest health-related qualification” 
(Cat3_healthqual) based on the argument that in the public sector, since policy is 
fixed and all facilities are supposed to be manned by trained professionals, this variable 
would be unimportant. Following the variable exclusion, the general interpretation of the 
results does not change. 
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Appendix 9 
 
 
Output from the public sector model showing the adjusted predictive power of 
training (trainedProg) for the outcome “stocked at least 1 QAACT”, excluding 
the variable “Category of highest health-related qualification” 
(Cat3_healthqual) and substituting the variable “Number of 
prescribers/dispensers employed” (Cat3_NoOfPrescribers) with “Number of 
employees” (Cat4_NoOfWorkers_auto)  
 
--------------------------------------------------------------------------------------- 
                      |             Linearized 
            outAmCat1 | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
        1.trainedProg |    1.07773   .3438558     0.23   0.815     .5681469    2.044368 
                      | 
Cat4_NoOfWorkers_auto | 
                   1  |   1.474161   .8657724     0.66   0.512     .4536582    4.790283 
                   2  |   1.343505   .6238488     0.64   0.528     .5291445    3.411175 
                   3  |   1.487179   .5202753     1.13   0.262     .7370308    3.000825 
                      | 
              1.Urban |   .6297032   .2920018    -1.00   0.323     .2483254    1.596801 
                      | 
          EcolZoneCFS | 
                   2  |   .7389265   .3363269    -0.66   0.509     .2964448    1.841869 
                   3  |   2.510021   1.455519     1.59   0.119     .7840133    8.035841 
                      | 
                _cons |   2.832003   1.469987     2.01   0.050      .999409    8.024983 
---------------------------------------------------------------------------------------                       
--------------------------------------------------------- 
                      |         df           F        P>F 
----------------------+---------------------------------- 
Cat4_NoOfWorkers_auto |          3        0.42     0.7424 
               Design |         52 
--------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        2.71     0.0761 
      Design |         52 
------------------------------------------------ 
 
In this model we exclude the variable “Category of highest health-related qualification” 
(Cat3_healthqual) based on the argument that in the public sector, since policy is 
fixed and all facilities are supposed to be manned by trained professionals, this variable 
would be unimportant. We also replace the variable “Number of prescribers/dispensers 
employed” (Cat3_NoOfPrescribers) with “Number of employees” 
(Cat4_NoOfWorkers_auto) because they are both proxies for outlet size, and since 
prescribers are a sub-set of workers, the two cannot be used concurrently in a model. 
Following the variable exclusion and substitution, the non-significant role of training 
remains the same, while the number of turns out to be a non-significant predictor of the 
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outcome (p=0.7424). The variable “ecological zone” becomes border-line non-significant 
(p value was 0.029 in our selected model, but in this model it is 0.076). 
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Appendix 10 
 
 
Discussion on the choice of proxies for outlet size 
 
The number of workers, number of prescribers, number of antimalarials audited, number 
of antimalarial treatments sold in past week, and relative sales volume of QAACTs with 
logo sold are all measures that can be used as proxies to describe outlet size. However we 
believe the most appropriate proxy measure for size is the number of workers. We justify 
our position as follows: The number of workers reflects all the work associated with the 
outlet. The larger the outlet, the more workers are required to run it. There could be a 
rather small number of prescribers working in an outlet even though it may be large, 
making number of prescribers a less sensitive proxy for outlet size. Also, the number, 
sales volume, relative sales volume etc. of antimalarials may not adequately reflect its 
true size because the data limits us to information on only antimalarials and no other 
drugs. Further, if indeed per our hypothesis, malaria prevalence influences stocking and 
sales, then number of antimalarials audited or sales volumes will not adequately reflect 
outlet size. 
 
Arguably, a better approach is not to use number of workers, number of prescribers, 
number of antimalarials audited, number of antimalarial treatments sold in past week, and 
relative sales volume of QAACTs with logo sold as proxy measures for outlet size per se, 
but rather as important characteristics than stand on their own and are interpreted 
literally. This is useful because each of the variables could hold policy relevance, 
especially if they were statistically significant in the adjusted model. We therefore ended 
up using only number of workers as proxy for size, and included number of co-paid 
QAACTs audited as an independent variable in our analyses. Using number of QAACTs 
audited is better than sales volume because there could be a high sales volume of a 
particular QAACT and no variety in the number of QAACTs audited, and that would not 
necessarily increase the chance of at least one QAACT being stocked at RRP (one of our 
outcome measures), compared to if there were several different QAACTs audited, which 
would increase the chance of one being at RRP, even though sales volume might be low 
or high. 
 
Using a composite measure (such a ratio of AETD sold to number of workers) could be 
statistically elegant, but is not very useful from a policy perspective although it. Another 
challenge with creating and using this composite measure is that the AETDs of all 
antimalarials sold accounts for only antimalarials, and not all the drugs in the shop and so 
might bias the measure created.  
 
See the following for examples of proxy measures for outlet size which support our 
choices: 
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1. Page 22 of: AHRQ. (2012). 2012 Preliminary Comparative Results: Pharmacy 
Survey on Patient Safety Culture (No. 12 - 0085 - 1 - EF) (p. 34). Rockville, MD: 
Agency for Healthcare Research and Quality. Retrieved from 
http://www.ahrq.gov/professionals/quality-patient-
safety/patientsafetyculture/pharmacy/2012/PharmSOPS_PilotResults.pdf  
2. Page 7 of: Heinsohn, J. G., & Flessa, S. (2013). Competition in the German 
pharmacy market: an empirical analysis. BMC Health Services Research, 13(1), 
407. doi:10.1186/1472-6963-13-407 
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Appendix 11 
 
 
Output from the model showing the adjusted predictive power of “Respondent 
knew and specified the RRP” (identRrp) for the outcome “At least 1 co-paid 
QAACTs sold at RRP” (AtleastqaactRRP) with inclusion of the variable 
“Stocked at least 1 non-QAACT” (outAmCat2)  
 
-------------------------------------------------------------------------------------------- 
                           |             Linearized 
           AtleastqaactRRP | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------------+---------------------------------------------------------------- 
                1.identRrp |   10.29776   3.349853     7.17   0.000     5.361081    19.78031 
                           | 
                Cat3_PPfpr | 
                        1  |   1.545896   .2988966     2.25   0.029     1.048774    2.278656 
                        2  |   1.972155   .5275619     2.54   0.014     1.152966    3.373381 
                           | 
              typeQWLavail | 
                        2  |   3.227687   1.258369     3.01   0.004     1.476154    7.057503 
                        3  |   3.177604   1.284617     2.86   0.006     1.411842    7.151765 
                           | 
Cat3_numberofqaactwithlogo | 
                        1  |   1.147761    .279015     0.57   0.573     .7046936    1.869403 
                        2  |   2.133818   .7441649     2.17   0.034      1.05982    4.296183 
                           | 
               1.outAmCat2 |   1.228805   .3002596     0.84   0.403     .7525526    2.006452 
                     _cons |   .0799426   .0375858    -5.37   0.000     .0311204    .2053576 
--------------------------------------------------------------------------------------------                      
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
  Cat3_PPfpr |          2        5.48     0.0070 
      Design |         52 
------------------------------------------------ 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
typeQWLavail |          2        4.68     0.0136 
      Design |         52 
------------------------------------------------ 
-------------------------------------------------------------- 
                           |         df           F        P>F 
---------------------------+---------------------------------- 
Cat3_numberofqaactwithlogo |          2        2.69     0.0774 
                    Design |         52 
-------------------------------------------------------------- 
 
In this model we include the variable “Stocked some non-QAACTs” (outAmCat2) 
because although it was significant in the unadjusted analysis (p=0.040), we did not 
include it in the adjusted model. It was excluded because we did not hypothesize any 
relationship between stocking particular classes of antimalarials and the outcome. Even if 
we find a statistical relationship between stocking non-QAACTs and stocking at least 1 
co-paid QAACT at RRP, it is likely to be a function of outlet size, which we already 
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account for using the variable “Number of employees”. The included variable 
(Cat3_NoOfPrescribers) was non-significant in this adjusted analysis (p=0.403), 
and the general conclusions from our selected model do not change. 
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Appendix 12 
 
Output from the model showing the adjusted predictive power of “Respondent 
knew and specified the RRP” (identRrp) for the outcome “All co-paid QAACTs 
sold at RRP” (allqaactRRP) with inclusion of the variables “Stocked some oral 
AMTs” (outAmCat3_Oral), “Stocked some non-AMFm QAACTs” 
(outAmCat1_nologo), “Stocked some non-QAACTs” (outAmCat2), and 
“Stocked at least 1 nAT” (fixedoutAmCat4)  
 
-------------------------------------------------------------------------------------------- 
                           |             Linearized 
               allqaactRRP | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------------+---------------------------------------------------------------- 
                1.identRrp |    8.25939   3.819536     4.57   0.000     3.265398    20.89103 
                   1.Owner |   1.400462   .3572607     1.32   0.193     .8393754    2.336612 
           1.healthqualind |   1.372549   .4127335     1.05   0.297     .7507064    2.509491 
                  1.urbrur |   .7957971   .3032704    -0.60   0.552     .3704176    1.709673 
                           | 
               EcolZoneCFS | 
                        2  |   .9758725   .3448939    -0.07   0.945     .4801702    1.983312 
                        3  |   1.254869   .6156406     0.46   0.645     .4688684    3.358502 
                           | 
                Cat3_PPfpr | 
                        1  |    1.64426   .6345301     1.29   0.203     .7579883    3.566796 
                        2  |   1.641601   .6704967     1.21   0.230     .7233046     3.72575 
                           | 
     Cat4_NoOfWorkers_auto | 
                        1  |   .4841403   .1756909    -2.00   0.051     .2337326     1.00282 
                        2  |   .4914284   .2549549    -1.37   0.177     .1735143    1.391826 
                        3  |   .3547428   .2575651    -1.43   0.159     .0826359    1.522855 
                           | 
              typeQWLavail | 
                        2  |   3.264235   1.510069     2.56   0.014     1.290113    8.259146 
                        3  |   1.307988   .7332914     0.48   0.634     .4246513    4.028795 
                           | 
           1.AP_QWLprivate |   .0514801    .026975    -5.66   0.000     .0179885    .1473274 
                           | 
Cat3_numberofqaactwithlogo | 
                        1  |   .3241924    .107813    -3.39   0.001     .1663359    .6318582 
                        2  |   .0083454   .0077145    -5.18   0.000     .0013057    .0533388 
                           | 
          1.outAmCat3_Oral |   .8867839   .2458497    -0.43   0.667     .5084077    1.546762 
        1.outAmCat1_nologo |    .887891   .2772713    -0.38   0.705     .4744763    1.661517 
               1.outAmCat2 |   1.422769   .5703282     0.88   0.383     .6364975    3.180331 
          1.fixedoutAmCat4 |   .9837043   .2397978    -0.07   0.947     .6031493    1.604369 
                     _cons |   .1820575    .153868    -2.02   0.049     .0333942    .9925363 
--------------------------------------------------------------------------------------------                      
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        0.14     0.8735 
      Design |         52 
------------------------------------------------ 
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------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
  Cat3_PPfpr |          2        1.03     0.3637 
      Design |         52 
------------------------------------------------ 
--------------------------------------------------------- 
                      |         df           F        P>F 
----------------------+---------------------------------- 
Cat4_NoOfWorkers_auto |          3        1.33     0.2760 
               Design |         52 
--------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
typeQWLavail |          2        5.95     0.0048 
      Design |         52 
------------------------------------------------ 
-------------------------------------------------------------- 
                           |         df           F        P>F 
---------------------------+---------------------------------- 
Cat3_numberofqaactwithlogo |          2       15.43     0.0000 
                    Design |         52 
-------------------------------------------------------------- 
 
In this model we include the four variables reflecting stocking various classes of 
antimalarials. We did not include these in the model we selected because although they 
were significant in the unadjusted analysis, we did not hypothesize any relationship 
between stocking particular classes of antimalarials and the outcome. Even if we find a 
statistical relationship between these added variables and stocking at least 1 co-paid 
QAACT at RRP, it is likely to be a function of outlet size, which we already account for 
using the variable “Number of employees”. However, none of the included variables was 
significant in this adjusted analysis, and the general conclusions from our selected model 
do not change. 
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Appendix 13 
 
 
 
 
Output from the model for the outcome “At least 1 co-paid QAACTs sold at <= 1 
USD” (AtleastqaactRRP_oneUSD) instead of “At least 1 co-paid QAACTs sold 
at RRP” (AtleastqaactRRP) 
 
 
-------------------------------------------------------------------------------------------- 
                           |             Linearized 
    AtleastqaactRRP_oneUSD | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------------+---------------------------------------------------------------- 
                1.identRrp |   10.53377   3.432102     7.23   0.000     5.478231    20.25476 
                           | 
                Cat3_PPfpr | 
                        1  |   1.471979   .2916105     1.95   0.056     .9891345    2.190522 
                        2  |    1.90867   .5014428     2.46   0.017     1.126622     3.23358 
                           | 
              typeQWLavail | 
                        2  |   3.153474    1.21927     2.97   0.004     1.451573    6.850772 
                        3  |   3.171005   1.279801     2.86   0.006     1.410828    7.127214 
                           | 
Cat3_numberofqaactwithlogo | 
                        1  |   1.158661   .2799667     0.61   0.545     .7134806    1.881614 
                        2  |    2.16562   .7729834     2.16   0.035     1.058091    4.432427 
                           | 
                     _cons |   .0942585   .0416519    -5.34   0.000     .0388351    .2287795 
--------------------------------------------------------------------------------------------                      
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
  Cat3_PPfpr |          2        4.75     0.0128 
      Design |         52 
------------------------------------------------ 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
typeQWLavail |          2        4.61     0.0144 
      Design |         52 
------------------------------------------------ 
-------------------------------------------------------------- 
                           |         df           F        P>F 
---------------------------+---------------------------------- 
Cat3_numberofqaactwithlogo |          2        2.62     0.0827 
                    Design |         52 
-------------------------------------------------------------- 
 
There is no change in the p-values for all of the variables in the model from those 
obtained from our selected model. 
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Appendix 14 
 
 
 
 
Output from the model for the outcome “All co-paid QAACTs sold at <= 1 USD” 
(allqaactRRP_oneUSD) instead of “All co-paid QAACTs sold at RRP” 
(allqaactRRP) 
 
-------------------------------------------------------------------------------------------- 
                           |             Linearized 
        allqaactRRP_oneUSD | Odds Ratio   Std. Err.      t    P>|t|     [95% Conf. Interval] 
---------------------------+---------------------------------------------------------------- 
                1.identRrp |   8.635461   4.019658     4.63   0.000      3.39335    21.97568 
                   1.Owner |   1.358621   .3334408     1.25   0.217     .8302629    2.223213 
           1.healthqualind |   1.355021   .3945592     1.04   0.302     .7554177    2.430552 
                  1.urbrur |   .8161193   .2996159    -0.55   0.582     .3906746    1.704873 
                           | 
               EcolZoneCFS | 
                        2  |   .9826406   .3405465    -0.05   0.960     .4902006     1.96977 
                        3  |   1.251216   .6065787     0.46   0.646     .4729859     3.30991 
                           | 
                Cat3_PPfpr | 
                        1  |   1.624427   .5494878     1.43   0.157     .8239669     3.20251 
                        2  |   1.701506   .6225446     1.45   0.152     .8165437    3.545584 
                           | 
     Cat4_NoOfWorkers_auto | 
                        1  |   .4892435   .1756885    -1.99   0.052     .2379996    1.005713 
                        2  |   .5205003   .2618968    -1.30   0.200     .1896383    1.428617 
                        3  |   .3868127   .2518223    -1.46   0.151       .10475    1.428393 
                           | 
              typeQWLavail | 
                        2  |   3.323853    1.57515     2.53   0.014     1.284269    8.602561 
                        3  |    1.30437    .728368     0.48   0.636      .425367    3.999797 
                           | 
           1.AP_QWLprivate |   .0475996   .0263899    -5.49   0.000     .0156475    .1447977 
                           | 
Cat3_numberofqaactwithlogo | 
                        1  |   .3391898   .1057658    -3.47   0.001     .1814264    .6341402 
                        2  |    .009005   .0082636    -5.13   0.000     .0014281    .0567823 
                           | 
                     _cons |   .1959749   .1626646    -1.96   0.055     .0370554    1.036453 
-------------------------------------------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
 EcolZoneCFS |          2        0.13     0.8772 
      Design |         52 
------------------------------------------------ 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
  Cat3_PPfpr |          2        1.48     0.2376 
      Design |         52 
------------------------------------------------ 
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--------------------------------------------------------- 
                      |         df           F        P>F 
----------------------+---------------------------------- 
Cat4_NoOfWorkers_auto |          3        1.34     0.2719 
               Design |         52 
--------------------------------------------------------- 
------------------------------------------------ 
             |         df           F        P>F 
-------------+---------------------------------- 
typeQWLavail |          2        5.89     0.0050 
      Design |         52 
------------------------------------------------ 
 
-------------------------------------------------------------- 
                           |         df           F        P>F 
---------------------------+---------------------------------- 
Cat3_numberofqaactwithlogo |          2       15.78     0.0000 
                    Design |         52 
-------------------------------------------------------------- 
 
 
Here too there is no change in the p-values for all of the variables in the model from those 
obtained from our selected model. 
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Appendix 15 
 
 
 
 
Distribution of actual price per treatment of adult does of co-paid QAACTs 
 
 
 
 
 
 
 
N= Total number of adult co-paid QAACTs audited in private sector 
 
 
 
 
While almost twice as much of AL compared to ASAQ was sold between 90 and 110% 
of the RRP, more the twice as much ASAQ compared to AL was stocked at >150% of 
the RRP, signaling a problem with ASAQ. 
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Appendix 16 
 
 
 
 
Graph showing the relationship between percentage of co-paid QAACTs at RRP 
and number of co-paid QAACTs per outlet 
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Appendix 17 
 
Jitter plots showing the relationship between the predicted probability of (a) 
stocking at least 1 co-paid QAACT at RRP, (b) stocking all co-paid QAACT at RRP 
and malaria prevalence  
(a) 
 
(b) 
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Appendix 18 
 
 
 
 
Distribution of outlets that had only 1 co-paid QAACT at RRP (a) 
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Appendix 19 
 
 
 
 
Distribution of outlets that had only 1 co-paid QAACT at RRP (b) 
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Appendix 20 
 
 
 
 
Mean, median (p50), and interquartile range prices per AETD of co-paid ASAQ 
and AL in our sample 
 
 
 
 
typeQWL |      mean       p50       iqr         N 
--------+---------------------------------------- 
   ASAQ |  1.725192  1.251238  .9384283       299 
     AL |  1.162543  .9384283  .3128093       830 
--------+---------------------------------------- 
  Total |  1.311553  .9384283  .3128093      1129 
------------------------------------------------- 
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Appendix 21 
 
Predicted probabilities of knowing the RRP for various outlet characteristics 
 
Predictive margins                                Number of obs   =        542 
Model VCE    : Linearized 
 
Expression   : Pr(identRrp), predict() 
--------------------------------------------------------------------------------------- 
                      |            Delta-method 
                      |     Margin   Std. Err.      z    P>|z|     [95% Conf. Interval] 
----------------------+---------------------------------------------------------------- 
             pharmlcs | 
                   0  |   .7675388   .0234849    32.68   0.000     .7215091    .8135684 
                   1  |   .8355199   .0407303    20.51   0.000     .7556899    .9153498 
                      | 
           Cat3_PPfpr | 
                   0  |   .8505939    .048611    17.50   0.000     .7553181    .9458697 
                   1  |   .7547581   .0442549    17.05   0.000       .66802    .8414962 
                   2  |   .7567741   .0403037    18.78   0.000     .6777803    .8357678 
                      | 
          EcolZoneCFS | 
                   1  |   .7577382   .0528153    14.35   0.000     .6542222    .8612542 
                   2  |   .7854747   .0323679    24.27   0.000     .7220347    .8489147 
                   3  |   .7681075   .0458777    16.74   0.000     .6781888    .8580261 
                      | 
Cat4_NoOfWorkers_auto | 
                   0  |   .8035816   .0329135    24.41   0.000     .7390724    .8680908 
                   1  |    .755864   .0241442    31.31   0.000     .7085422    .8031858 
                   2  |   .7680387   .0429212    17.89   0.000     .6839146    .8521627 
                   3  |   .8378993   .0413728    20.25   0.000     .7568101    .9189885 
                      | 
               second | 
                   0  |   .6847942    .078031     8.78   0.000     .5318562    .8377322 
                   1  |   .7863744   .0243142    32.34   0.000     .7387195    .8340292 
                      | 
        healthqualind | 
                   0  |   .7769768   .0234426    33.14   0.000       .73103    .8229235 
                   1  |   .7643934    .033284    22.97   0.000     .6991579    .8296288 
                      | 
                 test | 
                   0  |   .7738688   .0217525    35.58   0.000     .7312346     .816503 
                   1  |   .7802518   .0770506    10.13   0.000     .6292353    .9312683 
                      | 
               urbrur | 
                   0  |   .6444028   .0471453    13.67   0.000     .5519997    .7368059 
                   1  |   .8680627   .0222102    39.08   0.000     .8245314    .9115939 
                      | 
          trainedProg | 
                   0  |   .6704743   .0335916    19.96   0.000      .604636    .7363126 
                   1  |   .8735287   .0213009    41.01   0.000     .8317797    .9152776 
                      | 
   urbrur#trainedProg | 
                 0 0  |   .3906688   .0797265     4.90   0.000     .2344076      .54693 
                 0 1  |   .8511157   .0389453    21.85   0.000     .7747844     .927447 
                 1 0  |   .8421236   .0337287    24.97   0.000     .7760166    .9082306 
                 1 1  |   .8897528   .0248498    35.81   0.000     .8410481    .9384576 
--------------------------------------------------------------------------------------- 
 152 
 
Appendix 22 
 
 
 
 
 
Adjusted Odds Ratios of Knowing the RRP for Selected Outlet Characteristics 
 
 
Outlet Characteristics 
Knowledge of the RRP 
Odds Ratio p-value 
Location and Training categories (using 
urban and untrained as the reference 
group)§ 
Urban and Untrained Ref. - 
Urban and Trained 1.53 0.204 
Rural and Trained 1.07 0.854 
Rural and Untrained 0.10 *<0.001 
Type of outlet 
Licensed chemical shop Ref. 
0.162 
Pharmacy 1.81 
Falciparum malaria prevalence (%) 
Low (10-24) Ref. 
0.342 Medium (25-34) 0.44 
High (35-70) 0.44 
  
*Statistically significant p-value (≤0.05) 
§This is the interaction (location*training) 
 
 
 
Although several variables were included in our model, none of them were significantly 
associated with our knowing the RRP (including type of private outlet and malaria 
prevalence), except for training and urban/rural location which were interacted. 
  
For outlets in rural locations, the odds of having knowledge of the RRP was 9 times 
lower for those without any training compared to urban outlets also with no training 
(p<0.001). The similarity of the two odds ratios (1.53 and 1.07) indicates that training 
raises outlets in rural locations to an odds ratio of having knowledge of the RRP 
equivalent to that of outlets in urban locations that had not undergone any training (rural 
untrained outlets as reference group). Thus, the impact of training on knowledge was 
only felt in rural areas. We believe that this difference is due to there being many other 
sources of knowledge of the AMFm beyond training, which are biased towards urban 
areas so that they already have high knowledge. This allows less room for improvement 
in knowledge with training in urban areas compared to rural areas. 
 
 
 153 
 
Appendix 23 
 
 
 
 
 
Output showing the marginal impact of training for rural outlets as increasing the 
probability of knowledge by 46% (p<0.001), while for urban outlets it was only 
4.8% (p=0.208) 
 
 
 
 
 
. margins, dydx(trainedProg) at(urbrur=(0 1)) 
 
Average marginal effects                          Number of obs   =        542 
Model VCE    : Linearized 
 
Expression   : Pr(identRrp), predict() 
dy/dx w.r.t. : 1.trainedProg 
 
1._at        : urbrur          =           0 
 
2._at        : urbrur          =           1 
 
-------------------------------------------------------------------------------- 
               |            Delta-method 
               |      dy/dx   Std. Err.      z    P>|z|     [95% Conf. Interval] 
---------------+---------------------------------------------------------------- 
1.trainedProg  | 
           _at | 
            1  |   .4604469   .0761221     6.05   0.000     .3112504    .6096434 
            2  |   .0476292   .0378127     1.26   0.208    -.0264824    .1217409 
-------------------------------------------------------------------------------- 
Note: dy/dx for factor levels is the discrete change from the base level. 
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Appendix 24 
 
 
 
 
 
 
 
 
 
 
 
We argue that focusing more knowledge-generating activities in rural and high malaria 
prevalence areas might not necessarily lead to improved AMFm outcomes. This is so 
because the high number of cases-per-outlet seen in the high prevalence area and 
northern savanna zones also suggests that there are simply not enough outlets to serve the 
cases. Therefore even if all the outlets in the rural and high malaria prevalence areas 
receive training, malaria will still abound. 
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Appendix 25 
 
 
 
 
 
Percentage of the population living in censused “clusters” with outlets with quality 
assured ACTs in stock at the time of survey, Ghana, 2011. 
 
 
 
 
AMFm IE indicator: Population living in a censused “cluster” where there was at least one of a given type of 
outlet with a quality-assured ACT in stock at the time of the survey visit (n) as a percentage of the total 
population living in all the censused “clusters” (N), by location. 
  
Urban   Rural Total 
Percentage 
(95% CI) N   
Percentage 
(95% CI) N 
Percentage 
(95% CI) N 
At least one public health 
facility stocking quality 
assured ACTs 
28.6 
363,574 
76.7 
437,796 
53.5 
801,370 
(16.1, 45.5) (60.1, 87.8) (43.1, 63.6) 
                
At least one private not for 
profit health facility 
stocking quality assured 
ACTs 
21.4 
363,574 
23.3 
437,796 
22.4 
801,370 (9.3, 42.0)  (12.2, 39.9) (13.7, 34.5) 
                
At least one private for 
profit outlet stocking 
quality assured ACTs 
100 363,574 
90 
437,796 
94.8 
801,370 
(74.9, 96.4) (86.7, 98.1) 
                
At least one community 
health worker stocking 
quality assured ACTs 
100 363,574  100 437,796 100 801,370 
                
At least one outlet of any 
type stocking quality 
assured ACTs 
100 363,574   100 437,796 100 801,370 
  
Source: AMFm Phase 1 Independent Evaluation Outlet Survey (Endline) 
 
 
 
 
